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INTRODUCTION 
  Pharmaceutical Analytical Chemistry is an important part in monitoring the 
quality of pharmaceutical products for safety and efficacy. With the advancement in 
synthetic organic chemistry and other branches of chemistry including bioanalytical 
sciences and biotechnology, the scope of analytical chemistry has enhanced to, much 
higher levels. the emphasis in current use of analytical methods particularly involving 
advance analytical installation technology has made it possible not only to evaluate the 
potency of active ingredients in dosage forms and APIs but also to characterize, elucidate, 
identify and quantify impotent constituents like active moiety, impurities, metabolites, 
isomers, polymers and chiral components of some of the most potent medicines. Not only 
is it important in today's field of pharmaceutical analytical Chemistry to quantify the 
active ingredients in dosage form, but also have a prediction of the degradations likely 
impurities being generated and understanding the impact of the impurities and 
degradation on the safety of a patient who has to use this medicine throughout life. The 
current trends in Pharmacopeias rely more on instrumental techniques rather than the 
classical wet chemistry methods. This has resulted in the availability of indigenous 
instruments like spectrophotometer, high performance liquid chromatography (HPLC), 
gas chromatography (GC) and Ultra performance liquid chromatography (UPLC) etc in 
almost all analytical laboratories and pharmaceutical companies. Due to the advent of 
automation, small sample size and high sensitivity of the instrument, very accurate and 
precise assay and degradation products methods can be developed on chromatographic 
Instruments with a considerable reduction in the total analysis time. Furthermore 
application of techniques like Photo Diode Array, Fourier transform Infrared 
spectroscopy and X-ray diffraction etc. ensure the confirmation of the identity of 
individual components, ensure integrity and purity of the molecule. With these 
advancements in analytical techniques, the ability to develop methods with short run time 
and relatively simple sample procedure for simultaneous estimation of Individual active 
components in a combination drug product is central to the role of analytical chemists. 
Normally, individual estimation of each of the drugs would have been time consuming, 
with no cost effectiveness and tedious in routine analysis. 
 
ABOUT THE PRESENT RESEARCH WORK: 
In The present research work a modest attempt has been made to develop 
validated analytical methods for the determination of single or combined dosage form and 
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2 
estimation of degradants generated during formulation and storage of finished products 
using techniques like UV-Visible Spectrophotometry, High performance liquid 
chromatography (HPLC), Gas chromatograph and also by using the instruments like Ultra 
performance liquid chromatography (UPLC) were used which is more sophisticated, 
faster sensitive than HPLC which ensures a higher sample throughput with more 
information per sample which may decrease the time to market, an important driving 
force in today's pharmaceutical industry 
ACQUITY Ultra performance LC™ systems defined as UPLC™, is a new 
category of analytical separation science which retains the practicality and principles of 
HPLC while using the overall interlaced attributes of speed, sensitivity, and resolution 
with a significant decrease in time and solvent consumption and the system allows 
chromatographers to work at higher efficiencies with a much wider range of linear cities, 
flow rates, and backpressures.)  
A comprehensive summary of the work to be incorporated in the thesis entitled 
“Method development, validation and application of some bioactive compounds” has 
been describe as under, 
  
PART A:  HPLC METHOD DEVELOPMENT AND VALIDATION OF SOME  
PHARMACEUTICAL FORMULATIONS. 
SECTION-I: Development and validation of a stability indicating HPLC assay 
method for determination of warfarin sodium in tablet formulation. 
SECTION-II: HPLC method development and validation of chlorhexidine gluconate 
and lidocaine hydrochloride in throat spray. 
 
PART B:  UPLC METHOD DEVELOPMENT AND VALIDATION OF 
CHLORHEXIDINE GLUCONATE AND LIDOCAINE 
HYDROCHLORIDE IN COMBINED DOSAGE FORM. 
 
PART C:  GAS CHROMATOGRAPHIC METHOD DEVELOPMENT AND 
VALIDATION OF TICLOPIDINE HYDROCHLORIDE. 
 
PART D: UV-VISIBLE SPECTROPHOTOMETRIC METHOD 
DEVELOPMENT AND VALIDATION OF SPIRONOLACTONE 
AND FUROSEMIDE IN COMBINED DOSAGE FORM. 
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PART A:  HPLC METHOD DEVELOPMENT AND VALIDATION OF SOME 
PHARMACEUTICAL FORMULATIONS. 
 The research work undertaken in these studies mainly addresses analysis, 
development of stability indicating HPLC methods and validation protocol, according to 
ICH guidelines.  
 
AIM OF WORK 
 
To develop stability indicating high performance liquid chromatographic method 
for the estimation of some active pharmaceutical ingredient from their single/combine 
pharmaceutical dosage forms by HPLC and to perform the validation procedure for same. 
 
EXPERIMENTAL WORK  
 
Development of analytical method Validation of analytical method 
Selection of mobile phase Specificity 
Selection of stationary phase Linearity and range 
Choice of flow-mode and flow rate Precision & Intermediate precision 
Wavelength selection Accuracy 
Injection volume / Concentration Robustness 
Selection of diluents Solution stability 
    
We have undertaken work on different bioactive compounds which are described 
as under the following section, 
 
SECTION-I: DEVELOPMENT AND VALIDATION OF A STABILITY 
INDICATING HPLC ASSAY METHOD FOR DETERMINATION 
OF WARFARIN SODIUM IN TABLET FORMULATION. 
Warfarin sodium is a synthetic derivative of coumarin. Warfarin decreases blood 
coagulation by inhibiting vitamin K epoxide reductase, an enzyme that recycles oxidized 
vitamin K to its reduced form after it has participated in the carboxylation of several 
blood coagulation proteins, mainly prothrombin and factor VII. For this reason, drugs in 
this class are also referred to as vitamin K antagonists. It is also significantly used as 
vitamin K antagonists and Warfarin treatment can help prevent formation of future blood 
clots and help reduce the risk of embolism. Warfarin is chemically (RS)-4-hydroxy- 3-(3- 
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oxo- 1-phenylbutyl)- 2H- chromen- 2-one [Figure 1]. Its molecular formula is C19H16O4 
having molecular weight 308.33 g/mol.  
 
O O
OH CH3
O
 
[1] 
 
 
 
Developed Chromatographic parameters are as under 
 
Mobile phase : Buffer: Acetonitrile (50: 50, v/v) 
  
Buffer: 0.05 M sodium hydrogen phosphate dibasic dihydrate  
buffer, pH 3.0 with orthophosphoric acid 
Column : Wakosil II 5C8RS 4.6 x 150mm, 5 μm 
Flow rate : 1 ml/min 
Wavelength : 280 nm 
Injection volume : 20 µl 
Diluent : Water 
 The developed procedure has been evaluated over the specificity, linearity, 
accuracy, precision, limit of detection, limit of quantification and robustness in order to 
ascertain the stability of the analytical method. It has been proved that it was specific, 
linear, precise, accurate and robust and stability indicating. Hence, the method is 
recommended for routine quality control analysis and also stability sample analysis. 
 
SECTION-II: HPLC METHOD DEVELOPMENT AND VALIDATION OF 
CHLORHEXIDINE GLUCONATE AND LIDOCAINE HYDROCHLORIDE IN 
THROAT SPRAY. 
 
Chlorhexidine Gluconate is a chemical antiseptic [Figure 2]. It kills (is 
bactericidal to) both gram-positive and gram-negative microbes, It also shows activity 
with enveloped viruses, However, chlorhexidine gluconate is safely used in very low 
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concentrations in some contact lens solutions. Chlorhexidine gluconate is present in oral 
rinses and skin cleansers, and in small quantities it is used as a preservative. Its molecular 
formula is C22H30Cl2N10•2C6H12O7 having molecular weight 897.72 g/mole.  
Lidocaine hydrochloride, the first amino amide-type local anesthetic [Figure 3]. 
Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium 
(Na+) channels in the neuronal cell membrane, which are responsible for signal 
propagation. With sufficient blockade, the membrane of the postsynaptic neuron will not 
depolarize and so fail to transmit an action potential, leading to its anesthetic effects. 
Chemically, Lidocaine Hydrochloride is 2-(diethylamino)-N-(2,6-
dimethylphenyl)acetamide hydrochloride. The molecular formula is C14H22N2O•HCl 
having molecular weight 270.84 g/mole. 
 
Developed Chromatographic parameters are as under 
  
Mobile phase : Buffer: Acetonitrile (Gradient elution) 
  Buffer: 0.05M sodium hydrogen phosphate dibasic dihydrate 
buffer pH 3 with orthophosphoric acid 
Column : Wakosil II 5C8RS 4.6 x 150mm, 5 μm 
Flow rate : 1 ml/min 
Wavelength :  215 nm 
Injection volume : 20 µl       
Diluent : Buffer : Acetonitrile (85:15, v/v)   
 
.
O
NH
N . HCl
NHNH
NHNH
NH
NH
NH
NH
NH
NH
Cl
Cl
2C6H12O7
 
   (2)      (3) 
 
The developed procedure has been evaluated over the specificity, linearity, 
accuracy, precision, limit of detection, limit of quantification and robustness in order to 
ascertain the stability of the analytical method. It has been proved that it was specific, 
linear, precise, accurate and robust and stability indicating. Hence, the method is 
recommended for routine quality control analysis and also stability sample analysis. 
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PART - [B]:  UPLC METHOD DEVELOPMENT AND VALIDATION OF 
CHLORHEXIDINE GLUCONATE AND LIDOCAINE HCl IN 
COMBINED DOSAGE FORM. 
The research work undertaken in this study in the area of pharmaceuticals and 
mainly addresses method development for determination of Chlorhexidine Gluconate and 
Lidocaine hydrochloride in drug product by UPLC. Developed analytical method was 
validated for its intended application as per ICH guideline. 
 
Chromatographic parameters 
 
Mobile phase : Buffer: Acetonitrile (Gradient elution) 
  Buffer: 0.02M sodium hydrogen phosphate dibasic dihydrate 
buffer pH 3 with orthophosphoric acid 
Column : Waters Acquity BEH C18, 2.4 x 50mm, 1.7µ 
Flow rate : 0.3 ml/min 
Wavelength :  215 nm 
Injection volume : 4 µl       
Diluent : Buffer : Acetonitrile (85:15, v/v)   
 
  
The developed procedure has been evaluated over the specificity, linearity, 
accuracy, precision, limit of detection, limit of quantification and robustness in order to 
ascertain the stability of the analytical method. It has been proved that it was specific, 
linear, precise, accurate and robust and stability indicating. Hence, the method is 
recommended for routine quality control analysis and also stability sample analysis. 
 
PART - [C]:  GAS CHROMATOGRAPHIC METHOD DEVELOPMENT AND 
VALIDATION OF TICLOPIDINE HYDROCHLORIDE. 
AIM OF WORK 
 
To develop a Gas chromatographic assay method for the estimation of Ticlopidine 
hydrochloride from their pharmaceutical formulation and to perform the validation 
procedure for same. 
 
Ticlopidine hydrochloride is an inhibitor of platelet aggregation used in the 
management and prevention of thromboembolic disorders. Ticlopidine hydrochloride is 
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chemically 5-[(2-chlorophenyl) methyl]-4, 5, 6, 7-tetrahydrothieno [3, 2-c] pyridine 
hydrochloride [Figure 1]. Its molecular formula is C14H14ClNS.HCl having molecular 
weight 300.25 g/mole. It is used as adenosine diphosphate [ADP] receptor antagonists in 
an antiplatelet therapy. It is also significantly reduces restenosis after endovascular 
therapy in femoropopliteal lesions.  
N
S
Cl
ClH.
Figure 1  
 
Developed chromatographic parameters are as under 
 
Injector Temperature : 290 °C 
Column : SGE BPX50 C5 30 meter, 0.25 mm*0.25 
Column oven temperature : Isothermal at 270 °C  
Carrier Gas : Nitrogen 
Carrier gas pressure : 200kPa 
Injection volume : 3 µl 
Detector : Flame ionization detector (FID) 
Detector temperature : 310 °C 
Diluent : Methanol 
 
 The developed procedure has been evaluated over the specificity, linearity, 
accuracy, precision and robustness in order to ascertain the stability of the analytical 
method. It has been proved that it was specific, linear, precise, accurate and robust and 
stability indicating. Hence, the method is recommended for routine quality control 
analysis and also stability sample analysis. 
 
PART - [C]:  SPECTROPHOTOMETRIC METHOD DEVELOPMENT AND 
VALIDATION OF SPIRONOLACTONE AND FUROSEMIDE IN 
COMBINED DOSAGE FORM. 
The research work undertaken in this study in the area of pharmaceuticals and 
mainly addresses method development for determination of spironolactone and 
furosemide in drug product by UV Visible spectrophotometer. Developed analytical 
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method was validated for its intended application as per ICH guideline.  
 
 
O
S
O CH3
O
O
Cl
S
O
NH2
O
O OH
NH
O
(1) (2)  
 
 
Spironolactone [Figure 1] inhibits the effect of aldosterone by competing for 
intracellular aldosterone receptors in the distal tubule cells. Furosemide is chemically 4-
chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid [Figure 2]. Its molecular 
formula is C12H11ClN2O5S  having molecular weight 330.74gm/mole. Furosemide, an 
anthranilic acid derivative, is a potent diuretic that inhibits the active reabsorption of 
chloride in the diluting segment of the loop of Henle, thus preventing the reabsorption of 
sodium, which passively follows chloride. This loop diuretic is commonly used for the 
treatment of renal diseases, congestive heart failure and hypertension. 
Developed Chromatographic parameters are as under 
 
Detection : 241 and 276 nm 
Cell pathlength : 1cm 
Diluent : Methanol: Water (50:50, v/v) 
 
 The developed procedure has been evaluated over the specificity, linearity, 
accuracy, precision and robustness in order to ascertain the stability of the analytical 
method. It has been proved that it was specific, linear, precise, accurate and robust. 
Hence, the method is recommended for routine quality control analysis and also stability 
sample analysis. 
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CONCLUSION 
All the analytical methods though rapid and sensitive were novel in their 
application due to the simultaneous determination of active moieties from the drug 
product. These methods allow high samples throughput due to short run time and 
relatively simple sample preparation procedure. Normally, individual estimation of each 
of the drugs would have been time consuming, with no cost effectiveness and tedious in 
routine analysis at mixing, blending, drying and compression stage where the productivity 
input would have been hampered. Hence the simplicity in application and quick turnover 
of sample results facilitate good QC testing on routine basis for the determination of 
assay, dissolution and degradation products.  
These methods are rapid, sensitive and selective; hence by optimizing injection 
volume of the samples, these methods can also be applied for analyzing swab and/or rinse 
samples.  
Chromatographic conditions were optimized so as to achieve a sensitive and 
producible method. All the system suitability parameters have been established during 
method validation. These method of analysis have been validated as per ICH guideline 
(International conference on harmonization of technical requirements for registration of 
pharmaceuticals for human use) to prove its accuracy and precision and the experimental 
results indicate that these methods are quick, simple and convenient; the rate of recovery 
is high and the results accurately reliable, it can successfully be applied in routine 
analysis. 
 PART - A 
 
 
 
 
 
 
 
 
 
 
 
HPLC method development 
and validation of some 
pharmaceutical formulations 
  
 
 
 
 
 
 
 
 
Introduction 
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1. INTRODUCTION 
 Analytical study is an integral part of pharmaceutical chemistry, which plays an 
essential role during synthesis of new molecules, testing their therapeutic activity, 
elucidating the mechanism of action, identification of metabolites etc. Today such 
activity is a function of the laboratories of the manufacturing industries and modern 
pharmaceutical analysis entail much more than the analysis of active pharmaceutical 
ingredients or the formulated product. Furthermore there is a need for quality assurance 
of pharmaceutical products throughout their shelf life. This requires that the study of 
interactions between the drug substance and the excipients in the presence of residual 
solvents, as well as other potential degradation reactions that may occur in the formulated 
product over a period of time under various stress conditions (these include conditions 
they may be subjected to during storage or shipment in the final package configuration) 
The pharmaceutical industry is under increased scrutiny from the government and public 
interest groups to contain costs and yet consistently deliver to market safe, efficacious 
products that fulfill unmet medical needs. As part of the crusade to hold the line on 
prescription drug prices, the industry has streamlined its operations with respect to drug 
discovery, development and manufacturing. The drive to bring innovative products to 
market faster without negatively impacting quality or safety has caused every company to 
challenge all existing processes and to look for ways to increase capacity, shorten time 
lines, and "do more with less". Analytical chemistry has played a major role in the 
changes facing the pharmaceutical industry today. Indeed, the demand for analytical data 
has become a critical path for the selection of candidate molecules for full development. 
Working under sample – limited conditions and in full compliance of current good 
manufacturing practices (cGMP), pharmaceutical analysts are called on to generate 
accurate and precise data - almost on demand. The science and technology utilized today, 
coupled with the new regulations that are now binding, have made pharmaceutical 
analysis much more complicated compared to what it was as little as ten years ago. 
 The pharmaceutical analyst plays a major role in assuring identity, safety, 
efficacy, purity and quality of a drug product. Safety and efficacy studies require that the 
drug substance and drug product meet the established identity and purity as well as 
bioavailability/dissolution requirements. The need for pharmaceutical analysis is driven 
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largely by regulatory requirements as regulatory considerations loom large when a 
commercial product does not meet its purported quality. New drug discovery and 
candidate optimization processes in the pharmaceutical industry are being extensively 
carried out these days. 
 The number of drugs introduced into the market is increasing every year. These 
drugs may be either new entities or partial structural modification of the existing one [1]. 
Very often there is a time delay from the date of introduction of a drug into the market to 
the date of its inclusion in pharmacopoeias. This happens because of the possible 
uncertainties in the continuous and wider usage of these drugs, reports of new toxicities 
(resulting in their withdrawal from the market), development of long-suffering opposition 
and introduction of better drugs by competitors. Under these conditions, standards and 
analytical procedures for these drugs may not be available in the pharmacopoeias. It 
becomes necessary, therefore to develop newer analytical methods for such drugs. 
 Also quality is important in every product or service but it is vital in medicines as 
it involves life. Quality control is a concept, which strives to produce a perfect product by 
series of measures designed to prevent and eliminate errors at different stage of 
production. The decision to release or reject a product is based on one or more type of 
control action. With the growth of pharmaceutical industry during last several years, there 
has been rapid progress in the field of pharmaceutical analysis involving complex 
instrumentation. Providing simple analytical procedure for complex formulation is a 
matter of most importance. 
In brief, the reasons for the development of newer methods of drug analysis are: 
 The drug or drug combination may not be official in any pharmacopoeias, 
 A proper analytical procedure for the drug may not be available in the literature 
due to patent regulations, 
 Analytical methods may not be available for the drug in the form of a formulation 
due to the interference caused by the formulation excipients, 
 Analytical methods for the quantitation of the drug in biological fluids may not be 
available, 
 Analytical methods for a drug in combination with other drugs may not be 
available, 
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 The existing analytical procedures may require expensive reagents and solvents. It 
may also involve cumbersome extraction and separation procedures and these 
may not be reliable. 
 
 Due to rapid growth of pharmaceutical industry during last several years, number 
of pharmaceutical formulations are enter as a part of health care system and thus, there 
has been rapid progress in the field of pharmaceutical analysis. Developing analytical 
method for newly introduced pharmaceutical formulation is a matter of most importance 
because drug or drug combination may not be official in any pharmacopoeias and thus, 
no analytical method for quantification is available. To check the quality standards of the 
medicine various analytical methods are used. Modern analytical techniques are playing 
key role in assessing chemical quality standards of medicine. Thus analytical techniques 
are required for fixing standards of medicines and its regular checking.  Out of all 
analytical techniques, the technique which is widely used to check the quality of drug is 
known as ‘CHROMATOGRAPHY’. 
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2. CHROMATOGRAPHY 
 In 1906, the Russian botanist M.S. Tswett reported separation of different colored 
constituents of extract of green leaves into a series of colored bands by allowing a solvent 
to percolate through column bed of powdered calcium carbonate [1]. He termed this 
technique as ‘chromatography’ from the Greek words meaning ‘color (chroma)’ and 
‘writing (graphy)’. As a matter of above fact, chromatography owes its origin to the 
efforts of him. Tswett’s this technique was virtually unnoticed in the literature until the 
early 1940s, when the well-known paper of Martin and Synge was published [2]. They 
reported the discovery of liquid-liquid partition chromatography, both on columns and on 
paper. They also provided a theoretical frame work for the basic chromatographic 
process, and they received the Nobel Prize in chemistry in 1952 for their work. The next 
major step that led to progress in this field was the development of gas-liquid 
chromatography by James and Martin [3]. The success of modern chromatography is 
greatly due to the excellent extensive treatment of chromatographic theory by Giddings in 
1965 through his book entitled Dynamics of Chromatography [4].
  
Afterwards, a number 
of well-known scientists whose contributions are too numerous to be recounted here, and 
their work has led to the development of modern liquid chromatography, which is often 
called high-pressure or high-performance liquid chromatography. This technique is also 
called as HPLC, or simply LC. 
General classification of chromatographic methods is as below [5]: 
1) Column chromatography 
2) Paper chromatography 
3) Thin-layer chromatography 
4) Gas chromatography 
5) High pressure liquid chromatography 
6) Ion-exchange chromatography 
7) Gel filtration chromatography 
8) Supercritical fluid chromatography 
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2.1 High-Performance Liquid Chromatography [6,7] 
 Based on the preceding discussion, chromatography can be simply defined as: 
‘Chromatography is the technique in which the components of a mixture are separated 
based upon the rates at which they are distributed through two phases, one of which does 
not move (stationary phase) and the other that moves (mobile phase)’. When mobile 
phase is liquid, this technique is known as ‘liquid chromatography’. Liquid 
chromatography (LC) is a method of chromatographic separation based on the difference 
in the distribution of species between two non-miscible phases, in which the mobile phase 
is a liquid which percolates through a stationary phase contained in a column. It is mainly 
based on mechanisms of adsorption, mass distribution, ion exchange, size exclusion or 
stereochemical interaction. Early liquid chromatography is carried out in long glass 
columns with wide diameter. Nowadays with the help of advent of latest technology, the 
particle diameters were reduced as small as to below 10 µm with replacement of glass 
columns to steel ones. The flow rate of the mobile phase was improved by applying high 
pressure to the column using pumps and hence the performance was improved. This 
development led to be mostly called as ‘high-performance liquid chromatography’ or 
‘high-pressure liquid chromatography’ (HPLC). 
 HPLC is most widely used analytical separation technique that offers major 
improvements over the old chromatography.  The technique is more popular because it is 
non-destructive and may be applied to thermally liable compounds (unlike GC). HPLC is 
ideally suitable for the separation of macromolecules and ionic species of biomedical 
interest, liable natural products, and diverse less stable and/or high molecular weight 
compounds. The   majority of difficult separations are often more readily attained by 
HPLC because both phases used in HPLC participate in the chromatographic process (as 
opposed to only one in GC) to increase more selective interactions with the sample 
molecule. Short, small-bore columns containing densely packed particles of stationary 
phase provide for the rapid exchange of compounds between the mobile and stationary 
phases. A large variety of unique column packings (stationary phase) provide a wide 
range of selectivity to separation through HPLC. HPLC also offers wide choice of 
detection methods as number of unique detectors are available. HPLC can easily be 
extended to trace determination of compounds which do not usually provide adequate 
detector response with the use of post-column derivatization methods that improve 
selectivity and detection limits. Facility to arrange gradient flow of mobile phase is often 
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use during method development and it is also provide the possibility to achieve difficult 
separation in reduced run-time. HPLC contains automatic instrumentation and calculation 
which is carried out by integrator itself that offers saving of manual labor. In addition to 
receiving and reporting detector output, computers are used to control chromatographic 
settings and operations, thus providing for long periods of unattended operation. All these 
advantages make HPLC more efficient over the all remaining chromatographic 
techniques in case of separation, speed, sensitivity, easy sample recovery, automation, 
integration, handling and maintenance. The wide applicability of HPLC makes it as a 
most important separation tool in scientific the field of analysis. 
 
 
2.1.1 Instrumentation of HPLC 
 
A schematic instrumentation of HPLC is given through Figure 1 as under: 
 
 
 
Figure 1: A schematic instrumentation of HPLC equipment 
 
 A liquid chromatograph consists of a reservoir containing the mobile phase, a 
pump to force the mobile phase through the system at high pressure, an injector to 
introduce the sample into the mobile phase, a chromatographic column (a column 
temperature controller may be also used) to attain retention, a detector to detect analyte 
response, and a data collection device such as a computer, integrator, or recorder. Further, 
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in some cases, degasser with vacuum pump and pre-column facility can implement in the 
modern HPLC, presented in Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Designing of HPLC path 
 
 
A brief introduction of HPLC components is given as under: 
(a) Pumping systems 
 HPLC pumping system delivers measured amounts of mobile phase from the 
solvent reservoirs to the column through high-pressure tubing and fittings. Operating 
pressures up to 5000 psi or higher, with delivery rates up to about 10 ml/minute is typical. 
Pumps used for quantitative analysis should be constructed of materials that inert to 
corrosive mobile phase components and be capable of delivering the mobile phase at a 
constant rate with minimal fluctuations over extended periods of time. Modern systems 
consist of microprocessor controlled metering pumps that can be programmed to deliver 
either constant (isocratic) flow of mobile phase or vary the ratio of mobile phase 
components, as is required for gradient run. Advanced pumping system is equipped with 
a degasser to remove dissolved air and other gases from the solvent through solvent 
delivery system.  
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(b) Injectors 
 After dissolution in mobile phase or suitable diluent, compounds to be 
chromatographed are injected into the mobile phase, either manually by syringe/loop 
injectors or automatically by autosampler. Autosampler consist of a carousel or rack to 
hold sample vials with tops that have a pierceable septum or stopper and an injection 
device to transfer sample from the vials to a loop from which it is loaded into the 
chromatograph. Autosampler can be programmed to control sample volume, the number 
of injections, the interval between injections and rinse cycles.  
 
(c) Columns [8-16] 
 The column is usually made up of stainless steel to withstand high pressure. 
Columns used for analytical separations usually have 10-30 cm length and 4-10 mm 
inside diameter containing stationary phase having particle diameter of 3-10 µm. Particles 
may range up to 50 µm or more for preparative columns. Stationary phases for modern, 
reverse-phase liquid chromatography typically consist of an organic phase chemically 
bound to silica or other materials. Small particles thinly coated with organic phase 
provide for low mass transfer resistance and, hence, rapid transfer of compounds between 
the stationary and mobile phases. Columns may be heated to give more efficient 
separations, but only rarely are they used at temperatures above 60 °C. Unmodified silica, 
porous graphite or polar chemically modified silica, e.g. cyanopropyl or diol, used as the 
stationary phase for normal-phase liquid chromatography. 
Most of separations for reversed-phase liquid chromatography are based upon partition 
mechanisms that utilize chemically modified silica as the stationary phase and polar 
solvents as the mobile phase. The surface of the support, e.g. the silanol groups of silica, 
is reacted with various silane reagents to produce covalently bound silyl derivatives 
covering a varying number of active sites on the surface of the support. The nature of the 
bonded phase is an important parameter for determining the separation properties of the 
chromatographic system.  
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Commonly used bonded phases are shown below:  
Octyl (C8)  = Si-[CH2]7-CH3     
Octadecyl (C18) = Si-[CH2]17-CH3     
Phenyl (C6H5)  = Si-[CH2] n -C6H5     
Cyanopropyl (CN) = Si-[CH2]3-CN     
Aminopropyl (NH2) = Si-[CH2]3-NH2     
Diol (OH)  = Si-[CH2]3-O-CH(OH)-CH2-OH   
 
 In ion-exchange chromatography, the stationary phases are usually synthetic 
organic resins; cation-exchange resins contain negatively charged active sites and is used 
to separate basic substances, while anion-exchange resins have positively charged active 
sites for separation of compounds with negatively charged groups. Water-soluble ionic or 
ionizable compounds are attracted to the resins, and differences in affinity bring about the 
chromatographic separation.  
 In size-exclusion chromatography, columns are packed with a porous stationary 
phase. Smaller molecules enter the pores and are increasingly retained as molecular size 
decreases. These columns are typically used to measure aggregation and degradation of 
large molecules. 
 For chiral chromatography, special chemically modified stationary phases, e.g. 
cellulose or amylose derivatives, proteins or peptides, cyclodextrins etc., use for the 
separation of enantiomers. 
 
(d) Detectors [17-22] 
 UV/Visible spectrophotometers, including diode array detectors, are the most 
commonly employed detectors. Fluorescence spectrophotometers, differential 
refractometers, electrochemical detectors, mass spectrometers, light scattering detectors, 
radioactivity detectors or other special detectors may also be used. 
 Detector consists of a flow-through cell mounted at the end of the column. A 
beam of UV radiation passes through the flow cell and into the detector. As compounds 
elute from the column, they pass through the cell and absorb the radiation, resulting in 
measurable energy level changes. Fixed (mercury lamp), variable (deuterium or high-
pressure xenon lamp), and multi-wavelength detectors are widely available. Modern 
variable wavelength detectors can be programmed to change wavelength while an 
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analysis is in progress. Multi-wavelength detectors measure absorbance at two or more 
wavelengths simultaneously. In diode array multi-wavelength detectors, continuous 
radiation is passed through the sample cell, and then resolved into its constituent 
wavelengths, which are individually detected by the photodiode array. These detectors 
acquire absorbance data over the entire UV-visible range, thus providing the analyst with 
chromatograms at multiple, selectable wavelengths, spectra of the eluting peaks and also 
peak purity.  
 Differential refractometer detectors measure the difference between the refractive 
index of the mobile phase alone and that of the mobile phase containing chromatographed 
compounds as it emerges from the column. Refractive index detectors are used to detect 
non-UV absorbing compounds. 
Fluorometric detectors are sensitive to compounds that are inherently fluorescent or that 
can be converted to fluorescent derivatives either by chemical transformation of the 
compound or by coupling with fluorescent reagents at specific functional groups.  
 Potentiometric, voltametric, or polarographic electrochemical detectors are useful 
for the quantitation of species that can be oxidized or reduced at a working electrode. 
These detectors are selective, sensitive, and reliable, but require conducting mobile 
phases free of dissolved oxygen and reducible metal ions. Electrochemical detectors with 
carbon-paste electrodes may be used advantageously to measure nanogram quantities of 
easily oxidized compounds, notably phenols and catechols.  
 
(e) Data collection devices 
 Modern data stations receive and store detector output and print out 
chromatograms complete with peak heights, peak areas, sample identification, and 
method variables. They are also used to program the liquid chromatograph, controlling 
most of variables and providing for long periods of unattended operation. 
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2.1.2 Modes of HPLC 
Various modes of HPLC utilized to separate compounds are classified as follows: 
 
1. Adsorption chromatography 
2. Normal-phase chromatography 
3. Reversed-phase chromatography 
4. Ion-pair chromatography 
5. Ion-exchange chromatography 
6. Size exclusion chromatography 
 
1. Adsorption chromatography 
 Adsorption chromatography uses polar stationary phases with relatively nonpolar 
mobile phases. Separations in adsorption chromatography result to a great extent from the 
interaction of sample polar functional groups with discrete adsorption sites on the 
stationary phase. Adsorption chromatography is usually considered appropriate for the 
separation of nonionic molecules that are soluble in organic solvents. 
 
2. Normal-phase chromatography 
 In HPLC, if stationary phase is more polar than the mobile phase, it is termed as 
normal-phase liquid chromatography. Polar bonded phases that have a diol, cyano, 
diethylamino, amino, or diamino functional groups are used as stationary phase in 
normal-phase chromatography. Due to lower affinity of nonpolar compounds to the 
stationary phases used, nonpolar compounds are elute first while polar compounds are 
retained for longer time. Normal-phase chromatography is widely applied for chiral 
separations. 
 
3. Reversed-phase chromatography 
 In HPLC, if stationary phase is less polar than the mobile phase, it is termed as 
reversed-phase liquid chromatography. In this technique, C18, C8, Phenyl, and cyano-
propyl functional groups that chemically bonded to microporous silica particles are used 
as stationary phase. Retention in reversed-phase chromatography occurs by nonspecific 
hydrophobic interactions of the solute with stationary phase. The ubiquitous application 
of reversed-phase chromatography arise from the fact that practically all organic 
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molecules have hydrophobic regions in their structures and effectively interact with the 
stationary phase. It is estimated that over 65% (possibly as high as 90%) of all HPLC 
separations are executed in the reversed-phase mode. The rationale for this includes the 
simplicity, versatility, and scope of the reversed-phase method [23].  
 
4. Ion-pair chromatography 
 Ionic or partially ionic compounds can be chromatographed on reversed-phase 
columns by using ion-pairing reagents. These reagents are typically long-chain alkyl 
anions or cations that, when used in dilute concentrations, can increase the retention of 
analyte ions. C-5 to C-10 alkylsulfonates are commonly used for cationic compounds 
while C-5 to C-8 alkyl ammonium salts are generally used in the cases of anionic solutes.  
 
5. Ion-exchange chromatography 
 Ion-exchange chromatography is an adaptable technique used primarily for the 
separation of ionic or easily ionizable species. The stationary phase is characterized by 
the presence of charged centers having exchangeable counterions. Both anions and 
cations can be separated by choosing the suitable ion-exchange medium. Ion-exchange 
chromatography employs the dynamic interactions between charged solute ions and 
stationary phases that have oppositely charged groups.   
 
6. Size exclusion chromatography 
 Size exclusion chromatography separates molecules according to their molecular 
mass. In size exclusion chromatography, column is filled with material having precisely 
controlled pore sizes and the sample is simply screened or filtered according to its 
solvated molecular size. Largest molecules are eluted first and the smallest molecules last. 
This method is generally used when a mixture contains compounds with a molecular 
mass difference of at least 10%. This mode can be further subdivided into gel permeation 
chromatography (with organic solvents) and gel filtration chromatography (with aqueous 
solvents).    
 
2.1.3 HPLC method development 
 A variety of patterns have been used to develop analytical separations. The 
discussion here is limited to conventional chromatographic approaches. These approaches 
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are advanced and often based on intuitive judgment and the knowledge of the 
chromatographer. Where as individual approaches may exhibit considerable diversity, 
method development often follows the series of steps summarized below. 
 Before starting the method development, it is need to review what is known about 
the sample. The aim of method development should also define at separation stage. The 
kinds of sample-related information that can be important that are nature of the sample, 
number of compounds present, chemical structure and molecular weight of the analytes, 
pKa values of the compounds, sample solubility and sample type (ionic or non-ioinic).      
 The choice of the mode of HPLC method should be made principally from the 
properties of the sample that has been determined about molecular weight (MW). On the 
basis of the solubility of the sample in polar or nonpolar solvents, mode of HPLC can be 
select as per below flow-chart: 
 
 
 
Sample 
MW > 
2000 
MW < 
2000 
Solvent: 
Organic 
Solvent: 
Water 
 
Solvent: 
Organic 
 
Solvent: 
Water 
 
Mode: 
Size Excl-
usion 
Mode: 
Gel per-
meation 
Type: 
Ionic 
Type: 
Non polar 
Type: 
Nonionic 
Type:  
Polar 
Mode: 
Reversed 
phase 
Mode: 
Reversed 
phase 
Mode: 
Ion-
exchange 
Mode: 
Reversed 
phase 
 
Mode: 
Normal 
phase 
Mode: 
Ion-pair 
 
Mode: 
Normal 
phase 
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 After selecting mode of HPLC, the choice of the column (stationary phase) should 
be made after thorough consideration of mode of chromatography, column-to-column 
variability, and a number of other considerations. The silica particles may be acquired in a 
variety of sizes, shapes, and degrees of porosity. In addition, various functional groups or 
polymeric layers can easily be attached to the silica surface, extending the usefulness of 
these particles for applications to any specific HPLC method. Sufficient time is also 
allowed for column equilibration before starting the analysis. 
 The selection of mobile phase is very important parameter in HPLC method 
development as the selectivity is altered by changing the mobile phase. When selecting 
organic solvents for use in mobile phases, various physical and chemical properties of the 
solvent should be consider. Selected solvent will have low viscosity, be compatible with 
the detection system, be easily available in pure form, and, if possible, have low 
flammability and toxicity. UV cutoff values of solvents are also important consideration 
from the standpoint of detection.  
 The term polarity concerns the ability of a sample or solvent molecule to interact 
by combination of dispersion, dipole, hydrogen boding, and dielectric interactions. The 
combination of these four intermolecular attractive forces constitutes the solvent polarity. 
Polarity is measure strength of solvent that affected selectivity. The changes in selectivity 
may be affected by making use of the following solvent properties: 
 Proton acceptors: amines, ethers, sulfoxides, amides, esters, and alcohols. 
 Proton donors: alcohols, carboxylic acids, phenols, and chloroform. 
 Large dipole solvents: methylene chloride, nitrites, sulfoxides, and ketones. 
  
 Application of reagents such as buffers, ion-pairing reagents, or other modifiers 
(such as triethylamine) to the mobile phase is carried out to improve reproducibility, 
selectivity, or peak shape. Buffers are used primarily to regulate the pH and the acid-base 
equilibrium of the solute in the mobile phase. They may also be utilized to affect the 
retention times of ionizable compounds. The buffer capacity should be at maximum and 
should not vary in the pH range of 2 to 8 commonly used in HPLC. The buffers should be 
soluble, stable, inert to analytes and compatible to the detector.   
 By employing gradient elution mode, required % of the organic phase can be 
estimated rapidly. For aqueous sample mixtures, the best way to start is with gradient 
reversed phase chromatography. Gradient run can be started with 5 to 10% organic phase 
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(acetonitrile or methanol) in the mobile phase and can be increased up to 90% within 30 
to 40 minutes. Separation can then be optimized by changing the initial mobile phase 
composition and the slope of the gradient according to the chromatogram obtained from 
the preliminary run. The initial mobile phase composition can be estimated on the basis of 
where the compounds of interest were eluted at what proportion of organic and aqueous 
component of the mobile phase. 
 For each samples, good analytical results will be obtained by careful selection of 
the wavelength used for detection. This choice requires known UV spectra of the sample. 
If analyte standards are available, their UV spectra can be measured prior to HPLC 
method development. Alternatively, PDA detector permits the acquisition of UV spectra 
for all sample components during method development. The wavelength chosen for 
detection must provide acceptable response by the various analytes in the sample and 
there is no interference of baseline noise. In most cases HPLC method development is 
carried out with UV detector. Alterative detectors are required when sample have low or 
no UV absorbance.  
 Diluent for test preparation shall be selected at initial stage of development on the 
basis of solubility of the drug. However, optimization of the diluent is based on its 
extraction efficiency, effect on peak symmetry, peak interference in estimation and 
stability of analyte in diluent. Test concentration and injection volume shall be set 
according to suitability with extraction process and detector response. Wherever it is 
necessary to filter the test preparation, filter compatibility shall be check for selection of 
proper type of filter.  
 To finalize HPLC method development, optimization can be started only after 
obtaining preliminary chromatogram that means with more or less symmetrical peaks of 
all analytes detected in the chromatogram. By slight change of the mobile phase 
composition, the position of the peaks can be predicted within the range of investigation. 
A finalized chromatographic condition is that one in which all the peaks having good 
theoretical plates are symmetrical and well separated in less run time in the produced 
chromatogram. With application of more specific column, good symmetry and resolution 
can be achieved. The parameters that are considered for good chromatographic condition 
and being optimized are:  
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1. Resolution (R) 
2. Theoretical plates (N)  
3. Tailing factor (T) 
4. Capacity factor (k’) 
5. Selectivity ( ) 
 
All above terms are explained according to figure 3 and figure 4 as below: 
 
Figure 3: Explanation for resolution, theoretical plates, capacity factor and selectivity 
 
Figure 4: Explanation for tailing factor 
 
1. Resolution (R) 
 Resolution expresses the separation of two components in a mixture that 
determined by the following equation: 
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R = 
12
12 )-(2
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tt
 
 
Where, t2 and t1 are the retention times of the two components, and W2 and W1 are the 
corresponding widths at the bases of the peaks obtained by extrapolating the relatively 
straight sides of the peaks to the baseline. 
 
Where electronic integrators are used, it may be convenient to determine the resolution, 
R, by the following equation. 
R = 
)WW(70.1
)-(2
2/12/2
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Where by h/2 1W  and h/2 2W  are the width at half-height of corresponding peaks. For better 
separation, the ideal value of R is 1.5 
 
2. Theoretical plates (N) 
  The number of theoretical plates is a measure of column efficiency. It is expressed 
by following equation. 
N = 
W
t
16
2
 =  
2/
2
54.5
hW
t
 
Where t is retention time of the peak and W is the with for the peak. Wh/2 is width at half-
height of the peak. Value of theoretical plates, higher than 4000 is indicating good 
column performance. 
 
3. Tailing factor (T) 
 The tailing factor (T) is a measure of peak symmetry. It is unity for perfectly 
symmetrical peak to value of 1.0 and its value increases as tailing becomes more 
pronounced. It is determined by following formula. 
T = 
f2
05.0W
 
 
Where by W0.05 is width of the peak at 5% height and f is distance from the peak 
maximum to the leading edge of the peak which being measured at a point of 5% of the 
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peak height from the baseline. In general, value of tailing factor should be less than 2.0 
 
4. Capacity Factor (k′) 
 Capacity factor is the ratio of the reduced retention volume to the dead volume. 
Capacity factor is a measure of how well the sample molecule is retained by a column 
during an isocratic separation. It is determined by using following formula. 
k′ = 
0
01
t
t-t
 
Where by t0 is the void volume of the column and t1 is the retention time of the 
corresponding peak. The ideal value of k′ ranges from 2-10.  
 
5. Selectivity ( ) 
 The selectivity is a measure of relative retention of two components in a mixture. 
Selectivity is the ratio of the capacity factors of both corresponding peaks. It can be 
calculated by following formula. 
 =  
01
12
t-t
t-t
 
Where by t0 is the void volume of the column and t1 and t2 are the retention times of the 
corresponding peak. The ideal value of  should not be less than 1.  
 
2.2 Analytical method validation   
 The developed analytical procedure used to measure the quality of pharmaceutical 
products. It is necessary to assure that the performance characteristics of the developed 
analytical procedure meet the requirements for the intended analytical application. The 
procedure which provides assurance for the same by the means of laboratory studies is 
defined as method validation. Method validation is the process of demonstrating that 
analytical procedures are suitable for their intended use and that they support the identity, 
strength and quality, for the quantification of the drug substances and drug products. 
 Method validation has received considerable attention in the literature and from 
industrial committees and regulatory agencies. The U.S. FDA CGMP[24] states for 
validation for the test methods employed by the firm. The U.S. FDA has also proposed 
industry guidance for Analytical Procedures and Methods Validation [25]. ISO/IEC 
17025 includes a chapter on the validation of methods [26] with list validation 
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parameters. The ICH [27] has developed a consensus text on the validation of analytical 
procedures. ICH also developed guidance with detailed methodology[28]. The U.S. EPA 
prepared guidance for method’s development and validation for the Resource 
Conservation and Recovery Act (RCRA) [29]. The AOAC, the EPA and other scientific 
organizations provide methods that are validated through multi-laboratory studies. The 
USP has published specific guidelines for method validation for compound evaluation 
[30]. The WHO published validation guidelines under the title, Validation of analytical 
procedures used in the examination of pharmaceutical materials in the 32
nd
 report of 
the WHO expert committee on specifications for pharmaceutical preparations. 
 Representatives of the pharmaceutical and chemical industry have published 
papers on the validation of analytical methods. Hokanson [31, 32]] applied the life cycle 
approach, developed for computerized systems, to the validation and revalidation of 
methods. Green [33] gave a practical guide for analytical method validation, with a 
description of a set of minimum requirements for a method. Wegscheider
34
 has published 
procedures for method validation with a special focus on calibration, recovery 
experiments, method comparison and investigation of ruggedness. Seno et. al. [35] have 
described how analytical methods are validated in a Japanese QC laboratory. The AOAC 
[36] has developed a Peer-Verified Methods validation program with detailed guidelines 
on exactly which parameters should be validated. Winslow and Meyer [37] recommend 
the definition and application of a master plan for validating analytical methods. J. 
Breaux and colleagues have published a study on analytical methods development and 
validation [38].  
 
2.2.1 Strategy for the validation of methods 
 Method development and validation are an iterative process. The influence of 
operating parameters on the performance of the method can be assessed at the validation 
stage which was not done during development/optimization stage of the method. The 
most significant point raised for validation is that the validity of a method can be 
demonstrated only through laboratory studies. It is not sufficient to simply review 
historical results; instead, laboratory studies must be conducted which are intended to 
validate the specific method, and those studies should be pre-planned and described in a 
suitable documentation. This documentation should clearly indicate the method's intended 
use and principles of operation, as well as the validation parameters to be studied, and a 
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rationale for why this method and these parameters were chosen. It also must include pre-
defined acceptance criteria and a description of the analytical procedure. 
 
2.2.2 Parameters for method validation 
  The parameters for method validation have been defined in different working 
groups of national and international committees and are described in the literature. An 
attempt at harmonization was made for pharmaceutical applications through the ICH [27-
28]. The defined validation parameters by the ICH and other regulatory bodies are 
summarized as under. 
(a) Specificity study 
(b) Linearity and range study 
(c) Limit of detection and  Limit of quantitation study  
(d) Precision study  
(e) Accuracy study  
(f) Robustness study 
(g) Solution stability study  
(h) System suitability  
 
A brief introduction of above parameters is as below: 
 
(a) Specificity study 
Specificity of an analytical method is its ability to measure accurately an analyte 
in the presence of interference, such as synthetic precursors, excipients, enantiomers and 
known (or likely) degradation products that may be expected to be present in the sample 
matrix. The term specificity is also referring to selectivity when a number of chemical 
entities that may or may not be distinguished from each other.  
  Specificity study should also assess interferences that may be caused by the 
matrix, e.g., urine, blood, soil, water or food. Optimized sample preparation can eliminate 
most of the matrix components, e.g. placebo. The absence of matrix interferences for a 
quantitative method should be demonstrated by the analysis of control matrix in 
specificity. An investigation of specificity should be conducted during the validation of 
identification tests, the determination of impurities and the assay. In order to check the 
interference of degradation products, analyte is forcefully subjected to chemical (acid, 
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alkali and oxidative) and physical (thermal and photolytic) degradation, known as stress 
application. In each stress application, peak purity of the analyte peak is also evaluated 
[39].  
 
(b) Linearity and range study 
 The linearity of an analytical method is its ability to elicit test results that are 
directly proportional to the concentration (amount) of analyte in samples within a given 
range. Linearity may be demonstrated directly on the test substance (by dilution of a 
standard stock solution) and/or by using separate weighings of synthetic mixtures of the 
test product components, using the proposed procedure. 
 Linearity is determined by replicate injections of 5 or more concentrations level 
within the range of 40–160 %. The response should be directly proportional to the 
concentrations of the analytes or proportional by means of a well-defined mathematical 
calculation. Linearity is evaluated graphically by plotting a graph of the relative responses 
on the y-axis and the corresponding concentrations on the x-axis. A linear regression 
equation is applied to the results to evaluate correlation coefficient. In addition, y-
intercept, slope of the regression line and residual sum of squares should also calculate.  
 The range of an analytical method is the interval between the upper and lower 
concentrations (amounts) of analyte in the sample (including these concentrations) for 
which it has been demonstrated that the analytical procedure has a suitable level of 
precision, accuracy and linearity. The range is normally expressed in the same units as the 
test results (e.g., percentage, parts per million) obtained by the analytical method. 
 
(c) Limit of detection (LOD) and Limit of quantitation (LOQ) study 
 The detection limit of an analytical method is the lowest amount of analyte in a 
sample which can be detected but not necessarily quantitated as an exact value. 
  In chromatography, the detection limit is the injected amount that results in a peak 
with a height at least two or three times as high as the baseline noise level. Besides this 
signal/noise method, LOD can be measured by another three different methods; (i) visual 
inspection (ii) standard deviation of the blank response (iii) standard deviation of the 
response based on the slope of the calibration curve.  
 The quantitation limit of an analytical method is the lowest amount of analyte in a 
sample which can be quantitated with suitable precision and accuracy.  
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 In chromatography, the quantitation limit is the minimum injected amount that 
produces quantitative measurements in the target matrix with acceptable precision, 
typically requiring peak heights 10 to 20 times higher than the baseline noise. Beside this 
signal/noise method, LOQ can be measured by another three different methods; (i) visual 
inspection (ii) standard deviation of the response (iii) standard deviation of the response 
based on the slope of the calibration curve.  
 
(d) Precision study 
  The precision of an analytical method expresses the closeness of agreement 
(degree of scatter) between a series of measurements obtained from multiple sampling of 
the homogeneous sample under the prescribed conditions.  
 The measurement of precision of an analytical method is performed on replicate 
standard preparations and replicate sample preparations. The results for the same are 
usually expressed as the variance, standard deviation or confidence level of a series of 
measurements. Precision is performed by means of repeatability, reproducibility and 
intermediate precision (ruggedness). 
 Repeatability expresses the precision under the same operating conditions over a 
short interval of time. Repeatability is also termed intra-assay precision.  
 Reproducibility expresses the precision between laboratories. The reproducibility 
of an analytical method is determined by analyzing aliquots from same homogeneous 
lots. 
 Intermediate precision expresses within-laboratories variations; different days, 
different analysts, different equipment, etc. The objective of intermediate precision 
validation is to verify that in the same laboratory the method will provide the same results 
once the development phase is over. The objective is also extent to verify that the method 
will provide the same results in different laboratories (ruggedness). 
 
(e) Accuracy study 
  The accuracy of the analytical method is the closeness of agreement between the 
value which is accepted either as a conventional true value or an accepted reference value, 
and the value found. The accuracy of an analytical method is the extent to which test 
results generated by the method and the true value agree. 
Introduction… 
 
 
 
32 
  The true value for accuracy assessment can be assessed by analyzing a sample 
with known concentrations (e.g., a control sample or certified reference material) and 
comparing the measured value with the true value as supplied with the material. If 
certified reference materials or control samples are not available, a blank sample matrix 
of interest can be spiked with a known concentration by weight or volume. After 
extraction of the analyte from the matrix and injection into the analytical instrument, its 
recovery can be determined by comparing the response of the extract with the response of 
the reference material dissolved in a pure solvent (without matrix). 
 The ICH document on validation methodology recommends accuracy to be 
assessed using a minimum of nine determinations over a minimum of three concentration 
levels covering the specified range (e.g., three concentrations/three replicates each). 
Accuracy should be reported as percent recovery by the assay of known added amount of 
analyte in the sample or as the difference between the mean and the accepted true value.  
 
(f) Robustness study 
 The robustness of an analytical method is a measure of its capacity to remain 
unaffected by small, but deliberate, variations in method parameters and provides an 
indication of its reliability during normal usage.  
 Robustness tests examine the effect that operational parameters have on the 
analysis results. For the determination of a method’s robustness, method parameters like 
pH, flow rate, column temperature, column lot or mobile phase composition, are varied 
within a realistic range, and the quantitative influence of the variables is determined. If 
the influence of the parameter is within a previously specified tolerance, the parameter is 
said to be within the method’s robustness range.  
 
(g) Solution stability study 
 Many solutes readily decompose prior to chromatographic investigations, for 
example, during the preparation of the sample solutions, extraction, cleanup, phase 
transfer or storage of prepared vials (in refrigerators or in an automatic sampler). Under 
these circumstances, method validation should investigate the stability of the analytes and 
standards in solution form (in analytical preparations). The standard and test preparations 
are stored up to specified period at specified temperature and its stability is evaluated by 
comparing solution preparations at different time intervals to that of initial. 
Introduction… 
 
 
 
33 
(h) System suitability study 
  In addition, prior to the start of laboratory studies to demonstrate method validity, 
some type of system suitability must be done to demonstrate that the analytical system is 
performing properly. System suitability should be determined by replicate analysis of the 
standard or reference solution. System suitability is considered appropriate when the 
RSD, theoretical plates, tailing factor and resolution parameters calculated on the results 
obtained at different time intervals, does not exceed more than of specified limit of the 
corresponding value of the system precision.  
 
2.2.1 Prior steps of validation 
 Prior to start method validation, validation aim should be a well-planned 
according to scientific soundness and completeness with pre-defined acceptance criteria. 
Because the type of analysis and the other information of a sample have so much 
influence on the validation, the objective and scope of the method should always be 
defined as the first step of any method validation. For an efficient validation process, it is 
of utmost importance to specify the right validation parameters.  
 Subsequent to the execution of the validation, results, conclusions and deviations 
should present in report. Provided the pre-defined acceptance criteria are met, and the 
deviations (if any) do not affect the scientific interpretation of the data, then the 
developed analytical method can be considered as valid. 
Introduction… 
 
 
 
34 
3. OBJECTIVE OF THE WORK 
The specific and main objectives of the work are:  
[Part A] 
Section I: Development and validation of a stability indicating HPLC assay method for 
determination of warfarin sodium in tablet formulation. 
Section II: Development and validation of HPLC assay method for determination of 
chlorhexidine gluconate and lidocaine hydrochloride in throat spray in presence of 
degradation product formed under ICH recommended stress condition. 
[Part B] 
Development and validation of stability indicating UPLC method for determination of 
chlorhexidine gluconate and lidocaine hydrochloride in throat spray in presence of 
degradation product formed under ICH recommended stress condition. 
[Part C]  
Gas chromatographic method development and validation of assay method for the 
determination of Ticlopidine hydrochloride in tablets formulation 
[Part D]  
UV spectrophotometric method development and validation of assay method for the 
determination  of Spironolactone and furosemide in combined dosage form 
 
3.1 Instruments used for whole research work 
3.1.1 Chromatographic system 
 The chromatographic system used to perform development and validation of this 
assay method was comprised of a LC-10ATvp binary pump, a SPD-M10Avp photo diode 
array detector and a rheodyne manual injector model 7725i with 20μl loop (Shimadzu, 
Kyoto, Japan) connected to a multi-instrument data acquisition and data processing 
system (Class-VP 6.13 SP2, Shimadzu) and the UPLC system of Waters Acquity 
consisting of PDA detector with Empower2 software, Shimadzu GC-14B, Gas 
chromatographic system is also used with Winchrom99 data processing system  
 
3.1.2 Spectrophotometer system 
 The spectrophotometer system used to perform development and validation of 
assay method was model Phamaspec-UV-1700, Shimadzu, Kyoto, Japan, with data 
processing system (UV probe, Shimadzu). 
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SECTION I: DEVELOPMENT AND VALIDATION OF A STABILITY 
INDICATING HPLC ASSAY METHOD FOR DETERMINATION OF WARFARIN 
SODIUM IN TABLET FORMULATION. 
 
1. INTRODUCTION OF WARFARIN SODIUM 
Warfarin (also known under the brand names Coumadin, Jantoven, Marevan, 
Lawarin, and Waran) is an anticoagulant. The name warfarin stems from the acronym 
WARF, for Wisconsin Alumni Research Foundation + the ending -arin indicating its link 
with coumarin. 
1.1 Description 
Chemically, warfarin is (RS)-4-hydroxy- 3-(3- oxo- 1-phenylbutyl)- 2H- chromen- 2-
one sodium salt [Figure 1] Warfarin was first registered for use as a rodenticide in the US in 
1948, and was immediately popular; although it was developed by Link, the warfarin 
financially supported the research and was assigned the patent  [1]. 
O O
O CH3
O
Na
 
Figure 1: (RS)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one sodium salt 
 
A few years after its introduction, warfarin was found to be effective and relatively 
safe for preventing thrombosis and embolism (abnormal formation and migration of blood 
clots) in many disorders. It was approved for use as a medication in the early 1950s and has 
remained popular ever since; warfarin is the most widely prescribed anticoagulant drug in 
North America [2]. 
Despite its effectiveness, treatment with warfarin has several shortcomings. Many 
commonly used medications interact with warfarin, as do some foods, and its activity has to 
be monitored by frequent blood testing for the international normalized ratio (INR) to ensure 
an adequate yet safe dose is taken.  
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Warfarin is a synthetic derivative of dicoumarol, a 4-hydroxycoumarin-derived 
mycotoxin anticoagulant found in spoiled clover-based animal feeds. Warfarin and related 4-
hydroxycoumarin-containing molecules decrease blood coagulation by inhibiting vitamin K 
epoxide reductase, an enzyme that recycles oxidized vitamin K to its reduced form after it 
has participated in the carboxylation of several blood coagulation proteins, mainly 
prothrombin and factor VII. For this reason, drugs in this class are also referred to as vitamin 
K antagonists  [3]. 
 
1.2 Pharmacokinetics 
Warfarin consists of a racemic mixture of two active enantiomers R- and S- forms 
each of which is cleared by different pathways. S-warfarin has five times the potency of the 
R-isomer with respect to vitamin K antagonism [4]. 
Warfarin is slower-acting than the common anticoagulant heparin, though it has a 
number of advantages. Heparin must be given by injection, whereas warfarin is available 
orally. Warfarin has a long half-life and need only be given once a day. Heparin can also 
cause a prothrombotic condition, heparin-induced thrombocytopenia (an antibody-mediated 
decrease in platelet levels), which increases the risk for thrombosis. It takes several days for 
warfarin to reach the therapeutic effect since the circulating coagulation factors are not 
affected by the drug (thrombin has a half-life time of days). Warfarin's long half life means 
that it remains effective for several days after it was stopped. Furthermore, if given initially 
without additional anticoagulant cover, it can increase thrombosis risk.  
 
1.3 Mechanism of action 
Warfarin inhibits the vitamin K-dependent synthesis of biologically active forms of 
the calcium-dependent clotting factors II, VII, IX and X, as well as the regulatory factors 
protein C, protein S, and protein Z [3, 5]. Other proteins not involved in blood clotting, such 
as osteocalcin, or matrix Gla protein, may also be affected. 
The precursors of these factors require carboxylation of their glutamic acid residues 
to allow the coagulation factors to bind to phospholipid surfaces inside blood vessels, on the 
vascular endothelium. The enzyme that carries out the carboxylation of glutamic acid is 
gamma-glutamyl carboxylase. The carboxylation reaction will proceed only if the 
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carboxylase enzyme is able to convert a reduced form of vitamin K (vitamin K 
hydroquinone) to vitamin K epoxide at the same time. The vitamin K epoxide is in turn 
recycled back to vitamin K and vitamin K hydroquinone by another enzyme, the vitamin K 
epoxide reductase (VKOR). Warfarin inhibits epoxide reductase [6] (specifically the 
VKORC1 subunit [7, 8], thereby diminishing available vitamin K and vitamin K 
hydroquinone in the tissues, which inhibits the carboxylation activity of the glutamyl 
carboxylase. When this occurs, the coagulation factors are no longer carboxylated at certain 
glutamic acid residues, and are incapable of binding to the endothelial surface of blood 
vessels, and are thus biologically inactive. As the body's stores of previously-produced active 
factors degrade (over several days) and are replaced by inactive factors, the anticoagulation 
effect becomes apparent. The coagulation factors are produced, but have decreased 
functionality due to undercarboxylation; they are collectively referred to as PIVKAs 
(proteins induced by vitamin K absence/antagonism), and individual coagulation factors as 
PIVKA-number (e.g. PIVKA-II). The end result of warfarin use, therefore, is to diminish 
blood clotting in the patient. 
When warfarin is newly started, it may promote clot formation temporarily. This is 
because the level of protein C and protein S are also dependent on vitamin K activity. 
Warfarin causes decline in protein C levels in first 36 hours. In addition, reduced levels of 
protein S lead to a reduction in activity of protein C (for which it is the co-factor) and 
therefore reduced degradation of factor Va and factor VIIIa. Although loading doses of 
warfarin over 5 mg also produce a precipitous decline in factor VII, resulting in an initial 
prolongation of the INR, full antithrombotic effect does not take place until significant 
reduction in factor II occurs days later. The hemostasis system becomes temporarily biased 
towards thrombus formation, leading to a prothrombotic state. Thus, when warfarin is loaded 
rapidly at greater than 5 mg per day, it is beneficial to co-administer heparin, an 
anticoagulant that acts upon antithrombin and helps reduce the risk of thrombosis, with 
warfarin therapy for four to five days, in order to have the benefit of anticoagulation from 
heparin until the full effect of warfarin has been achieved [9, 10]. 
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1.4 Drug interactions 
Warfarin interacts with many commonly-used drugs, and the metabolism of warfarin 
varies greatly between patients. Some foods have also been reported to interact with warfarin 
[2]. Apart from the metabolic interactions, highly protein bound drugs can displace warfarin 
from serum albumin and cause an increase in the INR  [11]. This makes finding the correct 
dosage difficult, and accentuates the need of monitoring; when initiating a medication that is 
known to interact with warfarin (e.g. simvastatin), INR checks are increased or dosages 
adjusted until a new ideal dosage is found. 
Many commonly-used antibiotics, such as metronidazole or the macrolides, will 
greatly increase the effect of warfarin by reducing the metabolism of warfarin in the body. 
Other broad-spectrum antibiotics can reduce the amount of the normal bacterial flora in the 
bowel, which make significant quantities of vitamin K, thus potentiating the effect of 
warfarin. [12]. In addition, food that contains large quantities of vitamin K will reduce the 
warfarin effect. [2] Thyroid activity also appears to influence warfarin dosing requirements; 
[13] hypothyroidism (decreased thyroid function) makes people less responsive to warfarin 
treatment, [14] while hyperthyroidism (overactive thyroid) boosts the anticoagulant effect. 
[15] Several mechanisms have been proposed for this effect, including changes in the rate of 
breakdown of clotting factors and changes in the metabolism of warfarin [16]. 
 
Use as pesticides 
Coumarins are used as rodenticides for controlling rats and mice in residential, 
industrial, and agricultural areas. Warfarin is both odorless and tasteless, and is effective 
when mixed with food bait, because the rodents will return to the bait and continue to feed 
over a period of days until a lethal dose is accumulated. It may also be mixed with talc and 
used as a tracking powder, which accumulates on the animal's skin and fur, and is 
subsequently consumed during grooming. The LD50 is 50–500 mg/kg. The IDLH value is 
100 mg/m³ (warfarin; various species) [17]. 
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2. LITERATURE REVIEW 
The literature reviews regarding warfarin sodium suggest that various analytical 
methods were reported for its determination as drug, in pharmaceutical formulation and in 
various biological fluids. The literature reviews for analysis of warfarin sodium are as under. 
 
2.1 Brubaker, Abram and his bioanalytical group have initiated a program designed to 
support anticoagulant types of drug-drug interaction studies utilizing chiral chromatography 
to separation and quantify R- and S-warfarin in clinical plasma samples.  A 100 µL aliquot of 
sample and 50 µL of working internal standard (warfarin-d5) solution were added to each 
well of 96-well plate followed by addition of 300 µL of aqueous formic acid (5% v/v).  The 
mixture was passed through a Waters Oasis MCX 96-well plate. Warfarin and internal 
standard were eluted from the neutral phase of the mixed mode bed using 500 µL of 5% 
formic acid in H2O/ACN (2:8, v/v) [18]. 
2.2 Kurihara, Yuko; Onoda, Motoshi; Takezawa, Masaaki; Dohiguchi, Yasuo; 
Uesugi, Keizo has developed an LC/MS/MS method for assay of four warfarin 
monohydroxylated metabolites and warfarin enantiomers in human plasma.  Preparation of 
samples from 0.05 ml of plasma involved simple protein precipitation. using hydrochloric 
acid/acetonitrile. Analytes remained stable during sample processing and storage.  
Chromatographic separation was conducted using a chiral (CHIROBIOTIC V) column and 
an achiral (Symmetry Shield RP18) column [19]. 
2.3 Locatelli, Igor; Kmetec, Vojko; Mrhar, Ales; Grabnar, Iztok has developed an 
HPLC methods with UV detection for measuring warfarin enantiomers and all five warfarin 
monohydroxylated metabolites in patient blood plasma.  Following liq./liq. extraction from 1 
ml of blood plasma a baseline separation of analytes was achieved on chiral (AGP) and 
achiral (C18) column.  Both methods were consistent (R.S.D. < 6.9% for warfarin 
enantiomers and < 8.9% for monohydroxylated metabolites) and linear (r > 0.998) [20]. 
2.4 Mohamed A El Dawy, Mokhtar M Mabrouk, Riad A El Barbary have developed 
a spectrofluorimetric method for the determination of drugs containing active methylene 
groups adjacent to carbonyl groups. The method was applied successfully to commercial 
tablets, and in spiked human plasma samples. The method involves the reaction of warfarin 
sodium with 0.2 ml (0.4 x 10
-3
M) N1-methylnicotinamide chloride reagent in the presence of 
HPLC…   Part-A (Section-I) 
 
 
 
43 
3 ml 1.0 N NaOH and cooling in ice for 8 minutes, followed by adjustment of the pH to 2.0, 
using formic acid and heating for 4 min, whereby a highly fluorescent reaction product is 
produced [21]. 
2.5 Ring, P. R.; Bostick, J. M. have developed a chiral HPLC method for the 
determination of (R) and (S)-warfarin in human plasma. (R)- and (S)- warfarin and the 
internal standard (oxybenzone) were extracted. A 50 µl aliquot was injected onto the HPLC 
system.  Separation was achieved on a β -cyclodextrin column (250x4.6 mm, 5 µm) with a 
mobile phase composed of acetonitrile:glacial acetic acid:triethylamine (1000:3:2.5, 
vol./vol./v).  Detection was by UV absorbance at 320 nm [22]. 
2.6 Weng Naidong, Jean W. Lee have developed an HPLC method for the quantitation 
of warfarin enantiomers in human. Baseline separation of S- and R-warfarin was achieved on 
a silica-bonded β-cyclodextrin column with a mobile phase of acetonitrile—acetic acid—
triethylamine (1000:3:2.5, v/v/v). The detection was performed at 320 nm with run time of 
25 min [23]. 
2.7 Weng Naidong and co-workers developed an LC-MS-MS method for the 
measurement of warfarin (WAR) enantiomers (R-WAR and S-WAR) in human plasma. 
Baseline resolution of S- and R-WAR as well as the internal standard enantiomers (S- and R-
p-ClWAR, S-IS and R-IS) was achieved on a β-cyclodextrin column with a mobile phase of 
acetonitrile–acetic acid–triethylamine (1000:3:2.5, v/v/v) [24]. 
2.8 Jingguo Hou, Jie Zheng, Shahab A. Shamsi have developed a chiral Micellar 
Electrokinetic Chromatography–Mass Spectrometry (MEKC–MS) method. By using a 
polymeric chiral surfactant, polysodium N-undecenoyl-l,l-leucyl-valinate (poly-l,l-SULV), as 
a pseudostationary phase for the chiral separation of (±)-warfarin (WAR) and (±)-coumachlor 
(COU, internal standard). Under optimum MEKC–MS conditions, the enantio-separation of 
both (±)-WAR and (±)-COU was achieved within 23 min [25]. 
2.9 Huang, Chenrong; Yang, Jian; Du, Yonghong; Miao, Liyan have reported a 
method of free warfarin in human plasma by UPLC-MS/MS. The plasma filtrate extracted by 
a liquid/liquid extraction (LLE) with ethyl acetate. The chromatographic separation was 
performed on an Acquity UPLC™ BEH C18 (2.1 mm x 50 mm, 1.7 μm, Waters) with a 
mobile phase consisting of 0.1% formic acid/ acetonitrile (50:50, v/v). The analysis were 
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carried out by multiple reaction monitoring (MRM) using the precursor-to-product 
combinations of m/z 307.3-161.2 for warfarin and m/z 347.2→161.3 for Cl-War [26]. 
2.10 T. J. McCormick; A. B. Gibson; F. J. Diana have developed a dissolution method 
for warfarin sodium-aspirin combination which utilizes USP apparatus 1 (baskets) at 50 rpm 
with 900 ml of phosphate buffer (pH 6.8; 0.05 M) medium at 37 ˚C. A reversed-phase liquid 
chromatographic method was also developed for the simultaneous determination of warfarin 
sodium, aspirin and salicylic acid on an octadecylsilica column using acetonitrile-
tetrahydrofuran-glacial acetic acid-water (23:5:5:67, v/v/v/v) as the mobile phase with UV 
detection at 282 nm [27]. 
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3. AIM OF PRESENT WORK 
Literature review reveals that various analytical methods like LC-MS-MS, Chiral 
HPLC, Micellar electrokinetic Mass spectrometry, UPLC-MS-MS and Dissolution methods 
are reported for the determination of warfarin in pharmaceutical formulations and in 
biological fluids. These methods applied to the pharmacokinetic studies of warfarin sodium. 
So far to our present knowledge, no validated stability indicating HPLC assay method for the 
determination of warfarin sodium in pharmaceutical formulation was available in literature. 
Present work deals with the forced degradation of warfarin sodium under stress condition 
like acid hydrolysis, base hydrolysis, oxidation, thermal and photolytic stress. This work also 
deals with the validation of the developed method for the assay of warfarin sodium from its 
formulations (tablets). Hence, the method is recommended for routine quality control 
analysis and also stability sample analysis. 
 
The aim and scope of the proposed work are as under: 
 To developed suitable HPLC method for warfarin sodium. 
 Forced degradation study of warfarin sodium under stress condition 
 To resolve all major impurities generated during the force degradation studies of 
warfarin sodium. 
 Perform the validation for the developed method. 
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4. EXPERIMENTAL 
4.1 Materials  
Warfarin sodium standard was provided by Luotian Hengxingyuan Chemical Co. Ltd, 
China. Tablets containing warfarin sodium 5 mg and the inactive ingredient used in drug 
matrix were obtained from market. Analytical grade sodium hydrogen phosphate dibasic 
dihydrate was purchased from Sisco Research Pvt. Ltd., Mumbai (India). HPLC grade 
acetonitrile was obtained from Spectrochem Pvt. Ltd., Mumbai (India). MiliQ (Milipore 
India (Pvt) Limited) water purification system is used to obtain HPLC grade water. 
Analytical grade hydrochloric acid, orthophosphoric acid, sodium hydroxide pellets and 30% 
v/v hydrogen peroxide solution were obtained from RANKEM, New Delhi (India).  
 
4.2 Instrumentation 
The chromatographic system used to perform development and validation of this 
assay method was comprised of a LC-10ATvp binary pump, a SPD-M10Avp photodiode-
array detector and a rheodyne manual injector model 7725i with 20μl loop (Shimadzu, 
Kyoto, Japan) connected to a multi-instrument data acquisition and data processing system 
(Class-VP 6.13 SP2, Shimadzu).  
 
4.3 Mobile phase preparation 
The mobile phase consisted of acetonitrile – 50 mM sodium hydrogen phosphate 
dibasic dihydrate buffer pH 3.0 (50:50, v/v). Buffer solution was prepared by dissolving 8.9 g 
sodium hydrogen phosphate dibasic dihydrate in 900 ml HPLC grade water and adjusted to 
pH 3.0 with orthophosphoric acid and final volume was made upto 1000 ml with HPLC 
grade water. Mobile phase was filtered through a 0.45 μm nylon membrane (Millipore Pvt. 
Ltd. Bengaluru, India) and degassed for 15 minutes in an ultrasonic bath. HPLC grade water 
was used as diluent. 
 
4.4 Standard preparation  
A Warfarin sodium standard solution containing 100μg/ml was prepared in a 100 ml 
volumetric flask by dissolving 10.00 mg of warfarin sodium in diluent and diluted to volume 
with diluent.  
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4.5 Test preparation  
Twenty tablets were weighed and the average weight of tablet was determined. From 
that, five tablets were weighed and transferred into a 250 ml volumetric flask. About 50 ml 
diluent was added and sonicated for a minimum 30 minutes with intermittent shaking. Then 
content was brought back to ambient temperature and diluted to volume with diluent. The 
sample was filtered through 0.45μm nylon syringe filter. The concentration obtained was 100 
μg/ml of warfarin sodium.  
 
4.6 Chromatographic conditions  
Chromatographic analysis was performed on a SGE make SS Wakosil II 5C8RS 
column (150mm x 4.6mm i.d., 5 μm particle size). The flow rate of the mobile phase was 
adjusted to 1.0 ml/min and the injection volume was 20 μl. Detection was performed at 
280nm on a photo diode array (PDA) detector.  
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5.  RESULT AND DISCUSSION 
5.1 Development and optimization of the HPLC method 
 Proper selection of the methods depends upon the nature of the sample (ionic or 
ionisable or neutral molecule), its molecular weight and solubility. Warfarin sodium is 
soluble in polar solvent therefore reversed phase mode of HPLC was chosen. To develop a 
rugged and suitable HPLC method for the quantitative determination of warfarin sodium, the 
analytical conditions were selected after testing the different parameters such as diluents, 
buffer, buffer concentration, organic solvent for mobile phase and mobile phase composition 
and other chromatographic conditions. Our preliminary trials using different composition of 
mobile phases consisting of water with methanol or acetonitrile, did not give good peak 
shape.  
 By using 50 mM disodium hydrogen phosphate dihydrate buffer, adjusted to pH 3.0 
with orthophosphoric acid and keeping mobile phase composition as acetonitrile – 50mM 
sodium hydrogen phosphate dibasic dihydrate buffer pH 3.0 (50:50, v/v), best peak shape was 
obtained. For the selection of organic constituent of mobile phase, acetonitrile was chosen to 
reduce backpressure, the longer retention time and to achieve good peak shape. Figure 2 and 
3 represents wavelength selection and PDA scan of standard preparation. Figure 4 and Figure 
5 represents the chromatograms of standard and test preparation respectively. 
 
Figure 2: Wavelength selection of standard preparation 
HPLC…   Part-A (Section-I) 
 
 
 
49 
 
Figure 3: PDA scan of standard preparation 
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Figure 4: Chromatogram of standard preparation 
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Figure 5: Chromatogram of test preparation 
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5.2 Degradation study 
The degradation samples were prepared by transferring powdered tablets, equivalent 
to 10 mg Warfarin sodium into a 100 ml round bottomed flask. Then prepared samples were 
employed for acidic, alkaline and oxidant media and also for thermal and photolytic 
conditions. After the degradation treatments were completed, the stress content solutions 
were allowed to equilibrate to ambient temperature and diluted with mobile phase to attain 
100 μg/ml concentrations. Specific conditions were described as follows. 
 
5.2.1 Acidic condition 
Acidic degradation study was performed by heating the drug content in 0.1 N HCl at 
80° C for 1.5 hours and mixture was neutralized. Warfarin sodium was found stable in acidic 
condition (Figure 6). 
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Figure 6: Chromatogram of acidic forced degradation study 
 
5.2.2 Alkaline condition 
Alkaline degradation study was performed by keeping the drug content in 1 N NaOH 
at ambient temperature for 2 hours and mixture was neutralized. In alkali degradation, it was 
found that around 2% of the drug degraded (Figure 7). 
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Figure 7: Chromatogram of alkali forced degradation study 
 
5.2.3 Oxidative condition 
Oxidation degradation study was performed by keeping the drug content in 3% v/v 
H2O2 at ambient temperature for 1 hour. Minor degradation was found in oxidative condition 
that 5 % of the drug was degraded. The major impurity peaks was found at 2.6 and 3.8 min.  
(Figure 8) 
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Figure 8: Chromatogram of oxidative forced degradation study 
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5.2.4 Thermal condition 
Thermal degradation was performed by exposing formulation at 80 °C for 72 hours. 
Warfarin sodium is found to be stable under thermal degradation condition. There is no 
degradation observed in above specific thermal condition. (Figure 9) 
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Figure 9: Chromatogram of thermal degradation study 
5.2.5 Photolytic condition 
Photolytic degradation study was performed by exposing the drug content in UV-light 
for 72 hours. In photolytic degradation, it was found that around 6.2 % of the drug degraded. 
(Figure 8) 
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Figure 10: Chromatogram of UV-light degradation study 
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5.3 Method validation 
5.3.1 Specificity 
   The evaluation of the specificity of the method was determined against placebo and 
stress (forced degradation) application. The interference of the excipients of the claimed 
placebo present in the pharmaceutical dosage form was derived from placebo solution. 
Further the specificity of the method toward the drug was established by means of the 
interference of the degradation products against drug during the forced degradation study. 
 
5.3 Linearity 
Seven points calibration curve was obtained in a concentration range from 40-160 
μg/ml for warfarin sodium. The response of the drug was found to be linear in the 
investigation concentration range and the linear regression equation(y = mx + c) was y = 
49503136.60714x+158762.26786 with correlation coefficient 0.9995. (Figure 11) 
Chromatogram obtain during linearity study were shown in figure 12-18. 
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Figure 11: Linearity curve for warfarin sodium 
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Figure 12: Linearity study chromatogram of level-1 (40%) 
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Figure 13: Linearity study chromatogram of level-2 (60%) 
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Figure 14: Linearity study chromatogram of level-3 (80%) 
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Figure 15: Linearity study chromatogram of level-4 (100%) 
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Figure 16: Linearity study chromatogram of level-5 (120%) 
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Figure 17: Linearity study chromatogram of level-6 (140%) 
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Figure 18: Linearity study chromatogram of level-7 (160%) 
 
5.4 LOD and LOQ 
 The limit of detection and limit of quantification were evaluated by serial dilutions of 
warfarin sodium stock solution in order to obtain signal to noise ratio of 3:1 for LOD and 
10:1 for LOQ. The LOD value for warfarin sodium was found to be 0.25 µg/ml and the LOQ 
value 0.5 µg/ml. Chromatogram of LOD and LOQ study were shown in Figure 19-20. 
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Figure 19: Chromatogram of LOD study of warfarin sodium  
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Figure 20: Chromatogram of LOQ study of warfarin sodium 
 
5.5 Precision 
 The result of repeatability and intermediate precision study are shown in Table 1. The 
developed method was found to be precise as the %RSD values for the repeatability and 
intermediate precision studies were 0.22 % and 0.70 %, respectively, which confirm that 
method was precise. 
Table 1: Evaluation data of precision study. 
Set Intraday (n = 6) Interday (n = 6) 
1 100.8 101.1 
2 100.4 99.9 
3 100.3 100.9 
4 100.3 100.5 
5 100.7 99.5 
6 100.3 99.5 
Mean 100.5 100.2 
Standard deviation 0.23 0.70 
% RSD 0.22 0.70 
 
5.6 Accuracy  
  The HPLC area responses for accuracy determination are depicted in Table 2. The 
result shows the best recoveries (98.95 - 99.15 %) of the spiked drug were obtained at each 
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added concentration, indicating that the method was accurate. Chromatogram obtain during 
accuracy study were shown in figure 21-23. 
Table 2: Evaluation data of accuracy study. 
Level (%) 
 
Amount added 
concentration
 a
 
(mg/ml) 
Amount found 
concentration
 a
 
(mg/ml) 
% Recovery % RSD 
50 0.05240 0.05196 99.15 0.42 
100 0.10168 0.10076 99.09 0.17 
150 0.15067 0.14908 98.95 0.28 
a
 Each value corresponds to the mean of three determinations 
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Figure 21: Accuracy study chromatogram of level-1 (50%) 
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Figure 22: Accuracy study chromatogram of level-2 (100%) 
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Figure 23: Accuracy study chromatogram of level-3 (150%) 
 
5.7 Solution stability study 
  Table 3 shows the results obtain in the solution stability study at different time 
intervals for test preparation. It was concluded that the test preparation solution was found 
stable up to 48 h at 2 - 8 ˚C and ambient temperature, as during this time the result was not 
decrease below the minimum percentage. 
Table 3: Evaluation data of solution stability study 
Intervals 
% Assay for test 
preparation solution 
stored at 2-8 ˚C 
% Assay for test preparation 
solution stored at ambient 
temperature 
Initial -- 100.3 
12 h 99.5 99.4 
24 h 98.9 100.1 
36 h 100.3 99.2 
48 h 99.6 99.7 
 
5.8 Robustness 
  The results of robustness study of the developed assay method are presented in Table 
4. The result shows that during all variance conditions, assay value of the test preparation 
solution was slightly affected and it was in accordance with that of actual. System suitability 
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parameters were also found satisfactory; hence the analytical method would be concluded as 
robust. Chromatogram obtain during robustness study were shown in figure 22-28. 
Table 4: Evaluation data of robustness study 
Robust conditions % Assay 
System suitability parameters 
Theoretical plates Asymmetry 
Flow 0.9 ml/min 100.9 1958.38 0.98 
Flow 1.1 ml/min 99.7 1959.38 1.00 
Buffer pH 2.5 97.0 2467.5 0.99 
Buffer pH 3.5 98.4 2485.28 1.01 
Buffer-ACN (52: 48,v/v) 102.9 2075.1 1.02 
Buffer-ACN (48: 52,v/v) 95.5 2063.39 1.00 
Column change 98.6 2526.77 1.00 
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Figure 22: Standard chromatogram (0.9 ml/min flow rate) 
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Figure 23: Standard chromatogram (1.1 ml/min flow rate) 
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Figure 24: Standard chromatogram (Buffer-ACN (52:48, v/v)) 
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Figure 25: Standard chromatogram (Buffer-ACN (48:52, v/v)) 
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Figure 26: Standard chromatogram (pH 3.5) 
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Figure 27: Standard chromatogram (pH 2.5) 
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Figure 28: Standard chromatogram (column change) 
 
5.9 System suitability 
  A system suitability test of the chromatographic system was performed before each 
validation run. Five replicate injections of standard preparation were injected and asymmetry, 
theoretical plate and % RSD of peak area were determined for the same. Acceptance criteria 
for system suitability, asymmetry not more than 2.0, theoretical plates not less than 1500 and 
% RSD of peak area not more than 2.0, were full fill during all validation parameter.  
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6 CALCULATION AND DATA 
 
Calculation formula used 
 
    
1. Calculation formula for % assay of warfarin sodium 
 
 
WeightTest
WeightStandard
AreaStandardMean
AreaTestMean
Assay
250
100
%  
 
StandardofPotency
ClaimLable
WeightTestMean
 
 
 
2. Relative standard deviation 
 
100%
sMeasurmentofValueMean
sMeasurmentofDeviationStandard
RSD  
 
 
3. Recovery 
 
100%
AddedAmount
foundAmount
Recovery  
 
 
4. Amount found  
 
ionConcentratStandard
AreaStandardMean
AreaTestMean
mlmgFoundAmount )/(  
 
 
5. Amount added 
 
Volume
Weight
mlmgAddedAmount )/(  
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Specificity study for analytical method validation of warfarin sodium tablets 
 
Observation 
Data for Standard preparation  Data for Test preparation 
   
Replicate Area  Replicate Area 
1 5159451  1 5510927 
2 5274958  2 5359738 
3 5300142  Average 5435333 
4 5184259  % Assay 99.7 
5 5242158    
Average 5232194    
Stdev 59443.84    
% RSD 1.14    
     
Standard weight 9.92 mg  Test weight 882 mg 
Standard potency 99.25 %  Label claim 5 mg 
Standard 
concentration (mg/ml) 
0.0992  
Mean test 
weight 
172mg 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
25.99
5
172
882
250
100
92.9
5232194
5435333
% Assay  
 
= 99.7 % 
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Linearity study for analytical method validation of warfarin sodium tablets 
 
 
 
 
Standard weight (mg) 10.1 
Standard dilution 100 
Standard potency 99.25 % 
Standard concentration (mg/ml) 0.101 
Concentration of linearity stock 
solution (mg/ml) 
0.5 
      
Replicate 1 2 3 4 5 
Standard area 5188960 5029298 4957716 5004827 4942643 
Mean standard area 5024689 
 Stdev 87883.60 
% RSD 1.75 
Concentration level 
(%) 
Volume of 
linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final concentration 
(mg/ml) 
Mean area 
40 8.0 100 0.0400 2158564 
60 12.0 100 0.0600 3137940 
80 16.0 100 0.0800 4067624 
100 20.0 100 0.1000 5204186 
120 24.0 100 0.1200 6003840 
140 28.0 100 0.1400 7037025 
160 32.0 100 0.1600 8154355 
  Correlation co-efficient 0.9995 
  Slope 49503136.61 
  Intercept 158762.27 
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Precision study for analytical method validation of warfarin sodium tablets 
 
 
 
 
Description Mean area Test weight (mg) % assay 
Set 1 5373592 881.0 100.8 
Set 2 5356539 882.0 100.4 
Set 3 5364275 884.0 100.3 
Set 4 5348979 881.0 100.3 
Set 5 5381033 883.0 100.7 
Set 6 5333672 879.0 100.3 
  Mean 100.5 
  Stdev 0.23 
  % RSD 0.22 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
25.99
5
176
881
250
100
86.9
5220281
5373592
% Assay  
     
    = 100.8 % 
 
Standard weight (mg) 9.86 
Standard dilution 100 
Standard potency 99.25 % 
Standard concentration (mg/ml) 0.0986 
      
Replicate 1 2 3 4 5 
Standard area 5168236 5256828 5249561 5201658 5225124 
Mean standard area 5220281 
 Stdev 36304.11 
% RSD 0.70 
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Intermediate precision study for analytical method validation of warfarin sodium 
tablets 
 
 
 
Description Mean area Test weight (mg) % assay 
Set 1 5384339 878 101.0 
Set 2 5333522 880 99.8 
Set 3 5411584 884 100.8 
Set 4 5370431 881 100.4 
Set 5 5322933 882 99.4 
Set 6 5304287 879 99.4 
  Mean 100.1 
  Stdev 0.70 
  % RSD 0.70 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
25.99
5
174
878
250
100
84.9
5223062
5384339
% Assay  
     
 
    = 101.0 % 
 
Standard weight (mg) 9.84 
Standard dilution 100 
Standard potency 99.25 % 
Standard concentration (mg/ml) 0.0984 
      
Replicate 1 2 3 4 5 
Standard area 5231458 5186574 5266847 5188740 5241689 
Mean standard area 5223062 
 Stdev 34799.27 
% RSD 0.67 
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Comparison for precision and intermediate precision study for analytical method 
validation for warfarin sodium tablets 
 
 
 Set %Assay 
Precision study 
1 100.8 
2 100.4 
3 100.3 
4 100.3 
5 100.7 
6 100.3 
Intermediate precision study 
1 101.0 
2 99.8 
3 100.8 
4 100.4 
5 99.4 
6 99.4 
 
Mean 100.3 
Stdev 0.525703 
Cumulative 
% RSD 
0.524131 
 
 
Accuracy study for analytical method validation of warfarin sodium tablets 
Standard weight (mg) 9.9 
Standard dilution 100 
Standard potency 99.25 % 
Standard concentration (mg/ml) 0.099 
      
Replicate 1 2 3 4 5 
Standard area 4914842 5018535 4972001 4965519 4997479 
Mean standard area 4973675 
 Stdev 39082.3 
% RSD 0.79 
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Accuracy study for analytical method validation of warfarin sodium tablets 
 
Recovery 
Level 
Set 
No. 
Mean 
area 
Wight 
(mg) 
Volume 
(ml) 
Amount added Amount found 
% 
Recovery 
Mean % 
Recovery 
Stdev % RSD concentration 
(mg/ml) 
concentration 
(mg/ml) 
50% 
Set 1 2697181 2.7 50 0.05400 0.05369 99.43 
99.15 0.42 0.42 Set 2 2555445 2.6 50 0.05120 0.05087 99.36 
Set 3 2577593 2.6 50 0.05200 0.05131 98.67 
100% 
Set 1 5227114 5.2 50 0.10480 0.10404 99.27 
99.09 0.17 0.17 Set 2 4971308 5.0 50 0.10000 0.09895 98.95 
Set 3 4987872 5.0 50 0.10025 0.09928 99.03 
150% 
Set 1 7727690 7.8 50 0.15580 0.15382 98.73 
98.95 0.27 0.28 Set 2 7380374 7.4 50 0.14800 0.1469 99.26 
Set 3 7360817 7.4 50 0.14820 0.14652 98.87 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
100
05400.0
05369.0
Recovery%  = 99.43 % 
 
099.0
4973675
2697181
)/( mlmgFoundAmount  = 0.05369 mg/ml 
 
100
7.2
)/( mlmgAddedAmount  = 0.05400 mg/ml 
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Solution stability study for analytical method validation of warfarin sodium tablets 
 
 
System suitability of standard preparation for solution stability 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 5640029 5621474 5839909 5712470 5371558 
2 5577296 5564042 5752531 5600637 5355399 
3 5542010 5767222 5694509 5597393 5407512 
4 5479608 5521962 5932965 5545894 5452427 
5 5723561 5725662 5780879 5559993 5320148 
Mean 5592501 5640072 5800159 5603277 5381409 
Stdev 93489.30 104366.17 90856.43 65442.75 50624.59 
%RSD 1.67 1.85 1.57 1.17 0.94 
 
 
 
 
Solution stability for standard preparation at 2 -8 °C 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 5621474 5839909 5712470 5371558 
2 5564042 5752531 5600637 5355399 
3 5767222 5694509 5597393 5407512 
4 5521962 5932965 5545894 5452427 
5 5725662 5780879 5559993 5320148 
Replicate Peak area Peak area Peak area Peak area 
1 5733543 5847437 5637393 5326697 
2 5721066 5780470 5725346 5430455 
Mean 5664996 5804100 5625589 5380599 
Stdev 95321.96 76956.38 70369.08 51064.86 
%RSD 1.68 1.33 1.25 0.95 
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Solution stability for standard preparation at ambient temperature 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 5621474 5839909 5712470 5371558 
2 5564042 5752531 5600637 5355399 
3 5767222 5694509 5597393 5407512 
4 5521962 5932965 5545894 5452427 
5 5725662 5780879 5559993 5320148 
Replicate Peak area Peak area Peak area Peak area 
1 5760483 5814172 5580904 5499288 
2 5685693 5749268 5531904 5433192 
Mean 5663791 5794890 5589885 5405646 
Stdev 96791.09 77040.59 59819.52 61530.77 
%RSD 1.71 1.33 1.07 1.14 
Solution stability for test preparation at 2 -8 °C 
 
Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 5640029 5621474 5839909 5712470 5371558 
2 5577296 5564042 5752531 5600637 5355399 
3 5542010 5767222 5694509 5597393 5407512 
4 5479608 5521962 5932965 5545894 5452427 
5 5723561 5725662 5780879 5559993 5320148 
Replicate Test area Test area Test area Test area Test area 
1 5437972 5441747 5730971 5413894 5398154 
2 5430075 5422416 5520576 5359017 5411464 
Mean 5434023.5 5432081.5 5625773.5 5386455.5 5404809 
% Assay 100.3 99.4 100.1 99.2 99.7 
Standard weight (mg) 5.2 5.2 5.2 5.2 5.0 
Test weight (mg) 891 899 872 875 885 
% Difference compare 
to that of initial 
-- 0.9 0.2 1.1 0.6 
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Solution stability for test preparation at ambient temperature 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 5640029 5621474 5839909 5712470 5371558 
2 5577296 5564042 5752531 5600637 5355399 
3 5542010 5767222 5694509 5597393 5407512 
4 5479608 5521962 5932965 5545894 5452427 
5 5723561 5725662 5780879 5559993 5320148 
Replicate Test area Test area Test area Test area Test area 
1 5437972 5440342 5486605 5452818 5386180 
2 5430075 5431431 5624211 5435184 5414842 
Mean 5434023.5 5435886.5 5555408 5444001 5400511 
% Assay 100.3 99.5 98.9 100.3 99.6 
Standard weight (mg) 5.2 5.2 5.2 5.2 5 
Test weight (mg) 891 899 872 875 1439.0 
% Difference 
compare to that of 
initial 
-- 0.8 1.4 0.0 0.7 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
25.99
5
179
891
250
100
4.10
5592501
5434023.5
% Assay  
 
         = 100.3 % 
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Robustness study for analytical method validation of warfarin sodium tablets 
 
 
 
Flow Rate at 
0.9 ml/min 
Flow Rate at 
1.1 ml/min 
Buffer-ACN 
48: 52 
Buffer- ACN 
52: 48 
Buffer pH 3.5 Buffer pH 2.5 
Column 
Change 
Replicate Standard area Standard area Standard area Standard area Standard area Standard area Standard area 
1 5431202 5185124 5371836 5376463 5388898 5483868 5472668 
2 5188898 5263256 5563206 5364801 5414591 5489296 5428644 
3 5414591 5124589 5478776 5395117 5476023 5444342 5378383 
4 5476023 5142546 5391956 5375634 5409119 5519618 5498452 
5 5409119 5245218 5423346 5375803 5587043 5482573 5399993 
Mean 5383967 5192147 5445824 5377564 5455135 5483939 5435628 
Stdev 112169.31 61128.32 77048.06 10943.49 80598.79 26793.10 49785.63 
% RSD 2.08 1.18 1.41 0.20 1.48 0.49 0.92 
Replicate Test area Test area Test area Test area Test area Test area Test area 
1 5587043 5263587 5366046 5369159 6064879 5351174 5475427 
2 6064879 5302148 5410931 5434323 5385550 5336057 5463297 
Mean 5825961 5282868 5388489 5401741 5725215 5343616 5469362 
Standard 
weight (mg) 
4.9 4.9 4.9 4.9 4.9 4.9 4.9 
Test weight 
(mg) 
920 920 920 920 920 920 920 
Label claim 
(mg) 
5 5 5 5 5 5 5 
Mean test 
weight (mg) 
184 184 184 184 184 184 184 
% Assay 100.9 99.7 97.0 98.4 102.9 95.5 98.6 
Calculation: Prototype calculation for one set: 25.99
5
184
920
250
50
9.4
5383967
5825961
% Assay  = 100.9 % 
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SECTION II: HPLC METHOD DEVELOPMENT AND VALIDATION OF 
CHLORHEXIDINE GLUCONATE AND LIDOCAINE HYDROCHLORIDE IN 
THROAT SPRAY. 
 
1. INTRODUCTION OF DRUGS 
1.1 Introduction of chlorhexidine gluconate 
Chlorhexidine gluconate is a chemical antiseptic [1], Which provides 
antimicrobial activity. It is present in throat sprays, oral rinses and skin cleansers. It is 
marketed under the brand names Medica (Throat spray), Peridex, or Periogard Oral 
Rinse. In the UK it is mainly marketed under the brand name Corsodyl. It kills (is 
bactericidal too) both gram-possitive and gram negative microbes. Although it is less 
effective with some gram negative microbes [2]. It is also bacteriostatic. 
 
1.1.1 Description 
Chemically, chlorhexidine gluconate is 1,1'-hexamethylene bis(5-(p-chlorophenyl) 
biguanide) digluconate (Figure 1). Its molecular formula is C22H30Cl2N10•2C6H12O7 
having molecular weight 897.72 g/mole. It is often used as an active ingredient in 
mouthwash designed to reduce dental plaque and oral bacteria. Chlorhexidine can thus be 
used to improve bad breath [3]. It has been shown to have an immediate bactericidal 
action and a prolonged bacteriostatic action due to adsorption onto the pellicle-coated 
enamel surface [4]. Chlorhexidine-based products are usually used to combat or prevent 
gum diseases such as gingivitis. According to Colgate[5],$ chlorhexidine gluconate has 
not been proven to reduce subgingival calculus and in some studies actually increased 
deposits. When combined with xylitol, a synergistic effect has been observed to enhance 
efficacy[6]. 
.
NHNH
NHNH
NH
NH
NH
NH
NH
NH
Cl
Cl
2C6H12O7
 
Figure: 1     1,1'-hexamethylene bis(5-(p-chlorophenyl) biguanide) digluconate 
 
1.1.2 Mechanism of action 
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The mechanism of action is membrane disruption, and not ATPase inactivation as 
previously thought. Because of its positive charge, the chlorhexidine molecule reacts with 
the microbial cell surface to destroy the integrity of the cell membrane. This novel 
mechanism of action makes it highly unlikely for the development of bacterial resistance. 
Chlorhexidine's antimicrobial effects are associated with the attractions between 
chlorhexidine (cation) and negatively charged bacterial cells. After chlorhexidine is 
absorpted onto the organism's cell wall, it disrupts the integrity of the cell membrane and 
causes the leakage of intracellular components of the organisms [7]. Many metazoan cells 
inhabit mechanically stressful environments and, consequently, their plasma membranes 
are frequently disrupted. Survival requires that the cell rapidly repair or reseal the 
disruption. Rapid resealing is an active and complex structural modification that employs 
endomembrane as its primary building block, and cytoskeletal and membrane fusion 
proteins as its catalysts. Endomembrane is delivered to the damaged plasma membrane 
through exocytosis, a ubiquitous Ca
2+ 
triggered response to disruption. Tissue and cell 
level architecture prevent disruptions from occurring, either by shielding cells from 
damaging levels of force, or, when this is not possible, by promoting safe force 
transmission through the plasma membrane via protein-based cables and linkages. 
Prevention of disruption also can be a dynamic cell or tissue level adaptation triggered 
when a damaging level of mechanical stress is imposed. Disease results from failure of 
either the preventive or resealing mechanisms [8].  
Chlorhexidine's role in preventing tooth decay (dental caries) is controversial[9]. 
Continued use of products containing chlorhexidine for long periods can cause stains on 
teeth, especially on silicate and resin restorations; prolonged use can also alter taste 
sensation - this latter symptom can be reversed by ceasing use of Chlorhexidine[10] A 
version which stains the teeth less has been developed[11]. Chlorhexidine is neutralized 
by common toothpaste additives such as sodium lauryl sulfate (SLS) and sodium 
monofluorophosphate (MFP). Although data is limited, in order to maximize 
effectiveness it may be best to keep a 30-minute to 2-hour interval between brushing and 
using the mouthwash [12]. 
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1.1.3 Use in humans 
Reported data indicates that nosocomial infection rate is reduced by chlorhexidine 
treatment with individual reduction in human respiratory infection rate by 69%, but not in 
wound, blood, and urinary nosocomial infection rates. In addition, GI colonization may 
be reduced secondarily from a reduction in the oropharyngeal flora. Also, it is 
hypothesized that the reduction in oropharyngeal flora in intubated patients by CHX 
treatment decreases transient bacteremias that occur via breaks in the mucosal barrier 
around the cuff of the endotracheal tube. Thus, this may reduce the hematogenous spread 
of bacteria. CHX decreases the total respiratory infection rate and the use of non-
prophylactic IVs  antibiotics in patients undergoing heart surgery [13]. 
1.1.4 Use in animals 
For use in animals, it is used as a topical disinfectant of wounds. It is more 
effective in killing bacteria (bactericidal) than both povidone-iodine and saline, and has 
residual effects up to 6 hours. Some common brand names are ChlorhexiDerm, 
ResiChlor, Germi-STAT Antimicrobial Skin Cleanser, Nolvasan Skin and Wound 
Cleaner, and Nolvasan Ointment. It is also more beneficial to wound healing than using 
saline solutions alone [14]. Note, however, that problems including deafness [15] have 
been associated with the use of chlorhexidine products in cats. It is commonly used to 
manage the skin infections suffered by Westie dogs. 
 
1.2 Introduction of lidocaine hydrochloride 
Lidocaine Hydrochloride, the first amino amide-type local anesthetic, was first 
synthesized under the name xylocaine by Swedish chemist Nils Löfgren in 1943. His 
colleague Bengt Lundqvist performed the first injection anesthesia experiments on 
himself [16]. Lidocaine is a common local anesthetic and class IB (membrane-stabilizing) 
antiarrhythmic drug. It was first marketed in 1949. Lidocaine is used topically to relieve 
itching, burning and pain from skin inflammations, injected as a dental anesthetic or as a 
local anesthetic for minor surgery. 
Lidocaine is currently listed by the World Anti-Doping Agency as an illegal substance 
[17]. 
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1.2.1 Description 
Lidocaine Hydrochloride is chemically 2-(diethylamino)-N-(2,6-dimethylphenyl) 
acetamide hydrochloride(Figure 2). The molecular formula is C14H22N2O•HCl having 
molecular weight 270.84 g/mole. Lidocaine alters signal conduction in neurons by 
blocking the fast voltage gated sodium (Na
+
) channels in the neuronal cell membrane, 
which are responsible for signal propagation [18]. With sufficient blockade, the 
membrane of the postsynaptic neuron will not depolarize and so fail to transmit an action 
potential, leading to its anaesthetic effects. Careful titration allows for a high degree of 
selectivity in the blockage of sensory neurons, whereas higher concentrations will also 
affect other modalities of neuron signaling. 
 
O
NH
N . HCl
 
Figure 2: 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide hydrochloride 
 
1.2.2 Mechanism of action 
Studies of the effects of therapeutic concentrations of lidocaine on the 
electrophysiological properties of mammalian Purkinje fibers have shown that lidocaine 
attenuates phase 4 diastolic depolarization, decreases automaticity, and causes a decrease 
or no change in excitability and membrane responsiveness.  Action potential duration and 
effective refractory period of Purkinje fibers are decreased, while the ratio of effective 
refractory period to action potential is increased.  Action potential duration and effective 
refractory period of ventricular muscle are also decreased.  Effective refractory period of 
the AV node may increase, decrease or remain unchanged, and atrial effective refractory 
period is unchanged.  Lidocaine raises the ventricular fibrillation threshold.  No 
significant interactions between lidocaine and the autonomic nervous system have been 
described and consequently, lidocaine has little or no effect on autonomic tone.  
Clinical electrophysiological studies with lidocaine have demonstrated no change 
in sinus node recovery time or sinoatrial conduction time.  AV nodal conduction time is 
unchanged or shortened, and His-Purkinje conduction time is unchanged. 
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1.2.3 Clinical use 
Topical lidocaine has been shown to relieve postherpetic neuralgia (arising, for 
example, from shingles) in some patients, though there is not enough study evidence to 
recommend it as a first-line treatment [19]. It also has uses as a temporary fix for tinnitus. 
Although not completely curing the illness, it has been shown to reduce the effects by 
around two thirds [20]. 
The efficacy profile of lidocaine as a local anesthetic is characterized by a rapid 
onset of action and intermediate duration of efficacy. Therefore, lidocaine is suitable for 
infiltration, block and surface anesthesia. Longer-acting substances such as bupivacaine 
are sometimes given preference for spinal and peridural anesthesias; lidocaine, on the 
other hand, has the advantage of a rapid onset of action. Adrenaline vasoconstricts 
arteries and hence delays the resorption of Lidocaine, almost doubling the duration of 
anaesthesia. For surface anesthesia several formulations are available that can be used e.g. 
for endoscopies, before intubations etc. 
Lidocaine is also the most important class 1B antiarrhythmic drug: it is used 
intravenously for the treatment of ventricular arrhythmias (for acute myocardial 
infarction, digitalis poisoning, cardioversion or cardiac catherization). However, a routine 
prophylactic administration is no longer recommended for acute cardiac infarction; the 
overall benefit of this measure is not convincing. Lidocaine has also been efficient in 
refractory cases of status epilepticus. 
 
1.2.4 Contraindications 
Contraindication for the use of lidocaine includes: 
 Heart block, second or third degree (without pacemaker). 
 Severe sinoatrial block (without pacemaker). 
 Serious adverse drug reaction to lidocaine or amide local anaesthetics. 
 Concurrent treatment with quinidine, flecainide, disopyramide, procainamide 
(Class I antiarrhythmic agents). 
 Prior use of amiodarone hydrochloride. 
 Hypotension not due to arrhythmia. 
 Bradycardia. 
 Accelerated idioventricular rhythm. 
 Pacemaker. 
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1.2.5 Precautions, side-effects and administration 
Cats tend to be more sensitive to the CNS effects of lidocaine; use with caution. 
Lidocaine is contraindicated in patients with known hypersensitivity to the amide-class 
local anesthetics, a severe degree of SA, AV or intraventricular heart block (if not being 
artificially paced), or Adams-Stokes syndrome. The use of lidocaine in patients with 
Wolff-Parkinson-White (WPW) syndrome is controversial. Some manufacturers state its 
use is contraindicated, but several physicians have used the drug in people. Adverse drug 
reactions (ADRs) are rare when lidocaine is used as a local anesthetic and is administered 
correctly. Most ADRs associated with lidocaine for anesthesia relate to administration 
technique (resulting in systemic exposure) or pharmacological effects of anesthesia, but 
allergic reactions only rarely occur [21]. The most common adverse effects reported are 
dose related (serum level) and mild. CNS signs include drowsiness, depression, ataxia, 
muscle tremors, etc. Nausea and vomiting may occur, but are usually transient. Adverse 
cardiac effects generally only occur at high plasma concentrations and are usually 
associated with PR and QRS interval prolongation and QT interval shortening [22]. The 
usual dose is 50 to 100 mg of lidocaine hydrochloride (0.7 to 1.4 mg/kg; 0.32 to 0.63 
mg/lb) administered intravenously under ECG monitoring.  This dose may be 
administered at the rate of approximately 25 to 50 mg/min (0.35 to 0.7 mg/kg/min; 0.16 
to 0.32 mg/lb/min).  Sufficient time should be allowed to enable a slow circulation to 
carry the drug to the site of action.  If the initial injection of 50 to 100 mg does not 
produce a desired response, a second dose may be injected after 5 minutes.  
 
1.2.6 Dosage forms 
Lidocaine, usually in the form of lidocaine hydrochloride, is available in various 
forms including: 
 Injected local anesthetic (sometimes combined with epinephrine to reduce 
bleeding) 
 Dermal patch (sometimes combined with prilocaine) 
 Intravenous injection (sometimes combined with epinephrine to reduce bleeding) 
 Intravenous infusion 
 Nasal instillation/spray (combined with phenylephrine) 
 Oral gel (often referred to as "viscous lidocaine" or abbreviated "lidocaine visc" or 
"lidocaine hcl visc" in pharmacology; used as teething gel) 
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 Topical gel (as with Aloe vera gels that include lidocaine) [23] 
 Topical liquid, Topical patch(lidocaine 5% patch is marketed as "Lidoderm" in the 
US (since 1999) and "Versatis" in the UK (since 2007 by Grünenthal)) 
 Topical aerosol spray, Oral liquid 
 Inhaled via a nebulizer 
Chlorhexidine and lidocaine …   Part-A (Section-II) 
 
 
83 
 
2. LITERATURE REVIEW 
2.1 Literature review of chlorhexidine gluconate 
The literature reviews regarding chlorhexidine gluconate reveals that various 
analytical methods were reported for its determination as drug, in pharmaceutical 
formulation and in various biological fluids. The literature reviews for analysis of 
chlorhexidine gluconate are as under:  
 
2.1.1 L. Havlíková and coworkers have developed reversed-phase HPLC method for 
simultaneous determination of chlorhexidine and its degradation product p-chloroaniline 
Zorbax SB Phenyl column (75 mm x 4.6 mm, 3.5 mm) was used for the separation. 
Mobile phase composed of acetonitrile and buffer solution of 0.08 M sodium phosphate 
monobasic containing 5 ml of triethylamine (0.5%) and adjust with 85% phosphoric acid 
to pH 3.0 in ratios 35:65 (v/v) pumped isocratically at flow rate 0.6 ml min
-1
. UV 
detection was performed at 239 nm.[24] 
2.1.2 M. H. Gaffney, M. Cooke and R. Simpson have reported an HPLC method for 
the determination of chlorhexidine in urine. Chromatographic separation was achieved on 
a C18 reversed-phase column using a mobile phase of methanol-20 mM sodium acetate 
solution (60:40) adjusted to pH 5 with glacial acetic acid. An ion-pair agent 
(pentadecafluorooctanoic acid) was used at a concentration of 100µg/ml. 3-
Bromobenzophenone was used as chromatographic standard (kappa' = 4.0). A series of 
urine samples was analyzed and no interferences were observed. The method analysis 
time of 30 min.[25] 
2.1.3 T. Pérez-Ruiz, C. Martínez-Lozano, A. Sanz and A. Sánchez have developed a 
spectrophotometric method for determination of chlorhexidine by liquid-liquid extraction 
using bromophenol blue with a flow system.[26] 
2.1.4 F. Bailey, P. N. Brittain and B. F. Williamson have developed method for the 
determination of chlorhexidine (Hibitane) and its salts in formulated pharmaceutical 
products by using HPLC.[27] 
2.1.5 K. Usui, T. Hishinuma, H. Yamaguchi, N.  Tachiiri and J. Goto have 
developed for identification of chlorhexidine (CHD) and nonylphenolethoxylates 
(NPEOn) in antiseptic and hemolyzed blood using electrospray ionization mass 
spectrometry (ESI-MS) were developed. Fragmental analysis provides accurate evidence 
Chlorhexidine and lidocaine …   Part-A (Section-II) 
 
 
84 
 
for the presence of CHD in the samples. For the determination of CHD in hemolyzed 
blood, the method was also developed using LC-ESI-MS.[28] 
2.1.6 D. Zhang, H. Liang, J. Zeng and G. Rao have reported an RP-HPLC method 
using phenacetin internal standard (IS) for simultaneous determination of chlorhexidine 
(CH) and its impurity 4-chloroaniline (4-CA). A Zorbax-C8 column (25cm x 4.6mm id, 
10 microns), a variable wave length UV detector. A mixture of methanol and 0.2 mol/L 
NaH2PO4 (50.5 : 49.5, pH 3.0) is used as mobile phase, with flow rate of 1.0 ml/min. 
Sample solution of 15 µl is injected onto the column, which is maintained at 30 degrees 
C. The eluent is monitored at 240nm.[29] 
2.1.7 E. Jacobsen and B. Glyseth studeied the electroreduction of chlorhexidine by 
D.C, A.C. and pulse polarography. Polarograms of the drug recorded from ammonium 
acetate buffers exhibit a single well-defined wave. The current is diffusion-controlled and 
proportional to the concentration. The reduction wave is due to an irreversible 8-electron 
reduction of the four > C=NH groups in the molecule to amino groups. The drug is 
strongly adsorbed on the electrode surface over a considerable potential range.[30] 
2.1.8 Y. W. Lam, D. C. Chan, S. Y. Rodriguez, J. H. Lintakoon and T. H. Lam 
have developed an HPLC method to determine salivary chlorhexidine concentration. 
Saliva sample (200 microliters) was extracted into methylene chloride. Chromatographic 
separation was achieved with a C18 column using a mobile phase of acetonitrile-0.05 M 
sodium acetate and 0.005 M heptanesulfonic acid (40:60, v/v). [31] 
2.1.9 Y. Xuec and colleagues presented the extraction and analysis of chlorhexidine 
(CHX) from whole blood using solid-phase extraction (SPE) together with (HPLC). 
Blood samples, spiked with chlorpromazine as an internal standard, were fortified with 
sodium acetate buffer and purified with Bakerbond C18 SPE columns. The HPLC was 
performed using a Capcell Pak C(18) MG column (4.6 x 250-mm) and monitored at 260 
nm, using a UV detector. A mobile phase consisting of acetonitrile/water (40:60 v/v), 
containing 0.05% trifluoroacetic acid, 0.05% heptafluorobutyric acid, and 0.1% 
triethylamine, was employed.[32] 
2.1.10 W. K. Gavlick and P. K. Davis have developed a gas chromatographic (GC) 
method with flame ionization detector to separate and quantitate p-chloroaniline (PCA) 
from other components in a chlorhexidine digluconate (CHG)-containing alcohol foam 
surgical scrub product. A simple sample preparation method was developed in which 1-
butanol was used to dissolve the foam and precipitate the CHG, which otherwise would 
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interfere with the GC analysis.[33] 
2.1.11 H. Okamoto, A. Uetake, R. Tamaya, T. Nakajima, K. Sagara and Y. Ito used 
hydrophobic interaction electrokinetic chromatography to determine seven active 
ingredients (diphenhydramine hydrochloride, dibucaine hydrochloride, chlorhexidine 
hydrochloride, phenylephrine hydrochloride, hydrocortisone acetate, allantoin and 
tocopherol acetate) simultaneously in an ointment. Not only hydrophobic but also ionic 
compounds were successfully separated by use of a mobile phase composed of 
acetonitrile-water (80:20, v/v), tetradecylammonium salt and ammonium chloride. [34] 
 
2.2. LITERATURE REVIEW OF LIDOCAINE HYDROCHLORIDE 
  The literature reviews regarding Lidocaine hydrochloride suggests that various 
analytical methods were reported for its determination as drug, in pharmaceutical 
formulation and in various biological fluids. The literature reviews for analysis of 
Chlorhexidine gluconate are as under.  
2.2.1 S. Salas, B. Talero, A. M. Rabasco and M. L. González-Rodríguez have 
developed an RP-HPLC method for the assay of lidocaine hydrochloride (LH) in 
Gantrez((R))-alginate microspheres. He used a LiChrospher C18 column and a mobile 
phase consisting of acetonitrile:ammonium acetate (0.0257M) adjusted to pH 4.85 with 
acetic acid, in the ratio 70:30 (v/v) and a flow rate of 0.6mL/min. [35] 
2.2.2 L. Zivanovic, S. Agatonovic-Kustrin, M. Vasiljevic and I. Nemcova developed 
an RP-HPLC and a thin-layer chromatographic (TLC)-UV densitometric methods for the 
quality control of lidocaine hydrochloride bulk drug and its injection solutions. The 
HPLC method used an RP-18 reversed-phase column with methanol-water-1% 
phosphoric acid-hexylamine (30:70:100:1.4, v/v/v/v) as the mobile phase and detection at 
254 nm, with a capacity factor k' = 0.8. The TLC-UV densitometric method was 
performed on silica gel plates using diisopropyl ether-acetone-diethylamine (85:10:5, 
v/v/v) as the developing solvent and UV detection at 254 nm.[36] 
2.2.3 L. Kang, H. W. Jun and J. W. McCall developed a method based on solid-phase 
extraction and reversed-phase liquid chromatography for the quantitation of Lidocaine 
(Lid) in dog plasma. Phenacemide was used as an internal standard (IS) in the extraction 
which employed C18 solid-phase extraction cartridges. The washing and eluting solutions 
were 2 ml acetonitrile-pH 9.0 phosphate buffer (10:90 v/v) and 0.5 ml acetonitrile-pH 4.0 
phosphate buffer (40:60 v/v) respectively. The eluent obtained from the cartridge was 
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directly analyzed on a reversed-phase ODS column with UV detection at 210 nm. The 
mobile phase was acetonitrile and pH 5.9 phosphate buffer (20:80 v/v). The retention 
times were 6.4 and 7.2 min for Lid and IS, respectively, at a flow rate of 1.0 ml min
-1
.[37] 
2.2.4 A. Sintov, R. Siden and R. J. Levy have developed a sensitive HPLC assay 
method using fluorescence detection for quantifying lidocaine levels in plasma. The 
method employed extracts the drug from plasma using 1-chlorobutane and a subsequent 
derivatization with 9-fluorenylmethylchloroformate in acetonitrile at 110°C. The 
derivative was chromatographed on a C18 reversed-phase column and measured with 
fluorescence detection (excitation 254 nm, emission 313 nm) [38]. 
2.2.5 Lili Chen, et. al. have developed a RP-HPLC method for determination of 
Nikethamide and lidocaine in human blood and cerebrospinal fluid. The method involves 
simple protein precipitation followed by quantification of analytes using HPLC at 263 
nm. Analytes were separated on a 5μ Zorbax Dikema C18 column (150 mm x 4.60 mm, 
i.d.) with a mobile phase of 22:78 (v/v) mixtures of methanol and a diethylamine-acetic 
acid buffer, pH 4.0.[39] 
2.2.6 J. Klein, D. Fernandes, M. Gazarian, G. Kent and G. Koren have developed 
an HPLC assay method for the measurement of prilocaine and lidocaine (components of 
the local anesthetic cream EMLA) as well as the prilocaine metabolite, o-toluidine, in 
plasma. The method uses UV detection. The plasma, together with the internal standard 
(bupivacaine) is extracted with diethyl ether under alkaline conditions, followed by the 
extraction of the analytes from the organic phase into dilute sulphuric acid. An aliquot of 
the acid extract is injected onto the HPLC system and the effluent is monitored by a UV 
detector.[40] 
2.2.7 L. D. Bo, P. Mazzucchelli and A. Marzo worked to develop an LC-MS-MS 
method for assaying lidocaine in human plasma. Lidocaine and an internal standard 
(bupivacaine) were extracted from 1 ml of alkalinized plasma with 3° butylmethyl ether, 
back-extracted to a H3PO4 acidified solution and injected into a C18 column. Acetonitrile 
26mMol/l ammonium acetate, pH 4.5 (70:30, v/v) was the mobile phase at a flow-rate of 
1 ml/min. The effluent was detected by PE Sciex API 365 LC-MS-MS system in positive 
ion mode. Ionisation was performed using an atmospheric pressure chemical ionization 
ion source operating at 400°C. The multi reaction monitoring transition 235-->86 was 
monitored.[41] 
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2.2.8 A. Malenovic, M. Medenica, D. Ivanovic, B. Jancic and S. Markovic have 
developed an RP-HPLC method, for the simultaneous determination of lidocaine and 
cetrimonium bromide in the presence of pellet color corrigent. Separations were 
performed on a Beckman Ultrasphere ODS 4.6 mm x 15 cm, 5 microm particle column at 
40°C. The mobile phase consisted of water phase and acetonitrile (72:28 v/v), pH 
adjusted to 2.0 with 85% ortophosphoric acid. Bisacodil was used as an internal standard 
with  flow rate of 1 ml/min and UV detector at 208 nm.[42] 
2.2.9 L. Zivanovic, M. Zecevic, S. Markovic, S. Petrovic and I. Ivanovic have 
reported an RP-HPLC method for simultaneous determination of lidocaine hydrochloride, 
dexamethasone acetate (DA) and calcium dobesilate (CD) in suppositories and 
ointment.[43] 
 
2.3. LITERATURE REVIEW OF CHLORHEXIDINE GLUCONATE AND 
LIDOCAINE HYDROCHLORIDE COMBINATION. 
2.3.1 Y. Xu and G. Yin Wong has reported an HPLC method for the simultaneous 
determination of lignocaine hydrochloride, chlorhexidine gluconate and triamcinolone 
acetonide in suspension is reported. Reverse phase chromatography was conducted using 
250 x 4.6 mm I.D. 5μm C18 column and monitored on a UV detector at 240nm. Two 
mobile phases were used: mobile phase A comprised a mixture of 
methanol/water/triethylamine (58:42:0.4) and the pH adjusted to 3 with phosphoric acid 
for analysing active ingredients, and mobile phase B was a mixture of methanol/0.01 N 
ammonium acetate (70:30) for limit testing related substances.[44] 
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3. AIM OF PRESENT WORK 
In recent time, there is increased tendency towards the development of stability-
indicating assays [45-47], using the approach of stress testing as enshrined in the 
International Conference on Harmonization (ICH) guideline Q1A (R2) [46]. Even this 
approach is being extended to drug combinations [48, 49] to allow accurate and precise 
quantitation of multiple drugs in presence of their degradation products and interaction 
product if any. 
Various publications are available regarding determination method of 
chlorhexidine gluconate and lidocaine hydrochloride but most of the methods are 
applicable either to chlorhexidine gluconate or lidocaine hydrochloride in various 
pharmaceutical formulations or in biological fluids. Spectrophotometric, ESI-MS, 
polarographic, gas chromatographic, hydrophobic interaction electrokinetic 
chromatography and HPLC methods are reported for determination of chlorhexidine. 
Thin layer chromatography, SPE-RP-HPLC, LC-MS-MS, HPLC methods are reported for 
the determination of lidocaine hydrochloride. Only one HPLC method is reported 
simultaneous determination of chlorhexidine gluconate and Lidocaine hydrochloride. As 
far as our knowledge is concern, no stability-indicating HPLC assay method is available 
for the determination of chlorhexidine gluconate and lidocaine hydrochloride in combined 
dosage form has been published. The previous published methods are not directly 
applicable for this issue and need more investigation for method development and 
validation.  
Consequently, the focus in the present study was to develop a validated stability 
indicating HPLC method for the combination, by degrading the drugs together under 
various stress conditions like acid hydrolysis, base hydrolysis, oxidation, thermal and 
photolytic stress which is recommended by ICH guideline. 
The aim and scope of the proposed work are as under: 
 To developed suitable HPLC method for simultaneous determination 
chlorhexidine gluconate and lidocaine hydrochloride in throat spray. 
 Forced degradation study of chlorhexidine gluconate and lidocaine hydrochloride 
under stress condition. 
 To resolve all major impurities generated during the forced degradation studies of 
chlorhexidine gluconate and lidocaine hydrochloride. 
 Perform the validation for the developed method. 
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4. EXPERIMENTAL 
4.1 Materials 
Chlorhexidine gluconate and Lidocaine hydrochloride standard was provided by 
Hetero Drugs Ltd., Hyderabad (India). The sample of throat spray containing 20mg 
chlorhexidine gluconate and 5mg lidocaine hydrochloride per 10ml of formulation and 
the inactive ingredients used in drug matrix were obtained from market. HPLC grade 
acetonitrile was purchased from Spectrochem Pvt. Ltd., Mumbai (India). MiliQ (Milipore 
India (Pvt.) Ltd.) water purification system is used to obtain HPLC grade water. 
Analytical grade sodium hydrogen phosphate monobasic dihydrate, hydrochloric acid, 
sodium hydroxide pellets and 30% v/v hydrogen peroxide solution were obtained from 
RANKEM, New Delhi (India). 
4.2 Instrumentation 
The chromatographic system used to perform development and validation of this 
assay method was comprised of a LC-10ATvp binary pump, a SPD-M10Avp photo-diode 
array detector and a rheodyne manual injector model 7725i with 20μl loop (Shimadzu, 
Kyoto, Japan) connected to a multi-instrument data acquisition and data processing 
system (Class-VP 6.13 SP2, Shimadzu). 
4.3 Mobile phase preparation 
The mobile phase consisted of acetonitrile – 50mM sodium hydrogen phosphate 
monobasic dihydrate buffer pH 3.0. To prepare the buffer solution, 7.8 gm sodium 
hydrogen phosphate monobasic dihydrate was weighed and dissolve in 900 ml HPLC 
grade water and 2.5ml triethylamine is added. The pH of the buffer was adjusted to 3.0 
with orthophosphoric acid. The volume is made upto 1000ml with HPLC grade water. 
Mobile phase was filtered through a 0.45μm nylon membrane (Millipore Pvt. Ltd. 
Bangaluru, India) and degassed in an ultrasonic bath (Spincotech Pvt. Ltd., Mumbai). 
 
4.4 Diluent preparation 
The mixture of phosphate buffer and acetonitrile (85:15, v/v) used as diluent.  
 
4.5 Standard preparation 
Chlorhexidine gluconate standard stock solution containing 1000.7µg/ml was 
prepared in a 100 ml volumetric flask by dissolving 509 mg of chlorhexidine gluconate 
solution in diluent. This solution is then sonicated for 10 minutes and diluted to volume 
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with diluent. Further 20 ml of this stock solution is taken in a 100 ml volumetric flask and 
made up to the mark with diluent (this standard solution of 200.14µg/ml). Lidocaine 
hydrochloride standard stock solution containing 250µg/ml was prepared in a 100 ml 
volumetric flask by dissolving 25.0 mg of lidocaine hydrochloride in diluent and diluted 
to volume with diluent. Further 20 ml of this stock solution is taken in  a 100 ml 
volumetric flask and make the volume up to mark with diluent (this standard solution of 
50µg/ml). 
4.6 Test preparation 
Test solution was prepared by taking 5ml of the sample in a 50 ml volumetric 
flask and about 30 ml of diluent was added and sonicated for a minimum 10 minute with 
intermittent shaking. Then content was brought back to ambient temperature and diluted 
to volume with diluent. The sample was filtered through 0.45µm nylon syringe filter. The 
concentration obtained was 200 µg/ml of chlorhexidine gluconate and 50 µg/ml of 
lidocaine hydrochloride. 
 
4.7 Chromatographic conditions 
Chromatographic analysis was performed on a SGE make SS Wakosil II 5C8RS 
column (150mm x 4.6mm i.d., 5 μm particle size). The flow rate of the mobile phase was 
adjusted to 1.0 ml/min with a gradient program used for the separation is shown below. 
Injection volume was 20 μl. Detection was performed on a photodiode array detector 
(PDA) at 215nm. 
Table 1: Gradient program used for separation of chlorhexidine gluconate and 
lidocaine hydrochloride 
Step Time (Minutes) Acetonitrile (%) Buffer (%) 
1 Initial 15 85 
2 2 15 85 
3 5 20 80 
4 9 25 75 
5 10 25 75 
6 12 30 70 
7 15 30 70 
8 20 30 70 
9 21 15 85 
10 23 15 85 
11 23.01 STOP STOP 
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5. RESULT AND DISCUSSION 
5.1 Development and optimization of the HPLC Method 
In the present work, an analytical method based on LC using UV detector was 
developed and validated for assay determination of chlorhexidine gluconate and lidocaine 
hydrochloride in liquid formulation. The analytical conditions were selected, keeping in 
mind the different chemical nature of chlorhexidine gluconate and lidocaine 
hydrochloride. The development trials were taken by using the degraded sample of each 
component was done, by keeping them in various extreme conditions. 
The column selection has been done on the basis of backpressure, resolution, peak 
shape, theoretical plates and day-to-day reproducibility of the retention time and 
resolution between chlorhexidine gluconate and lidocaine hydrochloride peak. After 
evaluating all these factors, SGE make SS Wakosil II (150mm x 4.6mm i. d., 5 μm 
particle size) C8 column was found to be giving satisfactory results. The selection of 
buffer based on chemical structure of both the drugs. The acidic pH range was found 
suitable for solubility, resolution, stability, theoretical plates and peak shape of both 
components. Considerably good results were obtained with 50mM sodium hydrogen 
phosphate monobasic dihydrate pH 3.0 with orthophosphoric acid solution. For the 
selection of organic constituent of mobile phase, acetonitrile was chosen to reduce the 
longer retention time and to attain good peak shape. To improve the shape the peaks of 
chlorhexidine gluconate and lidocaine hydrochloride, 0.25% triethylamine was added in 
the buffer. Finally, by fixing 50 mM sodium hydrogen phosphate monobasic dihydrate 
pH 3.0 and mobile phase composition consisting of a mixture of sodium hydrogen 
phosphate monobasic dihydrate pH 3.0-acetonitrile (85:15, v/v). During the development 
stage it was found that by using isocratic elution, the retention time of chlorhexidine 
gluconate was around 35 mins. Therefore, the gradient elution mode is selected to shorten 
the runtime. Optimized proportion of mobile phase has shown good resolution between 
chlorhexidine gluconate and lidocaine hydrochloride and also for degradation product 
which is generated during force degradation study. Wavelength selection and PDA scan 
graph are given in Figure 3 and 4 respectively. Figure 5 and Figure 6 represents the 
chromatograms of standard and test preparation respectively. 
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Figure 3: Wavelength scan overlay of standard preparation 
 
 
 
Figure 4: PDA scan of standard preparation 
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   Figure 5: Chromatogram of standard preparation 
 
Figure 6: Chromatogram of test preparation 
 
5.2 Forced degradation study 
In order to determine the analytical method and assay for the study of stability 
indicating method in liquid formulation of chlorhexidine gluconate combined with 
lidoacaine hydrochloride studies under various stressed conditions to conduct forced 
degradation studies. Regulatory guidance in ICH Q2A, Q2B, Q3B and FDA 21CFR 
section 211 all require the development and validation of stability-indicating potency 
assays. Unfortunately, the current guidance documents do not indicate detailed 
degradation conditions in stress testing. However, the used forced degradation conditions, 
stress agent concentration and times of stress, were found to effect degradation, 
preferably not less than 10% and not complete degradation of active materials. The 
discovery of such conditions was based on trial and error. 
The degradation samples were prepared by transferring liquid sample containing 
10 mg chlorhexidine gluconate and 2.5 ml hydrochloride into a 50 ml round bottomed 
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flask. Then prepared samples were employed for acidic, alkaline and oxidant media and 
also for thermal and photolytic stress conditions. After the degradation treatments were 
completed, the stress content solutions were allowed to equilibrate to ambient temperature 
and diluted with mobile phase to attain 0.2 mg/ml of chlorhexidine gluconate and 0.05 
mg/ml
 
of lidocaine hydrochloride concentration. Specific degradation conditions were 
described as follows. 
5.2.1 Acidic condition 
Acidic degradation study was performed by taking the drug content in 0.1 N HCl 
at ambient temperature for 1 hour and mixture was neutralized. The drug content was 
found to be degrading up to 9-15 % in acidic condition (Figure 7).   
 
Figure 7: Chromatogram of acidic forced degradation study 
5.2.2 Alkaline condition 
Alkaline degradation study was performed by taking the drug content in 0.1M 
NaOH at ambient temperature for 1 hour and mixture was neutralized. In alkali 
degradation, it was found that around 7-16 % of the drug degraded (Figure 8).  
 
Figure 8: Chromatogram of alkali forced degradation study 
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5.2.3 Oxidative condition 
Oxidation degradation study was performed by taking the drug content in 30% v/v 
H2O2 at ambient temperature for 1 hour. In oxidative degradation, it was found that 
around 12-24 % of the drug degraded (Figure 9). 
 
Figure 9: Chromatogram of oxidative forced degradation study 
5.2.4 Thermal condition 
Thermal degradation was performed by exposing formulation at 75˚ C for 72 
hour. Resultant chromatogram of thermal degradation study indicates that 12-24% of 
drugs are degraded under thermal degradation condition. (Figure 10) 
 
Figure 10: Chromatogram of thermal degradation study 
5.2.5 Photolytic condition 
Photolytic degradation study was performed by exposing the drug content in UV-
light for 72 h. There is major degradation (15-42%) is observed in photolytic condition. 
Retention time of major degradation product is at 17.1 minute (Figure 11) 
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Figure 11: Chromatogram of UV-light degradation study 
 
5.3 Method validation 
 
5.3.1 Specificity 
The specificity of the method was determined by checking the interference of 
placebo with analyte and the proposed method were eluted by checking the peak purity of 
chlorhexidine gluconate and lidocaine hydrochloride during the force degradation study. 
The peak purity of the chlorhexidine gluconate and lidocaine hydrochloride was found 
satisfactory under different stress condition. There was no interference of any peak of 
degradation product with drug peak Figure 12 and 13 are the chromatograms of Blank 
and placebo respectively. 
 
Figure 12: Chromatogram of blank preparation 
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Figure 13: Chromatogram of placebo preparation 
5.3.2 Linearity 
For linearity seven points calibration curve were obtained in a concentration range 
from 0.040-0.160 mg/ml for chlorhexidine gluconate and 0.016-0.064 mg/ml for 
lidocaine hydrochloride. The response of the drug was found to be linear in the 
investigation concentration range and the linear regression equation (y = mx + c), for 
chlorhexidine gluconate was y = 58207663.48x+ 855859.63 with correlation coefficient 
0.9983(Figure 14) and for lidocaine hydrochloride was y = 45959789.29x + 6293.39 with 
correlation coefficient 0.9998 (Figure 15). Where x is the concentration in mg/ml and y is 
the peak area in absorbance unit. Chromatograms obtained during linearity study are 
shown in Figure 14-22. 
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Figure 14: Linearity curve for chlorhexidine gluconate 
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Linearity Study of Lidocaine Hydrochloride
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Figure 15: Linearity curve for lidocaine hydrochloride 
 
Figure 16: Linearity study chromatogram of level-1 (40%) 
 
Figure17: Linearity study chromatogram of level-2 (60%) 
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Figure18: Linearity study chromatogram of level-3 (80%) 
 
Figure 19: Linearity study chromatogram of level-4 (100%) 
 
 
Figure 20: Linearity study chromatogram of level-5 (120%) 
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Figure 21: Linearity study chromatogram of level-6 (140%) 
 
Figure 22: Linearity study chromatogram of level-7 (160%) 
 
5.3.3 LOD and LOQ 
The limit of detection and limit of quantification were evaluated by serial dilutions 
of chlorhexidine gluconate and lidocaine hydrochloride stock solution in order to obtain 
signal to noise ratio of 3:1 for LOD and 10:1 fro LOQ. The LOD values for chlorhexidine 
gluconate and lidocaine hydrochloride were found to be 0.02 µg/ml and 0.05 µg/ml, 
respectively and the LOQ value 0.1 µg/ml and 0.09 µg/ml, respectively. Chromatogram 
of LOD and LOQ study were shown in Figure 23-26. 
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Figure 23: Chromatogram of LOD study of chlorhexidine gluconate  
 
 
 
Figure 24: Chromatogram of LOD study of lidocaine hydrochloride 
 
 
Figure 25: Chromatogram of LOQ study of chlorhexidine gluconate  
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Figure 26: Chromatogram of LOQ study of lidocaine hydrochloride  
 
 
5.3.4 Precision 
Data obtain from precision experiments are given in Table 2 for intraday and 
interday precision study for both chlorhexidine gluconate and lidocaine hydrochloride. 
The RSD values for intra day precision study and interday precision study was < 2.0 % 
for chlorhexidine gluconate and lidocaine hydrochloride, which confirms that the method 
was precise. 
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Table 2: Results of precision study  
Set 
chlorhexidine gluconate 
(%Assay) 
lidocaine hydrochloride 
(%Assay) 
Intraday 
(n = 6) 
Interday 
(n = 6) 
Intraday 
(n = 6) 
Intraday 
(n = 6) 
1 100.7 99.4 100.0 99.5 
2 99.4 100.6 99.1 99.3 
3 99.6 103.1 99.2 99.1 
4 101.2 99.6 99.0 99.2 
5 100.4 99.6 99.4 99.2 
6 100.7 101.5 99.4 99.4 
Mean 100.3 100.6 99.4 99.3 
Stdev 0.70 1.47 0.36 0.15 
% RSD 0.70 1.46 0.36 0.15 
 
5.3.5 Accuracy 
Recovery of chlorhexidine gluconate and lidocaine hydrochloride was determined 
at three different concentration levels. The mean recovery for chlorhexidine gluconate was 
100.74-102.60 % and 99.07-101.11 % for lidocaine hydrochloride (Table 3). The result 
indicating that the method was accurate. Chromatogram obtain during accuracy study were 
shown in Figure 27-29. 
 
Table 3: Results of accuracy study 
 
 
Level 
(%) 
 
Theoretical 
concentration
a
 
(µg/ml) 
Observed 
concentration
a
 
(µg/ml) 
% 
Recovery 
% RSD 
Chlorhexidine 
gluconate 
50 98.69 99.42 100.74 0.65 
100 196.99 197.71 100.36 0.76 
150 296.74 304.45 102.60 0.40 
Lidocaine 
hydrochloride 
50 25.07 25.09 100.12 1.22 
100 50.20 50.05 99.07 0.65 
150 75.00 75.83 101.11 0.33 
a
 Each value corresponds to the mean of three determinations 
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Figure 27: Accuracy study chromatogram of level-1 (50%) 
 Figure 28: Accuracy study chromatogram of level-2 (100%) 
 Figure 29: Accuracy study chromatogram of level-3 (150%) 
5.3.6 Solution stability study 
Table 4 shows the results obtain in the solution stability study at different time 
intervals for test preparation. It was concluded that the test preparation solution was found 
stable up to 48 h at 2 – 8 ˚C and ambient temperature with the consideration of < 2.0 % in 
%assay value difference against interval value. 
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Table 4: Evaluation data of solution stability study 
 
Intervals 
(hours) 
% Assay for test solution 
stored at 2 -8 ˚C 
% Assay for test solution 
stored at ambient 
temperature 
Chlorhexidine 
gluconate 
Lidocaine 
hydrochloride 
Chlorhexidine 
gluconate 
Lidocaine 
hydrochloride 
Initial -- -- 100.8 99.2 
12 100.4 98.6 100.4 98.9 
24 100.6 97.8 99.5 97.7 
48 100.6 98.0 100.9 97.6 
 
5.3.7 Robustness:  
The result of robustness study of the developed assay method was established in 
Table 5 and Table 6. The result shown that during all variance conditions, assay value of 
the test preparation solution was not affected and it was in accordance with that of actual. 
System suitability parameters were also found satisfactory; hence the analytical method 
would be concluded as robust. Chromatograms obtain during robustness study were 
shown in Figure 27-31. 
 
Table 5: Evaluation data of robustness study of chlorhexidine gluconate  
 
Robust conditions % Assay 
System suitability parameters 
Theoretical 
plates 
Asymmetry Resolution 
Flow 0.9 ml/min 99.1 64832 1.29 27.01 
Flow 1.1 ml/min 101.9 66345 1.27 28.26 
Buffer pH 3.5 101.6 64509 1.13 26.21 
Buffer pH 2.5 98.5 56877 1.49 27.35 
Column change 101.5 49547 1.24 28.44 
 
Table 6: Evaluation data of robustness study for lidocaine hydrochloride  
 
Robust conditions % Assay 
System suitability parameters 
Theoretical plates Asymmetry 
Flow 0.9 ml/min 99.7 5525 1.32 
Flow 1.1 ml/min 100.9 5617 1.33 
Buffer pH 3.5 98.2 5538 1.32 
Buffer pH 2.5 99.2 5580 1.28 
Column change 99.2 4458 1.29 
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Figure 27:  Standard chromatogram (0.9 ml/min flow rate) 
 
 
Figure 28: Standard chromatogram (1.1 ml/min flow rate) 
 
Figure 29: Standard chromatogram (Buffer pH 2.5) 
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Figure 30: Standard chromatogram (pH 3.5) 
 
Figure 31: Standard chromatogram (column change) 
 
5.3.8 System suitability:  
A system suitability test of the chromatographic system was performed before 
each validation run. Five replicate injections of standard preparation were injected and 
asymmetry, theoretical plate, resolution and % RSD of peak area were determined for 
same. Acceptance criteria for system suitability, asymmetry not more than 2.0, theoretical 
plate not less then 40000 for chlorhexidine gluconate and 2000 for lidocaine 
hydrochloride and  % RSD of peak area not more then 2.0, were full fill during all 
validation parameter.  
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6. CALCULATION AND DATA 
 
Calculation formula used 
 
1. Calculation formula for Chlorhexidine gluconate 
 
 
ClaimLabel
StandardofPotency
VolumeTest
WeightStandard
AreaStandardMean
AreaTestMean
Assay
50
100
20
100
%  
 
 
2.  Calculation formula for Lidocaine hydrochloride  
 
 
ClaimLabel
StandardofPotency
VolumeTest
WeightStandard
AreaStandardMean
AreaTestMean
Assay
50
100
20
100
%  
 
 
3. Relative standard deviation  
 
100
tsMeasuremenofValueMean
tMeasuremenofDeviationStandard
RSD
 
 s
%  
 
4. Recovery  
 
100
AddedAmount
FoundAmount
Recovery%  
 
5. Amount Found  
 
ionConcentratStandard
AreaMean
AreaTestMean
mlmgFoundAmount
Standard
)/(  
 
6. Amount added 
 
Volume
Weight
mlmgAddedAmount )/(  
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Specificity study for analytical method validation of chlorhexidine gluconate and 
lidocaine hydrochloride throat spray 
 
For chlorhexidine gluconate 
 
Observation 
Data for standard preparation  Data for test preparation 
   
Replicate Area  Replicate Area 
1 11275604  1 11792251 
2 11112232  2 11062242 
3 11614503  Average 11427246 
4 11566216  % Assay 100.8 
5 11394713    
Average 11392654    
Stdev 207172.74    
% RSD 1.81    
Standard weight 511 mg    
Standard potency 19.66%  Label claim (mg/ml) 2 
 
Calculation: 
 
2
66.19
5
50
100
20
100
511
11392654
11427246
% Assay  = 100.8 % 
 
For lidocaine hydrochloride 
 
Observation 
Data for standard preparation  Data for test preparation 
   
Replicate Area  Replicate Area 
1 2546848  1 2531197 
2 2664365  2 2514859 
3 2594371  Average 2523028 
4 2597015  % Assay 99.1 
5 2564965    
Average 2593513    
Stdev 44792.9    
% RSD 1.72    
Standard weight 25.6 mg    
Standard potency 99.483%  Label claim (mg/ml) 0.5 
 
Calculation: 
 
5.0
483.99
5
50
100
20
100
6.25
2593513
2523028
% Assay = 99.2 %   
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Linearity study for analytical method validation of chlorhexidine gluconate 
lidocaine hydrochloride throat spray 
 
For chlorhexidine gluconate 
 
 
 
 
Standard weight (mg) 510  
Standard dilution 100 20 100 
Standard potency (%) 19.66 
 
Standard concentration (mg/ml) 0.2005 
Concentration of linearity stock 
solution (mg/ml) 
5.1 
      
Replicate 1 2 3 4 5 
Standard area 11272245 11109624 11608758 11265688 11289965 
Mean standard area 11309256  
Stdev 182479.11 
% RSD 1.61 
Concentration level 
(%) 
Volume of 
linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final concentration 
(mg/ml) 
Mean area 
40 8 100 0.0802 4063240 
60 12 100 0.1203 6023495 
80 16 100 0.1604 8113501 
100 20 100 0.2005 10626956 
120 24 100 0.2406 13625370 
140 28 100 0.2807 15434031 
160 32 100 0.3208 17683121 
  Correlation co-efficient 0.9984 
  Slope 58207663.84 
  Intercept -845859.63 
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For lidocaine hydrochloride 
 
 
 
 
Standard weight (mg) 25   
Standard dilution 100 20 100 
Standard potency 99.483% 
 
Standard concentration (mg/ml) 0.0500 
Concentration of linearity stock 
solution (mg/ml) 
0.25 
    
Replicate 1 2 3 4 5 
Standard area 2270243 2270675 2280163 2268047 2283927 
Mean standard area 2274611  
Stdev 6986.96 
% RSD 0.31 
Concentration Level 
(%) 
Volume of 
linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final concentration 
(mg/ml) 
Mean area 
40 8 100 0.020 900704 
60 12 100 0.030 1380356 
80 16 100 0.040 1832130 
100 20 100 0.050 2283964 
120 24 100 0.060 2767930 
140 28 100 0.070 3234601 
160 32 100 0.080 3642188 
  Correlation co-efficient 0.9998 
  Slope 45959789.29 
  Intercept -6293.39 
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Precision study for analytical method validation of chlorhexidine gluconate and 
lidocaine hydrochloride throat spray 
 
For chlorhexidine gluconate 
 
 
 
 
 
 
Description Mean area % assay 
Set 1 11203416 99.7 
Set 2 11061419 99.4 
Set 3 11080865 99.6 
Set 4 11264095 101.2 
Set 5 11177823 100.4 
Set 6 11202213 100.7 
 Mean 100.3 
 Stdev 0.70 
 % RSD 0.70 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
2
66.19
5
50
100
20
100
515
11376993
11203416
% Assay  
 
       = 99.7 % 
 
 
 
 
Standard weight (mg) 515  
Standard dilution 100 20 100 
Standard potency 19.66% 
 Standard concentration (mg/ml) 0.2025 
  
     
Replicate 1 2 3 4 5 
Standard area 11223748 11102689 11602148 11559864 11396514 
Mean standard area 11376993  
Stdev 214035.25 
% RSD 1.88 
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For lidocaine hydrochloride 
 
 
 
Description Mean area % assay 
Set 1 2645834 100.0 
Set 2 2622228 99.1 
Set 3 2624754 99.2 
Set 4 2620925 99.0 
Set 5 2630012 99.4 
Set 6 2631510 99.4 
 Mean 99.4 
 Stdev 0.36 
 % RSD 0.36 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
2
483.99
5
50
100
20
100
2.25
2653859
2645834
% Assay  
 
       = 100.0 % 
Standard weight (mg) 25.2  
Standard dilution 100 20 100 
Standard potency 99.483% 
 
Standard concentration (mg/ml) 0.0501 
     
Replicate 1 2 3 4 5 
Standard area 2259666 2674189 2641024 2644852 2649562 
Mean standard area 2653859  
Stdev 13335.64 
% RSD 0.50 
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Intermediate precision study for analytical method validation of chlorhexidine 
gluconate and lidocaine hydrochloride throat spray 
 
For Chlorhexidine gluconate 
 
 
 
 
 
Description Mean area % Assay 
Set 1 11175024 99.6 
Set 2 11153518 99.4 
Set 3 11288073 100.6 
Set 4 11044656 98.4 
Set 5 11293253 100.6 
Set 6 11262860 100.4 
 Mean 99.8 
 Stdev 0.87 
 % RSD 0.87 
 
Calculation: 
 
Prototype calculation for one set: 
 
2
66.19
5
50
100
20
100
514
11396366
11175024
% Assay  
 
       = 99.6 % 
  
 
Standard weight (mg) 514  
Standard dilution 100 20 100 
Standard potency 19.66% 
 
Standard concentration (mg/ml) 202.1 
      
Replicate 1 2 3 4 5 
Standard area 11280142 11109899 11630168 11572001 11389622 
Mean standard area 11396366  
Stdev 212795.6 
% RSD 1.86 
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For lidocaine hydrochloride 
 
 
 
 
Description Mean area % Assay 
Set 1 2633208 99.5 
Set 2 2627533 99.3 
Set 3 2621843 99.1 
Set 4 2626557 99.2 
Set 5 2625047 99.2 
Set 6 2630012 99.4 
 Mean 99.3 
 Stdev 0.15 
 % RSD 0.15 
 
Calculation: 
 
Prototype calculation for one set: 
 
2
483.99
5
50
100
20
100
3.25
2664353
2633208
% Assay  
 
       = 99.5 % 
Standard weight (mg) 25.3  
Standard dilution 100 20 100 
Standard potency 99.483% 
 
Standard concentration (mg/ml) 0.0503 
      
Replicate 1 2 3 4 5 
Standard area 2652240 2666396 2659400 2678559 2665172 
Mean standard area 2664353  
Stdev 9719.97 
% RSD 0.36 
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Comparison for precision and intermediate precision study for analytical method 
validation for chlorhexidine gluconate and lidocaine hydrochloride throat spray 
 
 
 
  
 
 
 
 
 
 Set 
Chlorhexidine 
gluconate 
Lidocaine 
hydrochloride 
%Assay % Assay 
Precision study 
1 99.7 100.0 
2 99.4 99.1 
3 99.6 99.2 
4 101.2 99.0 
5 100.4 99.4 
6 100.7 99.4 
Intermediate 
precision study 
1 99.6 99.5 
2 99.4 99.3 
3 100.6 99.1 
4 98.4 99.2 
5 100.6 99.2 
6 100.4 99.4 
 Mean 100 99.3167 
 Stdev 0.77811 0.26227 
 
Cumulative 
% RSD 
0.78 0.26 
Chlorhexidine and lidocaine …   Part-A (Section-II) 
 
 
117 
 
Accuracy study for analytical method validation of chlorhexidine gluconate and lidocaine hydrochloride throat spray 
For chlorhexidine gluconate  
 
 
 
 
 
 
 
 
 
 
 
 
 
Standard weight (mg) 511  
Standard dilution 100 20 100 
Standard potency (%) 19.66 
 
Standard concentration (mg/ml) 200.9 
   
Replicate 1 2 3 4 5 
Standard area 11275411 11114528 11521423 11268659 11394157 
Mean standard area 11314836  
Stdev 152299.01 
% RSD 1.35 
Recovery 
level 
Set 
No. 
Mean area Wt. (mg) Volume (ml) 
Value added Value found 
% 
Recovery 
Mean % 
Recovery 
Std 
Dev 
% 
RSD 
concentration 
(mg/ml) 
concentration 
(mg/ml) 
50% 
Set 1 5630745 253 100 0.09948 0.09953 100.05 
100.74 0.66 0.65 Set 2 5614246 249 100 0.09791 0.09924 101.36 
Set 3 5628567 251 100 0.09869 0.09949 100.81 
100% 
Set 1 11129988 502 100 0.19739 0.19673 99.67 
100.36 0.76 0.76 Set 2 11216880 503 100 0.19778 0.19827 100.25 
Set 3 11208696 498 100 0.19581 0.19812 101.18 
150% 
Set 1 17248508 754 100 0.29647 0.30488 102.84 
102.60 0.41 0.40 Set 2 17220599 758 100 0.29805 0.30439 102.13 
Set 3 17203688 752 100 0.29569 0.30409 102.84 
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For lidocaine hydrochloride 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Standard weight (mg) 24.8  
Standard dilution 100 20 100 
Standard potency 99.483% 
  
Standard concentration (mg/ml) 0.0496 
      
Replicate 1 2 3 4 5 
Standard area 2278256 2270555 2277288 2285578 2283702 
Mean standard area 2279075  
Stdev 5919.3 
% RSD 0.26 
Recovery 
level 
Set No. Mean area Wt. (mg) 
Volume 
(ml) 
Value added Value found 
% Recovery 
Mean % 
Recovery 
Std 
Dev 
% 
RSD concentration (mg/ml) 
concentration 
(mg/ml) 
50% 
Set 1 1145710 12.5 100 0.02500 0.02514 100.56 
100.12 1.22 1.22 Set 2 1143313 12.7 100 0.02540 0.02508 98.74 
Set 3 1142205 12.4 100 0.02480 0.02506 101.05 
100% 
Set 1 2274654 25.1 100 0.05020 0.0499 99.40 
99.70 0.65 0.65 Set 2 2288954 25 100 0.05000 0.05022 100.44 
Set 3 2279814 25.2 100 0.05040 0.05002 99.25 
150% 
Set 1 3458969 37.4 100 0.07480 0.07589 101.46 
101.11 0.34 0.33 Set 2 3454657 37.6 100 0.07520 0.07579 100.78 
Set 3 3455944 37.5 100 0.07500 0.07582 101.09 
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Calculation:  
 
For Chlorhexidine gluconate 
 
Prototype calculation for one set: 
 
100
09948.0
0.09953
Recovery%  = 100.74 % 
 
 
2009.0
11314836
5630745
)/( mlmgFoundAmount  = 0.09953 mg/ml 
 
 
100
20
100
253
)/( mlmgAddedAmount  = 0.09948 mg/ml 
 
 
 
 
For Lidocaine hydrochloride 
 
 
Prototype calculation for one set: 
 
100
02500.0
0.02514
Recovery%  = 100.12 % 
 
 
04960.0
2279075
1145710
)/( mlmgFoundAmount  = 0.02514 mg/ml 
 
 
100
20
100
12.5
)/( mlmgAddedAmount  = 0.0250 mg/ml 
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Solution stability study for analytical method validation of chlorhexidine gluconate 
and lidocaine hydrochloride throat spray 
 
For Chlorhexidine gluconate 
 
System suitability of standard preparation for solution stability 
 
Initial 
After 12 
hours 
After 24 
hours 
After 48 
hours 
 Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 11275604 11961990 11845722 11542566 
2 11112232 11899401 11847523 11589485 
3 11614503 11874001 11893654 11549655 
4 11566216 11806207 11847516 11598645 
5 11394713 11932202 11854725 11562489 
Mean 11392654 11894760 11857828 11568568 
Stdev 207172.75 59615.19 20323.73 24560.67 
%RSD 1.82 0.50 0.17 0.21 
 
 
 
 
 
 Solution stability for standard preparation at 2-8 °C 
 
After 12 hours After 24 hours After 48 hours 
Standard Standard Standard 
Replicate Peak area Peak area Peak area 
1 11961990 11845722 11542566 
2 11899401 11847523 11589485 
3 11874001 11893654 11549655 
4 11806207 11847516 11598645 
5 11932202 11854725 11562489 
1 11532589 11628847 11245845 
2 11484524 11695756 11245754 
Mean 11784416 11801963 11476348 
Stdev 195126.94 98746.97 158766.48 
%RSD 1.66 0.84 1.38 
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Solution stability for test preparation at 2-8 °C 
 Initial 
After 12 
hours 
After 24 
hours 
After 48 
hours 
 Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 11275604 11961990 11845722 11542566 
2 11112232 11899401 11847523 11589485 
3 11614503 11874001 11893654 11549655 
4 11566216 11806207 11847516 11598645 
5 11394713 11932202 11854725 11562489 
Replicate Test area Test area Test area Test area 
1 11239111 11686324 11628847 11263597 
2 11239348 11679654 11695756 11425847 
Mean 11239229.5 11682989 11662301.5 11344722 
% Assay 100.47 99.64 99.58 99.29 
Standard weight (mg) 518 516 515 515 
% Difference 
compared to that of 
initial 
-- 0.83 0.89 1.18 
 
 
 
 
Solution stability for test preparation at ambient temperature 
 Initial 
After 12 
hours 
After 24 
hours 
After 48 
hours 
 Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 11275604 11961990 11845722 11542566 
2 11112232 11899401 11847523 11589485 
3 11614503 11874001 11893654 11549655 
4 11566216 11806207 11847516 11598645 
5 11394713 11932202 11854725 11562489 
Replicate Test area Test area Test area Test area 
1 11239111 11675842 11548596 11424542 
2 11239348 11684514 11547589 11405212 
Mean 11239229.5 11680178 11548092.5 11414877 
% Assay 100.47 99.62 98.60 99.90 
Standard weight 
(mg) 
518 516 515 515 
% Difference 
compared to that of 
initial 
-- 0.85 1.87 0.57 
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Calculation: 
 
Prototype calculation for one set: 
 
5.0
66.19
5
50
100
20
100
518
11392653
11239229
% Assay  
 
 
       = 100.4 % 
 
 
Solution stability for standard preparation at ambient temperature 
 
After 12 hours After 24 hours After 48 hours 
Standard Standard Standard 
Replicate Peak area Peak area Peak area 
1 11961990 11845722 11542566 
2 11899401 11847523 11589485 
3 11874001 11893654 11549655 
4 11806207 11847516 11598645 
5 11932202 11854725 11562489 
1 11470377 11470236 11263594 
2 11415935 11493652 11256486 
Mean 11765730 11750433 11480417 
Stdev 226218.84 184285.78 151889.88 
%RSD 1.92 1.57 1.32 
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For lidocaine hydrochloride 
 
 
System suitability of standard preparation for solution stability 
 Initial 
After 12 
hours 
After 24 
hours 
After 48 
hours 
 Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 2635628 2633277 2629245 2645812 
2 2638694 2632476 2685246 2645964 
3 2634516 2609235 2695145 2659637 
4 2637415 2632415 2654111 2628965 
5 2636954 2644200 2685774 2645887 
Mean 2636641 2630321 2669904 2645253 
Stdev 1616.61 12796.61 27508.70 10879.09 
%RSD 0.06 0.49 1.03 0.41 
Solution stability for standard preparation at 2 -8 °C 
 
After 12 hours After 24 hours After 48 hours 
Standard Standard Standard 
Replicate Peak area Peak area Peak area 
1 2633277 2629245 2645812 
2 2632476 2685246 2645964 
3 2609235 2695145 2659637 
4 2632415 2654111 2628965 
5 2644200 2685774 2645887 
1 2623128 2621425 2593325 
2 2608200 2625242 2614548 
Mean 2626133 2656598 2633448 
Stdev 13374.82 31970.11 22866.55 
%RSD 0.51 1.20 0.87 
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Solution stability for test preparation at 2-8°C 
 Initial 
After 12 
hours 
After 24 
hours 
After 48 
hours 
 Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 2635628 2633277 2629245 2645812 
2 2638694 2632476 2685246 2645964 
3 2634516 2609235 2695145 2659637 
4 2637415 2632415 2654111 2628965 
5 2636954 2644200 2685774 2645887 
Replicate Test area Test area Test area Test area 
1 2629584 2608125 2621425 2601486 
2 2628654 2605122 2625242 2608426 
Mean 2629119 2606624 2623333.5 2604956 
% Assay 99.2 98.98 97.75 98.75 
Standard weight (mg) 25.0 25.1 25 25.2 
% Difference compare 
to that of initial 
-- 
0.22 1.45 0.45 
Solution stability for standard preparation at ambient temperature 
 
After 12 hours After 24 hours After 48 hours 
Standard Standard Standard 
Replicate Peak area Peak area Peak area 
1 2633277 2629245 2645812 
2 2632476 2685246 2645964 
3 2609235 2695145 2659637 
4 2632415 2654111 2628965 
5 2644200 2685774 2645887 
1 2605558 2614289 2589879 
2 2602161 2658955 2588454 
Mean 2622760 2660395 2629228 
Stdev 16638.58 30569.26 28775.81 
%RSD 0.63 1.15 1.09 
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Calculation: 
 
Prototype calculation for one set: 
 
5.0
483.99
5
50
100
20
100
0.25
2629119
.2636641
% Assay  
 
= 99.2 %   
 
Solution stability for test preparation at ambient temperature 
 Initial 
After 12 
hours 
After 24 
hours 
After 48 
hours 
 Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 2635628 2633277 2629245 2645812 
2 2638694 2632476 2685246 2645964 
3 2634516 2609235 2695145 2659637 
4 2637415 2632415 2654111 2628965 
5 2636954 2644200 2685774 2645887 
Replicate Test area Test area Test area Test area 
1 2629584 2604356 2622486 2592463 
2 2628654 2627278 2621458 2595547 
Mean 2629119 2615817 2621972 2594005 
% Assay 99.2 99.33 97.70 98.34 
Standard weight 
(mg) 
25.0 25.1 25 25.2 
% Difference 
compare to that of 
initial 
-- -0.13 1.50 0.86 
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Robustness study for analytical method validation of chlorhexidine gluconate and lidocaine hydrochloride throat spray  
For chlorhexidine gluconate 
 
 
Flow rate at 
0.9ml/min 
Flow rate at 
1.1ml/min 
Buffer 
(pH 2.5 ) 
Buffer  
(pH 3.5) 
Column 
change 
Replicate Standard area Standard Area Standard area Standard area Standard area 
1 13275604 11321244 11210906 11142982 11454455 
2 13112232 11160855 11142954 11258683 11223146 
3 13614503 11100137 11123384 11160193 11226099 
4 13566216 11172481 11126960 11489343 11185349 
5 13394713 11062659 11109446 11270453 11323644 
Mean 13392654 11163475 11142730 11264331 11282539 
Stdev 207172.75 98937.60 39933.70 138085.19 108861.87 
% RSD 1.55 0.89 0.36 1.23 0.96 
Replicate Test area Test area Test area Test area Test area 
1 12999437 11137151 11040283 11013236 11289124 
2 12960899 11118019 11096824 11006304 11117015 
Mean 12980168 11127585 11068554 11009770 11203070 
Standard weight 
(mg) 
520 512 510 511 514 
Label claim (mg) 2 2 2 2 2 
% Assay 99.1 100.3 99.6 98.2 100.3 
Calculation:  
Prototype calculation for one set: 
5.0
66.19
5
50
100
20
100
520
13392654
.12999437
% Assay   
 
= 99.1 
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Robustness study for analytical method validation of chlorhexidine gluconate and lidocaine hydrochloride throat spray  
 
For lidocaine hydrochloride 
 
 
Flow rate at 
0.9ml/min 
Flow rate at 
1.1ml/min 
Buffer 
(pH 2.5) 
Buffer  
(pH 3.5) 
Column 
change 
Replicate Standard area Standard area Standard area Standard area Standard area 
1 2727611 2227611 2367963 2333259 2387123 
2 2721240 2221240 2359585 2323463 2373139 
3 2720314 2220314 2348580 2333762 2378531 
4 2713418 2213418 2360249 2321201 2381879 
5 2794981 2194981 2359621 2391370 2384444 
Mean 2735513 2215513 2359200 2340611 2381023 
Stdev 33622.17 12531.58 6910.15 28931.98 5431.70 
% RSD 1.23 0.57 0.29 1.24 0.23 
Replicate Test area Test area Test area Test area Test area 
1 2740867 2298034 2266513 2229573 2284648 
2 2739456 2288017 2256528 2211709 2282105 
Mean 2740162 2293026 2261521 2220641 2283377 
Standard weight 
(mg) 
25 24.5 26 26.1 26.3 
Label claim (mg) 0.5 0.5 0.5 0.5 0.5 
% Assay 99.7 100.9 99.2 98.5 100.4 
 
Calculation: Prototype calculation for one set: 
5.0
483.99
5
50
100
20
100
0.25
2735513
2740162
% Assay  
 
 = 99.7 % 
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UPLC method development 
and validation of 
chlorhexidine gluconate and 
lidocaine hydrochloride in 
throat spray. 
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Rs  =  
N 
 4 ( 
 -1 
   ) 
      k 
    k+1 (    ) 
Retentivity Selectivity System 
Efficiency 
1. INTRODUCTION TO UPLC 
History of chromatography can give an idea about improvement in technology 
from conventional column chromatography to high performance liquid chromatography 
and finally at this stage an ultra performance liquid chromatography or in other way a 
combination of pressurized chromatographic technology and sub 2 (two) micron particle 
size of stationary phase technology leads to advance Ultra Performance Liquid 
Chromatography (UPLC) or Rapid Resolution Liquid Chromatography (RRLC) 
technology. 
Technology of sub 2 (two) micron particle size leads many modifications in 
hardware part of the system like reduction of system volume, higher pump pressure 
capacity, injector and needle part, and cell volume of detector as well as in software area, 
data acquisition rate or capacity was increased for sufficient data collection. 
In brief detail, small particle size columns leads to increase in pump pressure so 
that area was improved and for accurate and precise injection volume needle in needle 
technology with teflon material was came into the picture. Detector cell volume was 
reduced for better signals and resolution. 
Smaller particle size of 2 micron technology altered the machine and its 
application for faster way of analysis in current scenario of separation science. 
Requirement of this technology can be explained by van deemter equation [1,4] and plot 
as shown in Figure 1. From this plot it reveals that there is minimum HETP against the 
linear velocity with the almost constant relation or maximum the theoretical plates can be 
achieved with particle size less than 2 micron. Finally as a known fact increasing in N 
leads to increase in Resolution as shown in formula; 
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Fig.1: Van Deemter plots-influence of particle size 
 
Now, for method conversion from HPLC to UPLC or for comparison of both the 
technology following aspects needs to take in consideration [2, 3]. 
 Ratio of column length to particle size (L/dp) needs to keep constant. i.e. 150 
mm/5 µm = 30,000 is closest to 50mm/1.7 µm = 29,500 
 Column selection should be based on same basic column chemistry i.e. C18 
column should be replaced by C18 column 
 5 µm to 1.7 µm particle size leads to increase in speed of 9X along with 9X 
pressure 
 3 µm to 1.7 µm particle size leads to increase in speed of 3X along with 3X 
pressure 
 5 µm to 1.7 µm particle size leads to increase in peak height of 1.7X 
 3 µm to 1.7 µm particle size leads to increase in peak height of 1.3X 
 5 µm to 1.7 µm particle size leads to decrease in peak width of 0.6X 
 3 µm to 1.7 µm particle size leads to decrease in peak width of 0.8X 
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 Column efficiency (N) is inversely proportional to dp 
 
 
 
i.e. 5 µm to 1.7 µm particle size leads to increase in column efficiency (N) 3X but 
  
 
So, resolution also increase by 1.7X 
Based on above fact practically an example for chromatogram comparison against 
column dimension for rune time and resolution is shown in fig 2. 
 
Where, X is used to express the mathematical relation in multi fold. i.e. pressure increase 
by three times 
 
1.1 Method development 
 
Method development in UPLC remains same as of HPLC but few areas of 
chromatographic conditions are different e.g. for gradient elution column equilibration 
time is very less as compare to HPLC due to lower column volume. 
 
Advance technology in column filled material for HPLC as well as UPLC allows 
higher pH and temperature stability for column for wider choice of mobile phase for 
different applications. e.g. pH of mobile phase or its buffer can selected based on 
compound chemical nature and that can be explain by fig.3 for reversed phase retention 
plot. 
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N
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Figure 2: Chromatogram comparison against column dimension 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Reversed phase retention plot 
 
From the above plot and fundamental theory of solvent gives following 
information for development consideration. 
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ACQUITY UPLC™ BEH C18 
 
 
 
ACQUITY UPLC™ BEH C8 
 
 
ACQUITY UPLC™ BEH Shield RP18 
 
 
ACQUITY UPLC™ BEH Phenyl 
 
1.1.1 Facts for basic compound  
 Alkaline pH increases retention of basic analytes 
 Methanol increases retention of all components compared to acetonitrile 
 Similar basic analytes differ little in selectivity, respective to one another, when 
they are either fully charged or uncharged 
 Largest selectivity differences between bonded phases occur with methanol and 
analytes in their unionized state 
 
1.1.2 Facts for acid compound  
 Acidic pH increases retention of acidic analytes 
 Methanol increases retention of all components compared to acetonitrile 
 Large differences in selectivity are observed when change in pH alters charge 
state 
 Largest selectivity differences between bonded phases occur with methanol and 
analytes in their unionized state 
 
Column chemistry for known columns UPLC is shown in Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Column chemistry of UPLC column 
 By many recent research and development, UPLC presents the ability to extend 
and expand the utility of separation science at a time when many scientists have reached 
separation barriers, pushing the limits of conventional HPLC. New chemistry and 
instrumentation technology can provide more information per unit of work as UPLC 
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begins to fulfil the promise of increased speed, resolution, and sensitivity predicted for 
liquid chromatography. As this is the concept for the scientist many of industries may 
take time to use in routine but it can be the future of the liquid chromatography. Hence 
present research work includes the extended area of HPLC to UPLC as a part of 
technology updating or a balance form of present HPLC and improved LC or UPLC for 
future scope for separation science. 
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UPLC METHOD DEVELOPMENT AND VALIDATION OF CHLORHEXIDINE 
GLUCONATE AND LIDOCAINE HYDROCHLORIDE IN THROAT SPRAY 
1. INTRODUCTION OF DRUG 
Introduction to drugs are same as per Part A: Section II, Page number 76 
 
2. LITERATURE REVIEW 
Literature review for methods developed for Chlorhexidine gluconate and 
lidocaine hydrochloride is mentioned in the Part A: Section II, Page number 83. 
 
3. AIM OF PRESENT WORK 
In recent time, there is increased tendency towards the development of stability-
indicating assays [43-45], using the approach of stress testing as enshrined in the 
International Conference on Harmonization (ICH) guideline Q1A (R2) [46]. Even this 
approach is being extended to drug combinations [47, 48] to allow accurate and precise 
quantitation of multiple drugs in presence of their degradation products and interaction 
product if any. 
Various publications are available regarding determination method of 
Chlorhexidine Gluconate and Lidocaine Hydrochloride but most of the methods are 
applicable either to Chlorhexidine Gluconate or Lidocaine Hydrochloride in various 
pharmaceutical formulations or in biological fluids. Spectrophotometric, ESI-MS, 
Polarographic, Gas chromatographic, Hydrophobic interaction electrokinetic 
chromatography and HPLC methods are reported for determination of chlorhexidine. 
Thin Layer chromatography, SPE-RP-HPLC, LC-MS-MS, HPLC methods are reported 
for the determination of Lidocaine hydrochloride. Only one HPLC method is reported 
simultaneous determination of Chlorhexidine Gluconate and Lidocaine hydrochloride. As 
far as our knowledge is concern, no stability-indicating analytical method for the 
determination of Chlorhexidine Gluconate and Lidocaine hydrochloride in combined 
dosage form has been published. The previous published methods are not directly 
applicable for this issue and need more investigation for method development and 
validation.  
Consequently, the focus in the present study was to develop a validated stability 
indicating UPLC method for the combination, by degrading the drugs together under 
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various stress conditions like acidic, alkali, oxidative, thermal and photolytic stress which 
is recommended by ICH guidelines. 
 
The aim and scope of the proposed work are as under: 
 To developed suitable UPLC method for simultaneous determination 
chlorhexidine gluconate and lidocaine hydrochloride in throat spray. 
 Forced degradation study of chlorhexidine gluconate and lidocaine hydrochloride 
under stress condition. 
 To separate all major impurities generated during the force degradation studies of 
chlorhexidine gluconate and lidocaine hydrochloride. 
 To perform the validation for the developed method. 
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4. EXPERIMENTAL 
4.1 Materials 
Chlorhexidine gluconate and Lidocaine hydrochloride standard of was provided 
by Hetero Drugs Ltd., Hyderabad (India). The sample of throat spray containing 20mg 
chlorhexidine gluconate and 5mg lidocaine hydrochloride per 10ml of formulation and 
the inactive ingredients used in drug matrix were obtained from market. HPLC grade 
acetonitrile was obtained from Spectrochem Pvt. Ltd., Mumbai (India). MiliQ (Milipore 
India (Pvt.) Ltd.) water purification system is used to obtain HPLC grade water. 
Analytical grade sodium dihydrogen phosphate dihydrate, phosphoric acid, hydrochloric 
acid, sodium hydroxide pellets and 30% v/v hydrogen peroxide solution were obtained 
from RANKEM, New Delhi (India). 
4.2 Instrumentation 
The liquid chromatographic system of Waters Acquity UPLC with PDA with 
Empower2 data processing system was used for this entire study and chromatographic 
separation was achieved by using Waters Acquity BEH C18, 2.4 x 50mm, 1.7µ column as 
stationary phase with binary gradient mode. 
4.3 Mobile phase preparation 
The mobile phase consisted of acetonitrile – 20mM sodium hydrogen phosphate 
monobasic monohydrate buffer pH 3.0 (Gradient Elution). To prepare the buffer solution, 
3.12 g sodium Dihydrogen phosphate was weighed and dissolved in 900 ml HPLC grade 
water, 2.5 ml triethylamine is added and pH was adjusted to 3.0 with orthophosphoric 
acid. The volume is made upto 1000 ml with HPLC grade water. Mobile phase was 
filtered through a 0.45 μm nylon membrane (Millipore Pvt. Ltd. Bengaluru, India) and 
degassed in an ultrasonic bath (Spincotech Pvt. Ltd., Mumbai). 
4.4 Diluent preparation 
The mixture of phosphate buffer and acetonitrile (85:15, v/v) used as diluent.  
4.5 Standard preparation 
Chlorhexidine gluconate standard stock solution containing 1000.7 µg/ml was 
prepared in a 100 ml volumetric flask by dissolving 509 mg of chlorhexidine gluconate 
solution in diluent and diluted to volume with diluent. Further 20 ml of this stock solution 
is taken in a 100 ml volumetric flask and made up to the mark with diluent (this standard 
solution of 200.14 µg/ml). Lidocaine hydrochloride standard stock solution containing 
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250 µg/ml was prepared in a 100 ml volumetric flask by dissolving 25.0 mg of Lidocaine 
hydrochloride in diluent and then diluted to volume with diluent. Further 20 ml of this 
stock solution is taken in  a 100 ml volumetric flask and make the volume up to mark 
with diluent (this standard solution of 50 µg/ml). 
4.6 Test preparation 
Test solution was prepared by taking 5ml of the sample in a 50 ml volumetric 
flask and about 30 ml of diluent was added and sonicated for a minimum 10 minute with 
intermittent shaking. Then content was brought back to ambient temperature and diluted 
to volume with diluent. The sample was filtered through 0.45µm nylon syringe filter. The 
concentration obtained was 200 µg/ml of chlorhexidine gluconate and 50 µg/ml of 
Lidocaine hydrochloride. 
4.7 Chromatographic conditions 
Chromatographic analysis was performed on a Waters Acquity BEH C18, 2.4 x 
50mm, 1.7µ column. The flow rate of the mobile phase was adjusted to 0.3 ml/min and 
the injection volume was 4μl partial loop with needle overfill. Detection was performed at 
215nm. A gradient program used for the separation is shown in Table 1. 
 
Table 1: Gradient program used for separation of chlorhexidine gluconate and 
lidocaine hydrochloride 
Step Time (minutes) Flow (ml/min) % Acetonitrile % Buffer 
1 Initial 0.3 85 15 
2 2 0.3 85 15 
3 4 0.3 70 30 
4 6 0.3 70 30 
5 7.5 0.3 85 15 
6 8 0.3 85 15 
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5. RESULT AND DISCUSSION 
5.1 Development and optimization of the UPLC Method 
Proper selection of the methods depends upon the nature of the sample (ionic or 
ionisable or neutral molecule) its molecular weight and solubility. Chlorhexidine 
gluconate and lidocaine hydrochloride is dissolved in polar solvent therefore Reversed 
phase-UPLC was selected to estimate them. To develop a rugged and suitable UPLC 
method for the quantitative determination of Chlorhexidine gluconate and lidocaine 
hydrochloride, the analytical condition were selected after testing the different parameters 
such as diluents, buffer, buffer concentration, organic solvent for mobile phase and 
mobile phase composition and other chromatographic conditions. Our initials trials  using 
different composition of mobile phases consisting of water with methanol or acetonitrile, 
did not give good peak shape.  
A method (Part A: Section II), which is developed using HPLC system is 
transferred to UPLC by considering the dimensions of column, diameter of particles. A 
software provided by the Waters Corporation suggested [5] possible UPLC method 
parameters by entering current HPLC analysis parameters. Software suggested various 
parameters, like optimum flow rate, injection volume, mobile phase composition, gradient 
program etc. The mobile phase consisted of acetonitrile – 20 mM sodium hydrogen 
phosphate monobasic dihydrate buffer pH 3.0. The mobile phase consisted of acetonitrile 
– 20mM (Gradient Elution). To prepare the buffer solution, 3.12 g sodium hydrogen 
phosphate monobasic dihydrate was weighed and dissolved in 900 ml HPLC grade water 
and 2.5ml triethylamine is added then pH of the buffer is adjusted to 3.0 with 
orthophosphoric acid. The volume is then made upto 1000ml with HPLC grade water. 
Mobile phase was filtered through a 0.45μm nylon membrane (Millipore Pvt. Ltd. 
Bengaluru, India) and degassed in an ultrasonic bath (Spincotech Pvt. Ltd., Mumbai). 
 After evaluating all these factors, Waters Acquity BEH C18, 2.4 x 50mm, 1.7µ 
column was found to be giving satisfactory results. The selection of buffer based on 
chemical structure of both the drugs. The acidic pH range was found suitable for 
solubility, resolution, stability, theoretical plates and peak shape of both components. 
Considerably good results were obtained with 20 mM sodium hydrogen phosphate 
monobasic dihydrate pH 3.0 with orthophosphoric acid solution. For the selection of 
organic constituent of mobile phase, acetonitrile was chosen to reduce the longer 
retention time and to attain good peak shape. To improve the shape the peaks of 
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chlorhexidine gluconate and Lidocaine hydrochloride, 0.25% Triethylamine was added in 
the buffer. Finally, by fixing 0.02M sodium hydrogen phosphate monobasic dihydrate pH 
3.0 and mobile phase composition consisting of a mixture of sodium dihydrogen 
phosphate dihydrate pH 3.0-acetonitrile (85:15, v/v). During the development stage it was 
found that by using isocratic elution, the retention time of chlorhexidine gluconate was 
around 13 mins and peak shape was not good. Therefore, the gradient elution mode is 
selected to shorten the runtime. Optimized proportion of mobile phase has shown good 
resolution between chlorhexidine gluconate and lidocaine hydrochloride and also for 
degradation product which is generated during forced degradation study. Figure of 
wavelength selection and PDA scan are given in Figure 3 and 4 respectively. Figure 4 and 
Figure 5 represents the chromatograms of standard and test preparation respectively. 
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Figure 3: Wavelength scan overlay  of standard preparation 
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Figure 4: PDA scan of standard preparation 
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   Figure 5: Chromatogram of standard preparation 
 
Figure 6: Chromatogram of test preparation 
5.2 Forced degradation study 
Various stress conditions are applied to establish a stability indicating assay 
method for determination of chlorhexidine gluconate combined with lidocaine 
hydrochloride in liquid formulation. Regulatory guidance in ICH Q2A, Q2B, Q3B and 
FDA 21CFR section 211 require the development and validation of stability-indicating 
potency assays. Unfortunately, the current guidance documents do not indicate detailed 
degradation conditions in stress testing. However, the used forced degradation conditions, 
stress agent concentration and times of stress, were found to effect degradation, 
preferably not less than 10% and not complete degradation of active materials. The 
discovery of such conditions was based on trial and error. 
The degradation samples were prepared by transferring liquid sample containing 
10 mg chlorhexidine gluconate and 2.5 mg Lidocaine hydrochloride into a 50 ml round 
bottom flask. Then prepared samples were employed for acidic, alkaline and oxidant 
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media and also for thermal and photolytic stress conditions. After the degradation 
treatments were completed, the stress content solutions were allowed to equilibrate to 
ambient temperature and diluted with mobile phase to attain 0.2 mg/ml of chlorhexidine 
gluconate and 0.05 mg/ml
 
of lidocaine hydrochloride concentration. Specific degradation 
conditions were described as follows. 
 
5.2.1 Acidic condition 
Acidic degradation study was performed by taking the drug content in 0.1 N HCl 
at ambient temperature for 1 hour and mixture was neutralized. The drug content was 
found to be degrading up to 10-17 % in acidic condition (Figure 7).   
 
Figure 7: Chromatogram of acidic forced degradation study 
5.2.2 Alkaline condition 
Alkaline degradation study was performed by taking the drug content in 0.1M 
NaOH at ambient temperature for 1 hour and mixture was neutralized. In alkali 
degradation, it was found that around 5-10% of the drug degraded (Figure 8).  
 
Figure 8: Chromatogram of alkali forced degradation study 
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5.2.3 Oxidative condition 
Oxidation degradation study was performed by taking the drug content in 30 % 
v/v H2O2 at ambient temperature for half an hour. In oxidative degradation, it was found 
that around 2-3 % of the drug degraded (Figure 9). 
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Figure 9: Chromatogram of oxidative forced degradation study 
 
5.2.4 Thermal condition 
Thermal degradation was performed by exposing formulation at 75 ˚C for 72 
hours. Resultant chromatogram of thermal degradation study indicates that 30-45% of 
drugs are degraded under thermal degradation condition. (Figure 10) 
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Figure 10: Chromatogram of thermal degradation study 
 
5.2.5 Photolytic condition 
Photolytic degradation study was performed by exposing the drug content in UV-
light for 72 h. There is major degradation (30%) is observed in above specific photolytic 
condition. Retention time of major degradation product is at 3.73 minute (Figure 11) 
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Figure 11: Chromatogram of UV-light degradation study 
 
5.3 Method validation 
5.3.1 Specificity 
The evaluation of the specificity of the method was determined against placebo 
and stress (forced degradation) application. The interference of the excipients of the 
claimed placebo present in the pharmaceutical formulation was derived from placebo 
solution. Further the specificity of the method toward the drug was established by means 
of the interference of the degradation products against drug during the forced degradation 
study by checking peak purity of individual drug. Figure 12 and 13 are chromatograms of 
blank and placebo preparation respectively. 
 
Figure 12: Chromatogram of blank preparation 
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Figure 13: Chromatogram of placebo preparation 
5.3.2 Linearity 
For linearity seven points calibration curve were obtained in a concentration range 
from 0.040-0.160 mg/ml for Chlorhexidine gluconate and 0.016-0.064 mg/ml for 
Lidocaine hydrochloride. The response of the drug was found to be linear in the 
investigation concentration range and the linear regression equation(y = mx + c), for 
Chlorhexidine gluconate was y = 29516386.61x - 210798.46 with correlation coefficient 
0.9997(Figure 14) and for Lidocaine hydrochloride was y = 28773953.57x – 5344.25 
with correlation coefficient 0.9994 (Figure 15). Where x is the concentration in mg/ml 
and y is the peak area in absorbance unit. Chromatograms obtained during linearity study 
are shown in Figure 16-22. 
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Figure 14: Linearity curve for Chlorhexidine hydrochloride 
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Figure 15: Linearity curve for Lidocaine hydrochloride 
 
Figure 16: Linearity study chromatogram of level-1 (40%) 
 
 
Figure17: Linearity study chromatogram of level-2 (60%) 
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Figure18: Linearity study chromatogram of level-3 (80%) 
 
 
Figure 19: Linearity study chromatogram of level-4 (100%) 
 
 
Figure 20: Linearity study chromatogram of level-5 (120%) 
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Figure 21: Linearity study chromatogram of level-6 (140%) 
 
 
Figure 22: Linearity study chromatogram of level-7 (160%) 
 
5.3.3 LOD and LOQ 
The limit of detection and limit of quantification were evaluated by serial dilutions 
of chlorhexidine gluconate and lidocaine hydrochloride stock solution in order to obtain 
signal to noise ratio of 3:1 for LOD and 10:1 fro LOQ. The LOD values for chlorhexidine 
gluconate and lidocaine hydrochloride were found to be 0.02 µg/ml and 0.01 µg/ml, 
respectively and the LOQ value 0.04 µg/ml and 0.25 µg/ml, respectively. Chromatogram 
of LOD and LOQ study were shown in Figure 23-26. 
 
UPLC…   Part-B 
 
 
 
151 
 
 
Figure 23: Chromatogram of LOD Study of chlorhexidine gluconate  
 
 
Figure 24: Chromatogram of LOD study of Lidocaine hydrochloride 
 
 
Figure 25: Chromatogram of LOQ study of chlorhexidine gluconate  
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Figure 26: Chromatogram of LOQ study of Lidocaine hydrochloride  
 
5.3.4 Precision 
Data obtain from precision experiments are given in Table 2 for intraday and 
interday precision study for both Chlorhexidine gluconate and lidocaine hydrochloride. 
The RSD values for intra day precision study and interday precision study was < 2.0 % 
for Chlorhexidine gluconate and lidocaine hydrochloride, which confirms that the method 
was precise. 
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Table 2: Results of precision study  
Set 
Chlorhexidine gluconate 
(%Assay) 
Lidocaine hydrochloride 
(%Assay) 
Intraday 
(n = 6) 
Interday 
(n = 6) 
Intraday 
(n = 6) 
Intraday 
(n = 6) 
1 100.5 100.8 99.7 99.5 
2 99.8 99.8 100.1 99.4 
3 100.6 100.7 99.7 99.7 
4 100.2 100.4 100.3 99.8 
5 99.9 101.0 99.9 99.5 
6 99.6 99.7 99.3 98.9 
Mean 100.2 100.4 99.9 99.5 
Stdev 0.42 0.53 0.33 0.33 
% RSD 0.42 0.53 0.33 0.33 
 
5.3.5 Accuracy 
Recovery of Chlorhexidine gluconate and lidocaine hydrochloride was determined 
at three different concentration levels. The mean recovery for Chlorhexidine gluconate was 
98.6-99.80 % and 99.17-99.52 % for Lidocaine hydrochloride (Table 3). The result 
indicating that the method was accurate. Chromatogram obtain during accuracy study were 
shown in Figure 27-29. 
 
Table 3: Results of accuracy study 
 
Level 
(%) 
 
Theoretical 
concentration
a
 
(µg/ml) 
Observed 
concentration
a
 
(µg/ml) 
% 
Recovery 
% RSD 
Chlorhexidine 
gluconate 
50 97.78 97.70 99.80 0.63 
100 199.35 196.55 98.60 0.34 
150 294.11 292.01 99.29 0.25 
Lidocaine 
hydrochloride 
50 24.90 24.73 99.31 0.99 
100 50.20 49.96 99.52 0.52 
150 75.07 74.45 99.17 0.90 
a
 Each value corresponds to the mean of three determinations 
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Figure 27: Accuracy study chromatogram of level-1 (50%) 
 
 Figure 28: Accuracy study chromatogram of level-2 (100%) 
 
 Figure 29: Accuracy study chromatogram of level-3 (150%) 
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5.3.6 Solution stability study 
Table 4 shows the results obtain in the solution stability study at different time 
intervals for test preparation. It was concluded that the test preparation solution was found 
stable up to 48 h at 2 - 8˚ C and ambient temperature with the consideration of < 2.0 % in 
% assay value difference against interval value. 
 
Table 4: Evaluation data of solution stability study 
Intervals 
hours 
% Assay for test solution 
stored at 2-8 ˚C 
% Assay for test solution 
stored at ambient 
temperature 
Chlorhexidine 
gluconate 
Lidocaine 
hydrochloride 
Chlorhexidine 
gluconate 
Lidocaine 
hydrochloride 
Initial -- -- 100.2 99.6 
12 100.1 99.5 100.1 99.9 
24 100.2 99.8 100.0 99.2 
36 100.2 99.1 100.4 99.0 
48 100.2 98.7 100.3 98.7 
 
5.3.7 Robustness:  
The result of robustness study of the developed assay method was established in 
Table 5 and Table 6 The result shown that during all variance conditions, assay value of 
the test preparation solution was not affected and it was in accordance with that of actual. 
System suitability parameters were also found satisfactory; hence the analytical method 
would be concluded as robust. Chromatogram obtain during robustness study were shown 
in Figure 30-34. 
UPLC…   Part-B 
 
 
 
156 
 
Table 5: Evaluation data of robustness study of chlorhexidine Gluconate  
Robust conditions % Assay 
System suitability parameters 
Theoretical plates Asymmetry Resolution 
Flow 0.2 ml/min 100.8 15814 1.51 28.55 
Flow 0.4 ml/min 100.3 15733 1.53 28.01 
Buffer pH 3.2 101.6 17517 1.48 27.66 
Buffer pH 2.8 98.5 17415 1.50 28.63 
Column change 100.5 16295 1.61 24.24 
 
Table 6: Evaluation data of robustness study for Lidocaine hydrochloride  
Robust conditions % Assay 
System suitability parameters 
Theoretical plates Asymmetry 
Flow 0.2 ml/min 99.4 3328 1.36 
Flow 0.4 ml/min 100.0 3964 1.31 
Buffer pH 3.2 99.4 3785 1.34 
Buffer pH 2.8 98.6 3458 1.29 
Column change 99.1 3013 1.30 
 
 
Figure 30:  Standard chromatogram (0.2 ml/min flow rate) 
 
Figure 31: Standard chromatogram (0.4 ml/min flow rate) 
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Figure 32: Standard chromatogram (Buffer pH 2.8 ) 
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Figure 33: Standard chromatogram (pH 3.2) 
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Figure 34: Standard chromatogram (Column change) 
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5.3.8 System suitability:  
A system suitability test of the chromatographic system was performed before 
each validation run. Five replicate injections of standard preparation were injected and 
asymmetry, theoretical plate, resolution and % RSD of peak area were determined for 
same. Acceptance criteria for system suitability, Asymmetry not more than 2.0, 
theoretical plate not less then 2000 for chlorhexidine gluconate and lidocaine 
hydrochloride and  % RSD of peak area not more then 2.0, were fullfill during all 
validation parameter.  
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6. CALCULATION AND DATA 
 
Calculation formula used: 
 
1. Calculation formula for Chlorhexidine gluconate 
ClaimLabel
StandardofPotency
VolumeTest
WeightStandard
AreaStandardMean
AreaTestMean
Assay
50
100
20
100
%  
 
2.  Calculation formula for Lidocaine hydrochloride  
ClaimLabel
StandardofPotency
VolumeTest
WeightStandard
AreaStandardMean
AreaTestMean
Assay
50
100
20
100
%  
 
3. Relative standard deviation  
100
tsMeasuremenofValueMean
tMeasuremenofDeviationStandard
RSD
 
 s
%  
 
4. Recovery  
100
AddedAmount
FoundAmount
Recovery%  
 
5. Amount Found  
ionConcentratStandard
AreaMean
AreaTestMean
mlmgFoundAmount
Standard
)/(  
 
6. Amount added 
Volume
Weight
mlmgAddedAmount )/(  
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Specificity study for analytical method validation of chlorhexidine gluconate and 
lidocaine hydrochloride throat spray 
For chlorhexidine gluconate 
Observation 
Data for standard preparation  Data for test preparation 
   
Replicate Area  Replicate Area 
1 5691260  1 5595498 
2 5709854  2 5595434 
3 5708006  Average 5595466 
4 5705592  % Assay 99.9 
5 5709263    
Average 5704795    
Stdev 7741.099    
% RSD 0.14    
Standard weight 518 mg    
Standard potency 19.66%  Label claim (mg/ml) 2 
Calculation for Assay: 
2
66.19
5
50
100
20
100
518
5704795
5595466
% Assay  = 99.9 % 
 
For lidocaine hydrochloride 
Observation 
Data for Standard preparation  Data for Test preparation 
   
Replicate Area  Replicate Area 
1 1424382  1 1442279 
2 1425855  2 1455422 
3 1429992  Average 1448851 
4 1431669  % Assay 100.1 
5 1427254    
Average 1427830    
Stdev 2980.49    
% RSD 0.21    
Standard weight 24.8 mg    
Standard potency 99.483%  Label claim (mg/ml) 0.5 
Calculation for Assay: 
5.0
483.99
5
50
100
20
100
8.24
1427830
1448851
% Assay = 100.1 %   
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Linearity study for analytical method validation of chlorhexidine gluconate 
lidocaine hydrochloride throat spray 
 
For Chlorhexidine gluconate 
 
 
 
Standard weight (mg) 515  
Standard dilution 100 20 100 
Standard potency (%) 19.66 
 
Standard concentration (mg/ml) 0.2024 
Concentration of linearity stock 
solution (mg/ml) 
5.15 
      
Replicate 1 2 3 4 5 
Standard area 5701244 5698485 5710014 5714958 5705874 
Mean standard area 5706115  
Stdev 6621.98 
% RSD 0.11 
Concentration level 
(%) 
Volume of 
linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final concentration 
(mg/ml) 
Mean area 
40 8 100 0.0810 2179466 
60 12 100 0.1215 3355599 
80 16 100 0.1620 4396532 
100 20 100 0.2025 5773890 
120 24 100 0.2430 6857398 
140 28 100 0.2835 8006322 
160 32 100 0.3240 9278146 
  Correlation co-efficient 0.9997 
  Slope 29516386.61 
  Intercept -210798.46 
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For lidocaine hydrochloride 
 
 
Standard weight (mg) 25.1  
Standard dilution 100 20 100 
Standard potency 99.483% 
 
Standard concentration (mg/ml) 0.0502 
Concentration of linearity stock 
solution (mg/ml) 
0.251 
    
Replicate 1 2 3 4 5 
Standard area 1423547 1424968 1428865 1430896 1426745 
Mean standard area 1427004  
Stdev 2948.48 
% RSD 0.20 
Concentration level 
(%) 
Volume of 
linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final concentration 
(mg/ml) 
Mean area 
40 8 100 0.020 570421 
60 12 100 0.030 873500 
80 16 100 0.040 1124476 
100 20 100 0.050 1429380 
120 24 100 0.060 1709450 
140 28 100 0.070 2048749 
160 32 100 0.080 2277499 
  Correlation co-efficient 0.9994 
  Slope 28773953.57 
  Intercept -5344.25 
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Precision study for analytical method validation of chlorhexidine gluconate and 
lidocaine hydrochloride throat spray 
 
For chlorhexidine gluconate 
 
 
 
 
 
 
 
 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
2
66.19
5
50
100
20
100
510
5871425
5891109
% Assay  = 100.5 % 
Standard weight (mg) 510  
Standard dilution 100 20 100 
Standard potency 19.66%   
Standard concentration (mg/ml) 0.2005   
     
Replicate 1 2 3 4 5 
Standard area 5871425 5872845 5889652 5902153 5844263 
Mean standard area 5876069  
Stdev 21842.60 
% RSD 0.37 
Description Mean area % Assay 
Set 1 5891109 100.5 
Set 2 5846327 99.8 
Set 3 5896366 100.6 
Set 4 5872465 100.2 
Set 5 5856239 99.9 
Set 6 5835628 99.6 
 Mean 100.2 
 Stdev 0.42 
 % RSD 0.42 
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For lidocaine hydrochloride 
 
 
Description Mean area % Assay 
Set 1 1445245 99.7 
Set 2 1449949 100.1 
Set 3 1444289 99.7 
Set 4 1452886 100.3 
Set 5 1446983 99.9 
Set 6 1439016 99.3 
 Mean 99.9 
 Stdev 0.33 
 % RSD 0.33 
 
Calculation: 
Prototype calculation for one set: 
 
5.0
483.99
5
50
100
20
100
25
1441629
1445245
% Assay   
 
= 99.7% 
 
Standard weight (mg) 25  
Standard dilution 100 20 100 
Standard potency 99.483% 
 
Standard concentration (mg/ml) 0.05 
     
Replicate 1 2 3 4 5 
Standard area 1451277 1453654 1451142 1416845 1439409 
Mean standard area 1441629  
Stdev 15750.51 
% RSD 1.09 
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Intermediate precision study for analytical method validation of chlorhexidine 
gluconate and lidocaine hydrochloride throat spray 
 
For chlorhexidine gluconate 
 
Description Mean area % Assay 
Set 1 5795466 100.8 
Set 2 5741356 99.8 
Set 3 5792154 100.7 
Set 4 5773204 100.4 
Set 5 5807785 101.0 
Set 6 5733154 99.7 
 Mean 100.4 
 Stdev 0.53 
 % RSD 0.53 
 
Calculation: 
 
Prototype calculation for one set: 
2
66.19
5
50
100
20
100
520
5804786
5795466
% Assay   = 100.8 % 
Standard weight (mg) 520  
Standard dilution 100 20 100 
Standard potency 19.66% 
 
Standard concentration (mg/ml) 204.4 
      
Replicate 1 2 3 4 5 
Standard area 5870714 5875694 5893109 5922461 5833154 
Mean standard area 5804786  
Stdev 59421.8 
% RSD 1.02 
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For lidocaine hydrochloride 
 
 
Description Mean area % Assay 
Set 1 1448851 99.9 
Set 2 1447097 99.8 
Set 3 1451923 100.1 
Set 4 1452875 100.2 
Set 5 1448158 99.9 
Set 6 1439409 99.3 
 Mean 99.9 
 Stdev 0.33 
 % RSD 0.33 
 
Calculation: 
 
Prototype calculation for one set: 
 
5.0
483.99
5
50
100
20
100
1.25
1448137
1448851
% Assay  = 99.9 % 
Standard Weight (mg) 25.1  
Standard Dilution 100 20 100 
Standard Potency 99.483% 
 
Standard Concentration (mg/ml) 0.0502 
      
Replicate 1 2 3 4 5 
Standard area 1453402 1452347 1479710 1416845 1439409 
Mean standard area 1448137  
Stdev 16630.13 
% RSD 1.14 
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Comparison for precision and intermediate precision study for analytical method 
validation for chlorhexidine gluconate and lidocaine hydrochloride throat spray 
 
 
  
 
 
 
 
 
 Set 
Chlorhexidine 
gluconate 
Lidocaine 
hydrochloride 
%Assay % Assay 
Precision study 
1 99.7 100.5 
2 100.1 99.8 
3 99.7 100.6 
4 100.3 100.2 
5 99.9 99.9 
6 99.3 99.6 
Intermediate 
precision study 
1 100.8 99.9 
2 99.8 99.8 
3 100.7 100.1 
4 100.4 100.2 
5 101.0 99.9 
6 99.7 99.3 
 
Mean 100.2 100.0 
Stdev 0.53 0.36 
Cumulative 
% RSD 
0.52 0.36 
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Accuracy study for analytical method validation of chlorhexidine gluconate and lidocaine hydrochloride throat spray 
For chlorhexidine gluconate  
 
 
 
 
 
 
 
 
Standard weight (mg) 514   
Standard dilution 100 20 100 
Standard potency (%) 19.66 
 
Standard concentration (mg/ml) 202.1 
      
Replicate 1 2 3 4 5 
Standard area 5876528 5856324 5872356 5902965 5859632 
Mean standard area 5873561  
Stdev 18479.6 
% RSD 0.31 
Recovery 
Level 
Set No. 
Mean 
area 
Wt. 
(mg) 
Volume 
(ml) 
Value added Value found 
% 
Recovery 
Mean % 
Recovery 
Stdev 
% 
RSD 
concentration  
(mg/ml) 
concentration  
(mg/ml) 
50% 
Set 1 2863524 249 100 0.09791 0.09751 99.59 
99.80 0.63 0.63 Set 2 2855164 246 100 0.09673 0.09722 100.51 
Set 3 2877688 251 100 0.09869 0.09799 99.29 
100% 
Set 1 5794678 507 100 0.19935 0.19731 98.98 
98.60 0.34 0.34 Set 2 5753648 506 100 0.19896 0.19592 98.47 
Set 3 5768728 508 100 0.19975 0.19643 98.34 
150% 
Set 1 8576833 746 100 0.29333 0.29205 99.56 
99.29 0.25 0.25 Set 2 8567664 748 100 0.29411 0.29174 99.19 
Set 3 8582490 750 100 0.29490 0.29224 99.10 
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For lidocaine hydrochloride 
 
 
 
 
 
 
 
 
 
Standard weight (mg) 25.1  
Standard dilution 100 20 100 
Standard potency 99.483% 
 
Standard concentration (mg/ml) 0.0502 
      
Replicate 1 2 3 4 5 
Standard area 1452658 1454714 1474856 1454586 1438540 
Mean standard area 1455070  
Stdev 12950.9 
% RSD 0.89 
Recovery 
Level 
Set No. 
Mean 
area 
Wt. 
(mg) 
Volume 
(ml) 
Value added Value found 
% Recovery 
Mean % 
Recovery 
Std 
Dev 
% 
RSD 
concentration 
(mg/ml) 
concentration 
(mg/ml) 
50% 
Set 1 726055 12.4 100 0.02480 0.02495 100.60 
99.49 0.99 0.99 Set 2 718650 12.5 100 0.02490 0.02469 99.16 
Set 3 718142 12.5 100 0.02500 0.02468 98.72 
100% 
Set 1 1463036 25.1 100 0.05020 0.05027 100.14 
99.70 0.52 0.52 Set 2 1454047 25.2 100 0.05040 0.04996 99.13 
Set 3 1452523 25 100 0.05000 0.04991 99.82 
150% 
Set 1 2191102 37.5 100 0.07500 0.07529 100.39 
99.37 0.89 0.89 Set 2 2165200 37.6 100 0.07520 0.0744 98.94 
Set 3 2155718 37.5 100 0.07500 0.07408 98.77 
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Calculation:  
 
For chlorhexidine gluconate 
 
Prototype calculation for one set: 
 
100
09791.0
0.09751
Recovery%  = 99.59 % 
 
 
2021.0
5873561
2863524
)/( mlmgFoundAmount  = 0.09751 mg/ml 
 
 
100
20
100
249
)/( mlmgAddedAmount  = 0.09791 mg/ml 
 
For lidocaine hydrochloride 
 
Prototype calculation for one set: 
 
100
02480.0
0.02495
Recovery%  = 100.6 % 
 
 
0502.0
1455070
726055
)/( mlmgFoundAmount  = 0.02495 mg/ml 
 
 
100
20
100
12.4
)/( mlmgAddedAmount  = 0.0248 mg/ml 
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Solution stability study for analytical method validation of chlorhexidine gluconate 
and lidocaine hydrochloride throat spray 
 
For chlorhexidine gluconate 
 
System suitability of standard preparation for solution stability 
 
Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 5782653 5782869 5788421 5769965 5793896 
2 5781458 5796587 5784564 5722487 5724585 
3 5789924 5781253 5782262 5785697 5747182 
4 5788865 5784865 5786542 5785542 5742144 
5 5781021 5800124 5789664 5766895 5763998 
Mean 5784784 5789140 5786291 5766117 5754361 
Stdev 4267.25 8601.04 2966.16 25882.89 26188.22 
%RSD 0.07 0.15 0.05 0.45 0.46 
 
 
 
Solution stability for standard preparation at 2-8 °C 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 5782869 5788421 5769965 5793896 
2 5796587 5784564 5722487 5724585 
3 5781253 5782262 5785697 5747182 
4 5784865 5786542 5785542 5742144 
5 5800124 5789664 5766895 5763998 
1 5784280 5782452 5784968 5721684 
2 5786247 5785585 5783015 5788494 
Mean 5788032 5785641 5771224 5754569 
Stdev 7295.08 2812.92 22869.26 28797.67 
%RSD 0.13 0.05 0.40 0.50 
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Solution stability for test preparation at 2-8 °C 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 5782653 5782869 5788421 5769965 5793896 
2 5781458 5796587 5784564 5722487 5724585 
3 5789924 5781253 5782262 5785697 5747182 
4 5788865 5784865 5786542 5785542 5742144 
5 5781021 5800124 5789664 5766895 5763998 
Replicate Test area Test area Test area Test area Test area 
1 5781256 5781214 5782452 5786245 5721486 
2 5785841 5782663 5785585 5748548 5786245 
Mean 5783549 5781939 5784019 5767397 5753866 
% Assay 100.24 99.94 100.42 100.29 100.45 
Standard weight (mg) 510 509 511 510 511 
% Difference 
compare to that of 
initial 
-- 0.30 -0.18 -0.05 -0.21 
 
Solution stability for test preparation at ambient temperature 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 5782653 5782869 5788421 5769965 5793896 
2 5781458 5796587 5784564 5722487 5724585 
3 5789924 5781253 5782262 5785697 5747182 
4 5788865 5784865 5786542 5785542 5742144 
5 5781021 5800124 5789664 5766895 5763998 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 5781256 5781526 5753245 5769012 5786695 
2 5785841 5784613 5789988 5786301 5732458 
Mean 5783549 5783070 5771617 5777657 5759577 
% Assay 100.24 99.96 100.21 100.47 100.55 
Standard weight  510 509 511 510 511 
(mg) 
% Difference 
compare to that of 
initial 
-- 0.28 0.03 -0.23 -0.31 
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Solution stability for standard preparation at ambient temperature 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 5782869 5788421 5769965 5793896 
2 5796587 5784564 5722487 5724585 
3 5781253 5782262 5785697 5747182 
4 5784865 5786542 5785542 5742144 
5 5800124 5789664 5766895 5763998 
1 5782241 5786485 5792566 5730215 
2 5782415 5784221 5754215 5701265 
Mean 5787193 5786023 5768195 5743326 
Stdev 7769.70 2549.87 24120.08 29701.78 
%RSD 0.13 0.04 0.42 0.52 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
5.0
66.19
5
50
100
20
100
510
5784784
5783549
% Assay  
 
       = 100.24 % 
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For Lidocaine hydrochloride 
 
 
 
System suitability of standard preparation for solution stability 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1423659 1423648 1423669 1460298 1429987 
2 1425368 1425374 1430748 1430256 1425478 
3 1425478 1424741 1426335 1420156 1426585 
4 1423257 1423256 1466854 1420226 1422653 
5 1422142 1422749 1425845 1422568 1426368 
Mean 1423981 1423956 1434690 1430701 1426214 
Stdev 1429.56 1079.65 18162.91 17053.22 2627.70 
%RSD 0.10 0.08 1.27 1.19 0.18 
Solution stability for standard preparation at 2 -8 °C 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 1423648 1423669 1460298 1429987 
2 1425374 1430748 1430256 1425478 
3 1424741 1426335 1420156 1426585 
4 1423256 1466854 1420226 1422653 
5 1422749 1425845 1422568 1426368 
Replicate Peak area Peak area Peak area Peak area 
1 1423558 1426984 1469857 1423549 
2 1425447 1476232 1426785 1422015 
Mean 1424112 1439524 1435735 1425234 
Stdev 1070.36 22140.17 20552.28 2757.55 
%RSD 0.08 1.54 1.43 0.19 
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Solution stability for test preparation at 2-8 °C 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1423659 1423648 1423669 1460298 1429987 
2 1425368 1425374 1430748 1430256 1425478 
3 1425478 1424741 1426335 1420156 1426585 
4 1423257 1423256 1466854 1420226 1422653 
5 1422142 1422749 1425845 1422568 1426368 
Replicate Test area Test area Test area Test area Test area 
1 1428633 1422145 1426984 1423933 1416986 
2 1423365 1426658 1476232 1426545 1412142 
Mean 1425999 1424402 1451608 1425239 1414564 
% Assay 100.02 99.12 99.85 99.50 98.67 
Standard weight (mg) 25.1 24.9 24.8 25.1 25 
% Difference compare 
to that of Initial 
-- 0.90 0.17 0.52 1.35 
Solution stability for standard preparation at ambient temperature 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 1423648 1423669 1460298 1429987 
2 1425374 1430748 1430256 1425478 
3 1424741 1426335 1420156 1426585 
4 1423256 1466854 1420226 1422653 
5 1422749 1425845 1422568 1426368 
Replicate Peak area Peak area Peak area Peak area 
1 1426014 1442695 1487546 1402156 
2 1420368 1455847 1468530 1425628 
Mean 1423737 1438856 1444226 1422694 
Stdev 1890.17 16880.79 27523.36 9309.46 
%RSD 0.13 1.17 1.91 0.65 
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Calculation: 
 
Prototype calculation for one set: 
 
5.0
483.99
5
50
100
20
100
1.25
1423981
1425999
Assay%  
 
= 100.02 %   
 
Solution stability for test preparation at ambient temperature 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1423659 1423648 1423669 1460298 1429987 
2 1425368 1425374 1430748 1430256 1425478 
3 1425478 1424741 1426335 1420156 1426585 
4 1423257 1423256 1466854 1420226 1422653 
5 1422142 1422749 1425845 1422568 1426368 
Replicate Test area Test area Test area Test area Test area 
1 1428633 1435851 1436025 1425923 1410148 
2 1423365 1423698 1425689 1422635 1420156 
Mean 1425999 1429775 1430857 1424279 1415152 
% Assay 100.02 99.49 98.42 99.43 98.71 
Standard weight 
(mg) 
25.1 24.9 24.8 25.1 25 
% Difference 
compare to that of 
initial 
-- 0.53 1.60 0.59 1.31 
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Robustness study for analytical method validation of chlorhexidine gluconate and lidocaine hydrochloride throat spray 
For chlorhexidine gluconate 
 
 
Flow rate at 
0.2ml/min 
Flow rate at 
0.4ml/min 
Buffer (pH 2.8) Buffer (pH 3.2) Column change 
Replicate Standard area Standard area Standard area Standard area Standard area 
1 5996584 5563254 5783014 5788654 5766325 
2 5902547 5563289 5786632 5786224 5768542 
3 5902145 5564128 5790324 5754821 5786245 
4 5906587 5564257 5722140 5785549 5721400 
5 5908566 5560283 5805421 5780683 5723650 
Mean 5923286 5563042 5777506 5779186 5753232 
Stdev 41064.52 1610.41 32103.60 13924.43 29086.30 
% RSD 0.69 0.03 0.56 0.24 0.51 
Replicate Test area Test area Test area Test area Test area 
1 5943625 5563241 5796584 5782495 5766584 
2 5966374 5569672 5766534 5574850 5763254 
Mean 5955000 5566457 5781559 5678673 5764919 
Standard weight (mg) 510 510 510 511 514 
Label claim (mg) 2 2 2 2 2 
% Assay 100.8 100.3 98.5 100.3 100.5 
Calculation:  Prototype calculation for one set: 
2
66.19
5
50
100
20
100
510
5923286
5955000
% Assay   = 100.8% 
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Robustness study for analytical method validation of chlorhexidine gluconate and lidocaine hydrochloride throat spray  
For lidocaine hydrochloride 
 
 
Flow rate at 
0.2ml/min 
Flow rate at 
0.4ml/min 
Buffer (pH 2.8) Buffer (pH 3.2) Column change 
Replicate Standard area Standard area Standard area Standard area Standard area 
1 1632548 1255475 1452968 1458632 1452254 
2 1632547 1254214 1459867 1457486 1465833 
3 1636958 1225663 1450124 1455842 1466284 
4 1639985 1254474 1453021 1457481 1458745 
5 1638470 1259682 1453845 1452635 1452498 
Mean 1636102 1249902 1453965 1456415 1459123 
Stdev 3416.39 13727.09 3587.70 2335.34 6846.91 
% RSD 0.21 1.10 0.25 0.16 0.47 
Replicate Test area Test area Test area Test area Test area 
1 1635248 1245874 1450124 1433251 1453187 
2 1635228 1266358 1456685 1452495 1453764 
Mean 1635238 1256116 1453405 1442873 1453476 
Standard weight (mg) 25 25 25 25 25 
Label claim (mg) 0.5 0.5 0.5 0.5 0.5 
% Assay 99.4 100.0 99.4 98.6 99.1 
Calculation: Prototype calculation for one set: 
5.0
483.99
5
50
100
20
100
25
1636102
1635238
% Assay  = 99.7 % 
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Comparison of HPLC and UPLC methods for the determination of chlorhexidine 
gluconate and lidocaine hydrochloride 
UPLC has been proved to be an effective technique for the analysis of 
chlorhexidine gluconate and lidocaine hydrochloride in throat spray sample analysis. 
Total analysis time was 7.0 min and the retention times of chlorhexidine gluconate and 
Lidocaine hydrochloride were 1.3 min and 4.5 min, respectively. Other performance data 
for UPLC are discussed below in the critical comparison of UPLC   analysis   with   use   
of   HPLC. Use of classical HPLC, with C8 columns, for this purpose has been developed 
earlier. The conditions used for each type of chromatography are compared in Table 6. 
Phosphate Buffer: Acetonitrile  was always used as mobile phase  (MP)  and  all  the  
stationary  phases  were  based  on octadecylsilica; there were, however, significant 
differences between  other  properties  of  the  columns  used,  especially particle size, 
porosity, internal diameter, and column length. As would be expected, analysis time was 
longest for the conventional HPLC particulate column. Better   resolution,   speed,   and   
sensitivity   were obtained by use of the UPLC column packed with 1.7-μm particles, but 
at higher back-pressure, which the UPLC system can resist.  
Because of the high separation efficiency, small  particle  size,  and  narrow  
column  internal  diameter, UPLC  uses  very  low  mobile-phase  flow  rates  and  
analysis times  are  short.  In  summary,  use  of  UPLC columns  results  in  time  saving  
of  approximately  47  h  for analysis  of  one-hundred  samples.  Mobile phase 
consumption per minute in UPLC  is  approximately  one  third  that  in  HPLC,  which  is  
economically  important  to laboratories  processing  large  numbers  of  samples.  When 
the  different  internal  diameters  of  the  columns  are  taken into account (4.6 mm for the 
HPLC column), this effect on  solvent  consumption  can,  nevertheless,  be  regarded  as 
insignificant. 
Table 6:   Comparison of chromatographic conditions 
 UPLC HPLC 
Stationary phase Bridged ethylsiloxane/silica, 
hybrid C18  particles, 1.7µ 
C8, 5µ 
Column dimensions 2.4 x 50mm 4.6 x 150mm 
Flow rate (ml/min) 0.3 1 
Retention time in minutes 
Chlorhexidine gluconate 4.5 19.1 
Lidocaine hydrochloride 1.3 6.2 
Total analysis time (Minutes) 7 35 
Solvent consumption (ml per run) 2.1 35 
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Validation 
Validation data for analysis of chlorhexidine gluconate and lidocaine 
hydrochloride by use of the two chromatographic systems are compared in Table 7.  
Application of internal validation requirements reveals all the data are acceptable; there 
are, however, slight differences between some of the values. 
Area and retention time repeatability for retinol are perfect for analysis by UPLC, 
not exceeding 0.5% RSD.  The excellent injection precision is ensured by the partial 
loop with needle-overfill injection mode developed by Waters for the Acquity UPLC 
system. In this mode the needle and the valve are first overfilled with sample while the 
loop is in-line with the pump.  When the loop is switched to off-line, the syringe fills the 
loop with the appropriate volume of sample. To complete the injection the valve is 
switched back to in-line direction.  With  full-loop  injection,  this  type  of  sample 
injection  is  among  the  most  precise  injection  techniques. The correlation 
coefficients show that response is a linear function of concentration in the calibration 
ranges selected. Accuracy, determined for spiked samples, is best for conventional 
HPLC and UPLC. Although method sensitivity is  expected  to  be  higher  for  UPLC  
than  for  the  HPLC technique,  
 
Table 7:  Comparison of validation data for chlorhexidine gluconate and Lidocaine 
hydrochloride 
Parameter 
Chlorhexidine Gluconate Lidocaine hydrochloride 
UPLC HPLC UPLC HPLC 
Area repeatability( %RSD) 0.24 0.77 0.31 0.56 
Retention time repeatability (%RSD) 0.002 0.01 0.001 0.02 
Accuracy (%RSD) 0.35 0.76 0.52 0.65 
Calibration range (µg/ml) 0.08-0.32 0.08-0.32 0.02-0.08 0.02-0.08 
Correlation coefficient 0.9997 9984 0.9994 0.9998 
LOD (µg/ml) 0.02 0.02 0.01 0.05 
LOQ (µg/ml) 0.04 0.1 0.25 0.09 
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Conclusion  
A  novel  UPLC  method  for  determination  of  chlorhexidine gluconate and 
Lidocaine hydrochloride has been presented as a tool suitable  for  quality monitoring  of  
these  compounds.  The developed and validated UPLC method was compared   with 
HPLC method.   Analysis   time,   sensitivity, mobile phase consumption, validation data, 
and demands on instrument equipment and operation were compared for two methods. 
UPLC and HPLC   are valuable methods for routine monitoring of these drugs. 
The appropriate method should be low cost and highly   sensitive,   reproducibility   
should   be   acceptable, analysis  time  should  be  short,  and  the  method  should  be 
simple  to  perform;  all these  requirements  are  met  by  both methods.  Surprisingly, in 
our work UPLC analysis took only 7minutes to complete a single run. So UPLC method 
is can be considered ideal for busy laboratories analyzing large numbers of samples. 
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GAS CHROMATOGRAPHIC METHOD DEVELOPMENT AND VALIDATION OF 
TICLOPIDINE HYDROCHLORIDE 
1. GAS CHROMATOGRAPHY 
1.1 Principle 
In gas chromatography (GC) a sample is vaporized and injected onto the start of the 
chromatographic column. The sample is transported through the column by the flow of an 
inert gas. The column contains the stationary phase, which is either a liquid or solid. The rate 
at which the molecules progress along the column depends on the strength of adsorption or 
distribution, which in turn depends on the type of molecule and on the column chosen. 
Substances are identified by the order in which they emerge from the column and by the 
residence time of the analyte in the column. Because molecular adsorption and the rate of 
progression along the column depend on the temperature, this is carefully controlled. A 
number of detectors are used in GC. The most universally applicable is the thermal 
conductivity detector (TCD) and the most widely used is the flame ionisation detector (FID). 
[1, 2] 
1.2 Instrument [3] 
1.2.1 Source 
Because the source (mobile phase) is a gas, the samples must be volatile and 
thermally stable. The flow must be controlled and constant, hence pressure and flow 
regulators may be employed. The analytes have no interaction with the mobile phase and are 
simply transported by it through the column. Typical carrier gases used are helium, argon, 
nitrogen and carbon dioxide, the choice of which is determined in part by the detector used. 
1.2.2 Sample 
Gas samples are usually injected directly into the mobile phase gas flow using a gas-
tight syringe. Liquid samples are injected by syringe through a rubber septum and volatilized 
the high temperature injection port, entering the column as a gas. Volumes range from 
nanolitres to microlitres depending on the column being used. There are two main types of 
injection – split and splitless. 
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Figure 3.1 Schematic diagram of a gas chromatograph. 
 
Split injection is used for concentrated samples where only a small portion of the 
sample volume (_2 %) is introduced into the column. This is achieved by sending most of the 
sample to waste at the split vent. Injector temperature is high and the residence time of the 
sample in the injection port is short. It is used when resolution is most important and when 
sensitivity is not an issue. Splitless injection is used for dilute samples and means introducing 
most of the sample into the column. Injector temperature is lower and the residence time of 
the sample in the injection port is longer (approximately one minute), so solvent trapping or 
cold trapping may be required. It is used when sensitivity is most important. A third type of 
injection is on-column injection, where a sample is deposited directly onto the start of the 
column and the temperature is slowly raised just enough to volatilize the sample for 
chromatography but not so much that it decomposes. This mode of injection is used for 
quantitative work and for compounds that are thermally unstable above their boiling points. 
Another means of sampling is headspace analysis, where a sample vial contains gas or 
vapour above the liquid, and that headspace is injected directly into the GC. This technique 
avoids liquid or solid probing. Traditional headspace GC relies on equilibrium being 
achieved in a closed vial between the liquid sample and its volatile components. Temperature 
is a major factor in GC analysis and controlling it is important. Some methods require 
ramping/gradient control of  emperature (temperature programming) during a separation to 
allow elution of compounds with a large range of boiling points in the same run. An oven 
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controls the temperature of the column and the samples entering it. Compounds that are not 
volatile or thermally stable enough for direct analysis by GC can be derivatised with various 
functional groups to make them more amenable to this technique.  
1.2.3 Columns 
The column can be a packed capillary or, more usually now, an open tubular column. 
Open tubular columns are normally made of a narrow fused silica capillary where the walls 
are cased in polyimide for strength. They usually provide better resolution, more rapid 
separation and greater sensitivity than packed columns, but they cannot accommodate high 
sample amounts. Capillaries can be up to 100 m in length and have a narrow internal 
diameter, of 0.1–1 mm. There are three main types of open tubular columns – wall-coated, 
support-coated and porous layer, which are illustrated in Figure 3.2 
 
 
Figure 3.2 The three types of  column for GC. 
The wall-coated type has a layer of nonvolatile liquid stationary phase on the inside 
wall of the column. The support-coated type has solid particles attached to the inside wall of 
the capillary; the particles are coated with the liquid stationary phase. In either case, the 
liquid stationary phase must be chemically and thermally stable so that it does not ‘bleed’ off 
the capillary. The porous layer type has solid particles attached to the wall; the particles are 
themselves the stationary phase. In some capillaries, the stationary phase is covalently 
attached to the inner wall; this yields a more thermally stable ‘bonded’ column that is less 
Gas chromatographic…   Part-C 
 
 
 
186 
likely to experience bleed. Packed columns are usually made of stainless steel and are a few 
millimetres in diameter. The solid support particles can be the stationary phase or they can be 
coated with a liquid. To improve resolution and speed, the particles should be small and 
uniform in size. There are many kinds of stationary phase available in both packed and open 
tubular varieties of column covering the spectrum of polar to very nonpolar, which means a 
wide choice of capillaries when developing GC separations. Whichever type of column is 
chosen, it must be well equilibrated in the heated oven with mobile phase gas running 
through it before analysis begins. 
 
1.2.4 Detector 
A large number of GC detectors are available. In general, GC detectors are very 
sensitive and, thus, are ideal for trace analysis and environmental monitoring. The detectors 
that are more selective tend to be more sensitive. The most popular detector is the flame 
ionisation detector (FID). There are a number of possible detectors for GC, which include 
The following (the first four of these are based on ionisation processes):  
 Flame ionization detector Nitrogen phosphorus detector 
 Electron capture detector 
 Photoionization detector 
 Flame photometric detector 
 Thermal conductivity detector 
 Mass spectrometric detector. 
 
A flame ionisation detector (FID) uses a hydrogen/air flame to decompose the 
carbon containing sample molecules from the GC into ions by burning them and then 
measures the changes in current due to this. The FID detects most organic compounds when 
they are ionised and cause a voltage drop across the collector electrodes. The measured 
change is proportional to mass (number of carbon atoms) of the organic analyte. The 
background current and hence noise level are small. It is a destructive technique but is very 
sensitive («100 pg) and has a wide linear range (6–7 orders of magnitude). The response of 
the FID is almost independent of flow rate and so it is a very useful detector with capillary 
columns. The FID does not respond to fully oxidised carbon atoms and ether groups. It is 
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insensitive to water and permanent gases such as ammonia and sulfur dioxide. 
The nitrogen phosphorus detector (NPD) is a highly sensitive and selective detector 
that gives a very strong response to organic compounds containing nitrogen and/or 
phosphorus. It is capable of detecting as little as 10 pg of nitrogen or phosphorus, so it is 
commonly used to detect trace levels of pesticides, herbicides and drugs of abuse. The NPD 
is similar in design to the FID, except that the hydrogen flow rate is reduced to about 3 
mL/min and the actual sensor is a rubidium or caesium bead contained inside a small heater 
coil positioned near the jet orifice. The bead is heated and the gas mixture passes over it. The 
heated bead emits electrons by thermionic emission; these are collected at the anode and thus 
produce an ion current. When a solute containing nitrogen or phosphorus is eluted, the 
partially combusted nitrogen and phosphorus materials are adsorbed on the surface of the 
bead. This adsorbed material means that the emission of electrons is increased, which raises 
the anode current. Obviously nitrogen carrier gas cannot be used with this detector. 
The electron capture detector (ECD) consists of a small chamber (1–2 ml in volume) 
enclosing two metal electrodes. It can detect halogen-containing compounds, peroxides, nitro 
compounds and organometallic compounds among others but it is insensitive to 
hydrocarbons, amines and alcohols. The ECD contains a low energy radioactive â-ray source 
which is used to ionise the gas entering the chamber, producing electrons and a small 
background current. When analytes that have a high affi nity for electrons enter the chamber, 
they capture some of the electrons and reduce the  background current. This detector is 
probably the most sensitive of the GC detectors (about 50 fg) and is widely used in the 
analysis of halogenated compounds, in particular pesticides.  
The photoionisation detector (PID) is used for the selective determination of 
aromatic hydrocarbons and unsaturated compounds such as aliphatics, aromatics, ketones, 
esters, aldehydes, amines, heterocyclics and some organometallics. It is relatively insensitive 
to saturated hydrocarbons and halocarbons. This device uses ultraviolet light as a means of 
ionising the analytes exiting the GC column and the ions produced by this process are 
collected by electrodes. The current generated is therefore a measure of the analyte 
concentration. Since only a very small fraction of the analyte molecules are ionised, this 
detector is considered to be nondestructive and, as such, can be connected in series with 
another GC detector if required. It is a very sensitive detector («2 pg).  
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The flame photometric detector (FPD) is a spectroscopic detector and is used for the 
selective detection of a number of elements by optical emission. The most commonly 
analysed elements are phosphorus and sulfur since these compounds, when partially 
combusted in a hydrogen/air fl ame emit light at 536 and 394 nm respectively. It has similar 
sensitivity to the FID and can detect 100 pg of suitable compounds. 
The thermal conductivity detector (TCD) is the most universal and simple detector 
for GC. In the TCD, the thermal conductivity of helium or hydrogen carrier gas is relatively 
high but this is lowered in the presence of any analyte (organic or inorganic). When analyte 
exits the column, the heating filament gets hotter, the resistance, and hence the current, 
increases and changes the voltage. The measured voltage change is proportional to the 
concentration of the analyte. It is a nondestructive technique but is not as sensitive (only 1 
ng) as other GC detectors. The TCD is very sensitive towards flow and pressure and the 
sensor must be carefully thermostatted and fitted with reference cells to compensate for 
changes in pressure or flow rate. The device is simple, reliable and rugged. It is also often the 
detector of choice for process monitoring.  
The mass spectrometric detector is often coupled to GC to provide a very sensitive 
separation and detection instrument in one. This system is discussed in more detail in the 
section on hyphenated (hybrid) techniques.  
1.2.5 Output 
A computer is used to carry out  identification of compounds based on retention times 
from the chromatogram and integration of the peaks for quantitative work.  
 
Information obtained 
Gas chromatography can be used as a qualitative or quantitative technique. 
Qualitative information can allow the identification of a substance on the basis of retention 
time comparisons between a standard and the sample. Alternatively, and more definitively, 
the use of a mass spectrometric detector enables the molecular weight of eluting components 
to be determined and as long as those molecular weights are unique, unambiguous 
identification is possible. When used quantitatively, the GC can employ external or internal 
standards to generate a standard curve. Then, the peak area of the sample peak on the 
chromatogram can be used to obtain a concentration. 
Gas chromatographic…   Part-C 
 
 
 
189 
Developments/Specialist Techniques 
Sample preparation is often an issue prior to injection for GC analysis. One useful 
method of sample preparation is thermal desorption, which is widely used for extracting and 
isolating volatile and semivolatile compounds from various matrices. During the thermal 
desorption process, heat and a flow of inert gas are used to extract volatile and semi-volatile 
organics retained in a sample matrix or on a sorbent bed. The analytes desorb into the gas 
stream and are ultimately transferred to the GC. Some thermal desorbers have two stages, i.e. 
they preconcentrate the analytes desorbed from the sample tube before releasing them into 
the analytical system in as small a volume of vapor as possible. Another useful technique is 
solid phase microextraction. A fused silica fibre is attached to the base of a syringe with a 
fixed metal needle. The fibre is coated with a thin layer of stationary phase that is selective 
for the analytes of interest. The fibre is  dipped into the liquid sample or into the headspace 
above the liquid for a period of time, allowing a fraction of the analyte to be extracted into 
the fibre. The fibre is then retracted into the syringe and the syringe injected into the injection 
port where the analyte is thermally desorbed from the fibre into the GC. A third sample 
preparation method is ‘purge and trap,’ which aims to extract as close to all of the analyte as 
possible from the solid or liquid sample and is a deviation from headspace sampling. It works 
by bubbling a purge gas such as helium through the heated sample vial. The gas carries 
analyte up into an adsorption tube packed with selective stationary phase. After all the 
analyte has been trapped in the tube, the gas flow is reversed through the tube to remove any 
residual solvents. The tube is then directed to the injector port and, heated to desorb the 
analytes, which are then cold-trapped onto the head of the GC column. From there, the 
concentrated sample is heated for GC separation. Other new developments in GC include the 
capability to analyse larger, more labile molecules using high GC column flow rates and the 
use of solvent-free syringeless injection, which allows inorganic materials to be introduced 
directly onto a heated injection port of a GC for thermal desorption[4]. There have been 
advances in headspace GC techniques also[5]. Multidimensional GC is a technique that is 
used when there are so many components in a separation that one column may not be able to 
separate them all adequately. In this case, a portion of the first column’s effluent is 
transferred to a second column for analysis via column-switching apparatus. There are three 
main approaches for GC–GC depending on the application. The first is ‘heart-cutting,’ where 
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an unresolved section of the separation is sent to a second column (perhaps with very 
different chemistry) for improved separation. The second is enrichment, where the first 
column preconcentrates the sample and the second column analyses the sample. The third is 
backflushing, where highly retained solutes that have not yet been eluted can be subjected to 
a reversal of flow on the same column, and hence be separated. GC–GC is advantageous if 
the sample is complex or the analytes are very different from each other and more than one 
assay would otherwise be required for good separation. Thermo Electron Corp. has released 
TRACE GCxGC, which is suitable for the analysis of target compounds in complex matrices. 
Data is presented as a structured 3-D chromatogram.  
Applications 
Gas chromatography has found important applications in the fingerprinting of oil 
spills, where the pattern of peaks obtained from a sample can pinpoint the petroleum source, 
and can also be utilised to determine the long-term fate of the petroleum hydrocarbons[6]. 
Other common environmental examples of quantitative GC are in the determination of 
pesticides in water[7], dioxin levels in soil[8] and air pollutants. It is routinely used to 
examine levels of volatile organic compounds (VOCs), polycyclic aromatic hydrocarbons 
(PAHs) and polychlorinated biphenyls (PCBs). It is also a very important technique in the 
food industry, where it is used extensively for assay of fatty acids, flavors [9], sterols and 
residues such as insecticides, herbicides, preservatives, solvents [10] and veterinary drugs. 
Through chemical dramatization, more polar food compounds can be analyzed, including 
sugars and carboxylic acids. Tedetti et al. reported the analysis of low molecular weight 
carboxylic acids by GC with prior dramatization to dibutyl esters[11].  
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2. INTRODUCTION TO TICLOPIDINE HYDROCHLORIDE 
Ticlopidine hydrochloride is an inhibitor of platelet aggregation used in the 
management and prevention of thromboembolic disorders [12]. Ticlopidine hydrochloride is 
a white crystalline solid. It is freely soluble in water and self-buffers to a pH of 3.6. It also 
dissolves freely in methanol, is sparingly soluble in methylene chloride and ethanol, slightly 
soluble in acetone and insoluble in a buffer solution of pH 6.3. 
2.2 Description 
Ticlopidine hydrochloride is chemically 5-[(2-Chlorophenyl) methyl]-4, 5, 6, 7-
tetrahydrothieno [3, 2-c] pyridine hydrochloride (Fig.1). Its molecular formula is 
C14H14ClNS.HCl having molecular weight 300.25 g/mole. Its CAS Registry Number is 
55142-85-3. It is used as adenosine diphosphate [ADP] receptor antagonists in an antiplatelet 
therapy [13]. It is also significantly reduces restenosis after endovascular therapy in 
femoropopliteal lesions [14].  
N
S
Cl
ClH.
 
Figure: 1 5-[(2-Chlorophenyl) methyl]-4, 5, 6, 7-tetrahydrothieno [3, 2-c] pyridine 
hydrochloride 
2.3 Side effects 
Adverse reactions in stroke patients were relatively frequent with over 50% of 
patients reporting at least one. Most (30% to 40%) involved the gastrointestinal tract. Most 
adverse effects are mild, but 21% of patients discontinued therapy because of an adverse 
event, principally diarrhea, rash, nausea, vomiting, GI pain and neutropenia. Most adverse 
effects occur early in the course of treatment, but a new onset of adverse effects can occur 
after several months. 
2.4 Drug interaction 
Gas chromatographic…   Part-C 
 
 
 
192 
Therapeutic doses of TICLID caused a 30% increase in the plasma half-life of 
antipyrine and may cause analogous effects on similarly metabolized drugs. Therefore, the 
dose of drugs metabolized by hepatic microsomal enzymes with low therapeutic ratios or 
being given to patients with hepatic impairment may require adjustment to maintain optimal 
therapeutic blood levels when starting or stopping concomitant therapy with ticlopidine. 
Studies of specific drug interactions yielded the following results: 
Aspirin and Other NSAIDs: Ticlopidine potentiates the effect of aspirin or other NSAIDs on 
platelet aggregation. The safety of related use of ticlopidine and NSAIDs has not been 
established. The safety of concomitantuse of ticlopidine and aspirin beyond 30 days has not 
been established. Aspirin did not modify the ticlopidine-mediated inhibition of ADP-induced 
platelet aggregation, but ticlopidine potentiated the effect of aspirin on collagen-induced 
platelet aggregation. Caution should be exercised in patients who have lesions with a 
propensity to bleed, such as ulcers. Long-term concomitant use of aspirin and ticlopidine is 
not recommended . 
2.5 Precaution 
General: TICLID should be used with caution in patients who may be at risk of 
increased bleeding from trauma, surgery or pathological conditions. If it is desired to 
eliminate the antiplatelet effects of TICLID prior to elective surgery, the drug should be 
discontinued 10 to 14 days prior to surgery. Several controlled clinical studies have found 
increased surgical blood loss in patients undergoing surgery during treatment with 
ticlopidine. In TASS and CATS it was recommended that patients have ticlopidine 
discontinued prior to elective surgery. Several hundred patients underwent surgery during the 
trials, and no excessive surgical bleeding was reported. 
Prolonged bleeding time is normalized within 2 hours after administration of 20 mg 
methylprednisolone IV. Platelet transfusions may also be used to reverse the effect of 
TICLID on bleeding. Because platelet transfusions may accelerate thrombosis in patients 
with TTP on ticlopidine, they should, if possible, be avoided. 
2.6 Overdose 
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One case of deliberate overdosage with TICLID has been reported by a foreign 
postmarketing surveillance program. A 38-year-old male took a single 6000-mg dose of 
TICLID (equivalent to 24 standard 250-mg tablets). The only abnormalities reported were 
increased bleeding time and increased SGPT. No special therapy was instituted and the 
patient recovered without sequelae. 
2.7 Contraindications 
The use of TICLID is contraindicated in the following conditions: 
 Hypersensitivity to the drug , 
 Presence of hematopoietic disorders such as neutropenia and thrombocytopenia or 
a past history of either TTP or aplastic anemia , 
 Presence of a hemostatic disorder or active pathological bleeding (such as 
bleeding peptic ulcer or intracranial bleeding) , 
 Patients with severe liver impairment. 
2.8 Clinical pharmacology 
Mechanism of action: When taken orally, ticlopidine hydrochloride causes a time- and dose-
dependent inhibition of both platelet aggregation and release of platelet granule constituents, 
as well as a prolongation of bleeding time. The intact drug has no significant in vitro activity 
at the concentrations attained in vivo; and, although analysis of urine and plasma indicates at 
least 20 metabolites, no metabolite which accounts for the activity of ticlopidine has been 
isolated. 
Ticlopidine hydrochloride, after oral ingestion, interferes with platelet membrane 
function by inhibiting ADP-induced platelet-fibrinogen binding and subsequent platelet-
platelet interactions. The effect on platelet function is irreversible for the life of the platelet, 
as shown both by persistent inhibition of fibrinogen binding after washing platelets ex vivo 
and by inhibition of platelet aggregation after resuspension of platelets in buffered medium. 
Pharmacokinetics and Metabolism: After oral administration of a single 250-mg dose, 
ticlopidine hydrochloride is rapidly absorbed with peak plasma levels occurring at 
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approximately 2 hours after dosing and is extensively metabolized. Absorption is greater than 
80%. Administration after meals results in a 20% increase in the AUC of ticlopidine. 
Ticlopidine hydrochloride displays nonlinear pharmacokinetics and clearance 
decreases markedly on repeated dosing. In older volunteers the apparent half-life of 
ticlopidine after a single 250-mg dose is about 12.6 hours; with repeat dosing at 250 mg bid, 
the terminal elimination half-life rises to 4 to 5 days and steady-state levels of ticlopidine 
hydrochloride in plasma are obtained after approximately 14 to 21 days. 
Ticlopidine hydrochloride binds reversibly (98%) to plasma proteins, mainly to serum 
albumin and lipoproteins. The binding to albumin and lipoproteins is nonsaturable over a 
wide concentration range. Ticlopidine also binds to alpha-1 acid glycoprotein. At 
concentrations attained with the recommended dose, only 15% or less ticlopidine in plasma is 
bound to this protein. 
Ticlopidine hydrochloride is metabolized extensively by the liver; only trace amounts 
of intact drug are detected in the urine. Following an oral dose of radioactive ticlopidine 
hydrochloride administered in solution, 60% of the radioactivity is recovered in the urine and 
23% in the feces. Approximately 1/3 of the dose excreted in the feces is intact ticlopidine 
hydrochloride, possibly excreted in the bile. Ticlopidine hydrochloride is a minor component 
in plasma (5%) after a single dose, but at steady-state is the major component (15%). 
Approximately 40% to 50% of the radioactive metabolites circulating in plasma are 
covalently bound to plasma proteins, probably by acylation. 
Clearance of ticlopidine decreases with age. Steady-state trough values in elderly 
patients (mean age 70 years) are about twice those in younger volunteer populations. 
Pharmacodynamics: In healthy volunteers over the age of 50, substantial inhibition (over 
50%) of ADP-induced platelet aggregation is detected within 4 days after administration of 
ticlopidine hydrochloride 250 mg bid, and maximum platelet aggregation inhibition (60% to 
70%) is achieved after 8 to 11 days. Lower doses cause less, and more delayed, platelet 
aggregation inhibition, while doses above 250 mg bid give little additional effect on platelet 
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aggregation but an increased rate of adverse effects. The dose of 250 mg bid is the only dose 
that has been evaluated in controlled clinical trials. 
After discontinuation of ticlopidine hydrochloride, bleeding time and other platelet 
function tests return to normal within 2 weeks, in the majority of patients. 
At the recommended therapeutic dose (250 mg bid), ticlopidine hydrochloride has no 
known significant pharmacological actions in man other than inhibition of platelet function 
and prolongation of the bleeding time. [15] 
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3. LITERATURE REVIEW 
The literature reviews regarding ticlopidine hydrochloride suggest that various 
analytical methods were reported for its determination as drug, in pharmaceutical formulation 
and in various biological fluids. The literature reviews for analysis of ticlopidine 
hydrochloride are as under: 
3.1 C. K. Markopoulou, J. E. Koundourellis, M. G. Orkoula and C. G. Kontoyannis 
have developed quantitative nondestructive methods for the determination of ticlopidine in 
tablets using reflectance near-infrared and fourier transform raman spectroscopy.  The results 
were compared to those obtained by high-performance liquid chromatography (HPLC) [16].   
3.2 R. T. Sane, N. L. Chonkar, S. R. Surve, M. G. Gangrade and V. V. Bapat have 
developed extractive colorimetric determination of ticlopidine hydrochloride, buspirone 
hydrochloride, nefopam hydrochloride, and ketotifen fumarate in pharmaceutical 
preparations. The method involved simple, accurate, fast and precise extractive colorimetric 
technique for the determination of aforesaid compounds in pharmaceuticals with acid dyes 
like bromothymol blue, bromophenol blue, bromocresol purple and bromocresol green in 
presence of acidic buffers.  The colored complexes were extracted into chloroform and 
measured at the respective wavelengths of maximum absorption [17]. 
3.3 W. Li, H. Pu, H. Yong and Y. Zhang have reported study on pharmacokinetics and 
bioavailability of ticlopidine hydrochloride tablets. The relative bioavailability between two 
products of ticlopidine hydrochloride (tablet A and B) was evaluated. The plasma ticlopidine 
hydrochloride concentration was determined by HPLC method. The relative bioavailability 
of tablet A to tablet B was (105.6  30.4) %. There were no significant differences in the 
parameters of Cmax and AUC0  between two products [18]. 
3.4 E. Turkoz and A. Nur Onar have developed determination of ticlopidine in 
pharmaceutical products by voltammetry. The voltammetric behavior of ticlopidine-HCl was 
studied using square-wave, sampled d.c., and cyclic voltammetry.  The drug showed a 
cathodic peak at -0.01V vs. Ag/AgCl with hanging mercury drop electrode.  The current was 
investigated using cyclic voltammetry and characterized as diffusion controlled [19]. 
3.5 Xiu-Ling Zhang has developed a detection method for HPLC of ticlopidine 
hydrochloride in capsules and tablets. It was determinate by HPLC on a TWG-C18H37 
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column with Methanol-pH 3.0 sodium dihydrogen phosphate solution (70:30) as mobile 
phase, Ph benzoate as internal standard, and 268 nm as the detection wavelength. [20]. 
3.6 G. Furlan, N. Malusa, A, Strohmayer, F. B. Klugmann, G. Decorti and L. 
Candussio have developed method for determination of ticlopidine in serum by HPLC. In 
this study they verified whether HPLC with UV detection (HPLC-UV) could be optimised 
and hence become a useful method for measuring ticlopidine concentrations in patient blood.  
The extraction step was improved by adding isoamylic alcohol in the extraction mixture, 
resulting in a better recovery.  Moreover, the extraction efficiency was consistently 
ameliorated by evaporation to dryness of the organic extract; we could therefore utilise a 
lower (213 nm) wavelength, corresponding to the maximum of absorption, achieving a better 
sensitivity [21]. 
3.7 K. Rona, K. Ary, B. Gachalyi have developed validity of an HPLC method for the 
determination of ticlopidine in human plasma.  The separation of the investigated compound 
and internal standard was achieved on "BST Rutin" 10, C18 BD column with a 0.01 M, (pH 
4) potassium dihydrogen phosphate buffer acetonitrile-methanol (20:40:40 v/v) mobile phase 
at the wavelenght of 215 nm. The compounds were isolated from plasma by Bond Elut C18 
solid-phase extraction, the mean absolute recovery was 84.9% [22]. 
3.8 Minhui Chen, Lige Jia have developed quantitative determination of ticlopidine 
hydrochloride capsules by HPLC. The HPLC method for determination of ticlopidine 
hydrochloride capsules was: ODS column, mobile phase: 0.1% triethylamine (adjusted to pH 
2.5 with 85% phosphoric acid)-methanol (60:40), detector wavelength: 233 nm, flow rate: 
1.0 mL/min [23]. 
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4. AIM OF PRESENT WORK 
As per discussion in the literature review, reflectance near-infrared and Fourier 
transform Raman spectroscopy, Colorimetric, Volta metric and HPLC methods for the 
determination of ticlopidine hydrochloride in pharmaceutical dosage forms or in biological 
fluids are reported. HPLC methods applied to the pharmacokinetic studies of ticlopidine 
hydrochloride. So far to our present knowledge, no validated GC assay method for the 
determination of ticlopidine hydrochloride in pharmaceutical formulation was available in 
literature. This work deals with the validation of the developed method for the assay of 
ticlopidine hydrochloride from its formulation (tablets). Hence, the method is recommended 
for routine quality control analysis and also stability sample analysis. 
 
The aim and scope of the proposed work are as under: 
 To developed suitable gas chromatographic assay method for determination of 
ticlopidine hydrochloride. 
 Perform the validation for the developed method as per ICH validation guidelines. 
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5. EXPERIMENTAL 
5.1 Materials  
Ticlopidine hydrochloride standard was provided by Aarti Drugs Ltd., Boisar (India). 
Ticlopidine hydrochloride tablets containing 250mg ticlopidine hydrochloride and the 
inactive ingredient used in drug matrix were obtained from market. HPLC grade methanol 
and water were obtained from Spectrochem Pvt. Ltd., Mumbai (India).  
 
5.2 Instrumentation 
The gas chromatographic system used to perform development and validation of this 
assay method was a Shimadzu GC- 14B equipped with flame ionization detector (FID) 
(Shimadzu, Kyoto, Japan) connected to an instrument data acquisition and data processing 
system (winchrom99, Indtech Instruments).  
 
5.3 Diluent preparation  
HPLC grade methanol is used as diluent. 
 
5.4 Standard preparation  
A standard solution containing 2500 μg/ml ticlopidine hydrochloride was prepared in 
a 100 ml volumetric flask by dissolving 250 mg of ticlopidine hydrochloride in diluent and 
diluted to volume with methanol as diluent.  
 
5.5 Test preparation  
Twenty tablets were weighed and the average weight of tablet was determined. From 
these, five tablets were weighed and transfer into a 500 ml volumetric flask. About 50 ml 
methanol was added and sonicated for a minimum 30 min. with intermittent shaking. Then 
content was brought back to ambient temperature and diluted to volume with methanol. The 
sample was filtered through 0.45μm nylon syringe filter. The concentration obtained was 
2500 μg/ml of ticlopidine hydrochloride.  
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5.6 Chromatographic conditions  
Injector Temperature : 290°C 
Column : SGE C5 BPX50 30m x 0.25mm i. d. x 0.25µ capillary column 
Carrier gas : Nitrogen 
Carrier gas Pressure : 200 kPa 
Column oven temperature : Isothermal at 270°C 
Injection volume : 3µl 
Detector : Flame ionization detector 
Detector temperature : 310°C 
Diluent : Methanol 
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6. RESULT AND DISCUSSION 
6.1 Development and optimization of the GC Method 
 Proper selection of the methods depends upon the nature of the sample (volatile or 
nonvolatile molecule) its molecular weight, solubility and melting point. Ticlopidine 
hydrochloride is soluble in polar solvent hence gas chromatography was selected to estimate 
them. To develop a rugged and suitable GC method for the quantitative determination of 
ticlopidine hydrochloride, the analytical condition were selected after testing the different 
parameters such as diluents, melting point and other chromatographic conditions.  
 Figure 2 and 3 represent the chromatograms of standard and test preparation 
respectively. 
 
Figure 2: Chromatogram of standard preparation 
 
Figure 3: Chromatogram of test preparation 
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6.2 Method validation 
6.2.1 Specificity 
   The specificity of the method was determined by checking the interference of placebo 
with analyte and with the proposed method. There was no interference of any peak of 
excipients or any impurities with the analyte peak. 
 
6.2.2 Linearity 
Seven points calibration curve were obtained in a concentration range from 1000-
4000 μg/ml for ticlopidine hydrochloride. The response of the drug was found to be linear in 
the investigation concentration range and the linear regression equation was y = 412,673.29x 
- 61,103.79 with correlation coefficient 0.9980. (Figure 9) Chromatogram obtain during 
linearity study were shown in figure 5-11. 
 
 
Figure 4: Linearity curve for ticlopidine hydrochloride 
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Figure 5: Linearity study chromatogram of level-1 (40%) 
 
 
Figure 6: Linearity study chromatogram of level-2 (60%) 
 
Figure 7: Linearity study chromatogram of level-3 (80%) 
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Figure 8: Linearity study chromatogram of level-4 (100%) 
 
Figure 9: Linearity study chromatogram of level-5 (120%) 
 
 
 
 
Figure 10: Linearity study chromatogram of level-6 (140%) 
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Figure 11: Linearity study chromatogram of level-7 (160%) 
 
6.2.3 LOD and LOQ 
 The limit of detection and limit of quantification were evaluated by serial dilutions of 
ticlopidine hydrochloride stock solution in order to obtain signal to noise ratio of 3:1 for 
LOD and 10:1 fro LOQ. The LOD value for ticlopidine hydrochloride was found to be 25 
ppm and the LOQ value 0.25 ppm. Chromatogram of LOD and LOQ study were shown in 
Figure 17-18. 
 
 
Figure 12: Chromatogram of LOD study of ticlopidine hydrochloride  
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Figure 13: Chromatogram of LOQ study of ticlopidine hydrochloride 
 
6.2.4 Precision 
 The result of repeatability and intermediate precision study are shown in Table 1. The 
developed method was found to be precise as the %RSD values for the repeatability and 
intermediate precision studies were 0.83 % and 0.42 %, respectively, which confirm that 
method was precise. 
 
Table 1: Evaluation data of precision study 
Set Intraday (n = 6) Interday (n = 6) 
1 99.7 98.4 
2 100.3 99.5 
3 98.4 98.8 
4 98.7 98.6 
5 98.2 98.9 
6 99.4 98.4 
Mean 99.1 98.8 
Standard deviation 0.82 0.41 
% RSD 0.83 0.42 
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6.2.5 Accuracy  
  The GC area responses for accuracy determination are depicted in Table 2. The result 
shows that best recoveries (99.33-101.37 %) of the spiked drug were obtained at each added 
concentration, indicating that the method was accurate. Chromatogram obtain during 
accuracy study were shown in figure 17-19. 
Table 2: Evaluation data of accuracy study 
 
Level (%) 
 
Amount added 
concentration
 a
 
(mg/ml) 
Amount found 
concentration
 a
 
(mg/ml) 
% Recovery % RSD 
50 1.25100 1.24257 99.33 0.38 
100 2.50133 2.53567 101.37 0.42 
150 3.75167 3.79454 101.14 0.38 
 
a
 Each value corresponds to the mean of three determinations 
 
 
Figure 17: Accuracy study chromatogram of level-1 (50%) 
 
Gas chromatographic…   Part-C 
 
 
 
208 
 
Figure 18: Accuracy study chromatogram of level-2 (100%)  
 
 
Figure 19: Accuracy study chromatogram of level-3 (150%)  
 
6.2.6 Solution stability study 
  Table 3 shows the results obtain in the solution stability study at different time 
intervals for test preparation. It was concluded that the test preparation solution was found 
stable up to 48 h at 2 - 8˚ C and ambient temperature, as during this time the result was not 
decrease below the minimum percentage. 
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Table 3: Evaluation data of solution stability study 
Intervals 
% Assay for test 
preparation solution 
stored at 2-8 ˚C 
% Assay for test preparation 
solution stored at ambient 
temperature 
Initial 99.6 99.6 
12 h 99.4 99.3 
24 h 99.3 99.2 
36 h 99.8 97.4 
48 h 98.8 98.3 
 
6.2.7 Robustness 
  The result of robustness study of the developed assay method was established in 
Table 4. The result shown that during all variance conditions, assay value of the test 
preparation solution was not affected and it was in accordance with that of actual. System 
suitability parameters were also found satisfactory; hence the analytical method would be 
concluded as robust. Chromatogram obtain during robustness study were shown in figure 20-
26. 
 
Table 4: Evaluation data of robustness study 
Robust conditions % Assay 
System suitability parameters 
Theoretical plates Asymmetry 
Column oven temp. at 260° 101.8 220068 0.92 
Column oven temp at 280°C  101.5 201245 0.95 
Carrier gas pressure at 210kPa 99.9 181471 1.02 
Carrier gas pressure at 190kPa 102.1 145630 0.88 
Injection volume 2.5µl 98.9 232101 0.74 
Injection volume 3.5 µl 101.4 216544 0.89 
Column change 99.2 155741 1.08 
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Figure 20: Standard chromatogram (Column oven temperature at 280°C) 
 
 
  
Figure 21: Standard chromatogram (Column oven temperature at 260°C) 
  
Figure 22: Standard chromatogram (Injection volume, 2.5µl) 
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Figure 23: Standard chromatogram (Injection volume, 3.5µl) 
 
   
Figure 24: Standard chromatogram (Carrier gas pressure, 190kPa) 
 
 Figure 25: Standard chromatogram (Carrier gas pressure, 210kPa) 
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Figure 26: Standard chromatogram (Column change) 
 
6.2.8 System suitability 
  A system suitability test of the chromatographic system was performed before each 
validation run. Five replicate injections of standard preparation were injected and asymmetry, 
theoretical plate and % RSD of peak area were determined for same. Acceptance criteria for 
system suitability, asymmetry not more than 2.0, theoretical plate not less then 5000 and % 
RSD of peak area not more then 10, were found to be satisfactory, during all validation 
parameter.  
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7. CALCULATION AND DATA 
 
Calculation formula used 
 
    
1. Calculation formula for % assay of ticlopidine hydrochloride 
 
 
WeightTest
500
100
WeightStandard
AreaStandardMean
AreaTestMean
Assay%  
 
StandardofPotency
ClaimLable
WeightTestMean
 
 
 
2. Relative standard deviation 
 
100
sMeasurmentofValueMean
sMeasurmentofDeviationStandard
RSD%  
 
 
3. Recovery 
 
100
AddedAmount
foundAmount
Recovery%  
 
 
4. Amount found  
 
ionConcentratStandard
AreaMean
AreaTestMean
mlmgFoundAmount
Standard
)/(  
 
 
5. Amount added 
 
Volume
Weight
mlmgAddedAmount )/(  
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Specificity study for analytical method validation of ticlopidine hydrochloride tablets 
 
Observation 
Data for Standard preparation  Data for Test preparation 
   
Replicate Area  Replicate Area 
1 930670  1 904295 
2 900258  2 920145 
3 937800  Average 912220 
4 892441  % Assay 98.9 
5 911978    
Average 911318.16    
Stdev 19365.37    
% RSD 2.12  Average weight 288.8mg 
Standard weight 249mg  Test weight 1429.1mg 
Standard potency 100 %  Label claim 250mg 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
1.1429
500
100
249
912220
911318.16
% Assay 100
250
8.288
 
 
              
     = 98.9 % 
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Linearity study for analytical method validation of ticlopidine hydrochloride tablets 
 
 
 
 
 
 
 
 
Standard weight (mg) 258 
Standard dilution 100 
Standard potency 100.0 % 
Standard concentration (mg/ml) 0.258 
Concentration of linearity stock 
solution (mg/ml) 
2.58 
      
Replicate 1 2 3 4 5 
Standard area 964051 941374 919306 926638 959188 
Mean standard area 950301 
 Stdev 26627.12 
% RSD 2.8 
Concentration level 
(%) 
Volume of 
linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final concentration 
(mg/ml) 
Mean area 
40 4.0 50 1.032 375026 
60 6.0 50 1.548 566847 
80 8.0 50 2.064 735729 
100 10.0 50 2.580 960459 
120 12.0 50 3.096 1174172 
140 14.0 50 3.612 1347719 
160 16.0 50 4.128 1634106 
  Correlation co-efficient 0.9980 
  Slope 399877.2148 
  Intercept -61103.79 
Gas chromatographic…   Part-C 
 
 
 
216 
Precision study for analytical method validation of ticlopidine hydrochloride tablets 
 
 
Standard weight (mg) 25.6     
Standard dilution 100     
Standard potency 100.0 %     
Label claim (mg) 250     
Mean test weight (mg) 288.8     
Standard concentration (mg/ml) 0.256     
      
Replicate 1 2 3 4 5 
Standard area 896521 985602 968534 947068 965874 
Mean standard area 952719     
Stdev. 34258.61     
% RSD 3.60     
 
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 938952 1428.1 99.7 
Set 2 952910 1440.0 100.3 
Set 3 935013 1439.8 98.4 
Set 4 947478 1455.2 98.7 
Set 5 923596 1425.9 98.2 
Set 6 935994 1427.6 99.4 
  Mean 99.1 
  Stdev 0.82 
  % RSD 0.83 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
1.1439
500
100
250
952719
938952
% Assay 100
250
8.288
 
     
    = 99.7 % 
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Intermediate precision study for analytical method validation of ticlopidine 
hydrochloride tablet 
 
Standard weight (mg) 249.6     
Standard dilution 100     
Standard potency 100.0 %     
Label claim (mg) 250     
Mean test weight (mg) 288.8     
Standard concentration (mg/ml) 0.2496     
      
Replicate 1 2 3 4 5 
Standard area 890670 990258 857800 942441 961978 
Mean standard area 924188     
Stdev. 49296.26     
% RSD 5.33     
 
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 907220 1438.5 98.4 
Set 2 915760 1436.4 99.5 
Set 3 909398 1435.8 98.8 
Set 4 913815 1445.6 98.6 
Set 5 912307 1439 98.9 
Set 6 909124 1441.7 98.4 
  Mean 98.8 
  Stdev 0.41 
  % RSD 0.42 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
5.1438
500
100
6.249
915760
907220
% Assay 100
250
8.288
 
     
 
    = 98.4 % 
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Comparison for precision and intermediate precision study for analytical method 
validation for ticlopidine hydrochloride tablets 
 
 
 Set %Assay 
Precision study 
1 99.7 
2 100.3 
3 98.4 
4 98.7 
5 98.2 
6 99.4 
Intermediate precision study 
1 98.4 
2 99.5 
3 98.8 
4 98.6 
5 98.9 
6 98.4 
 Mean 98.9 
 Stdev 0.64 
 
Cumulative 
% RSD 0.65 
 
 
Accuracy study for analytical method validation of ticlopidine hydrochloride tablets 
 
Standard weight (mg) 25.8     
Standard dilution 100     
Standard potency 100.0 %     
Standard concentration 
(mg/ml) 
0.2580     
      
Replicate 1 2 3 4 5 
Standard area 974926 983297 944267 972680 907281 
Mean standard area 956490     
Stdev 31191     
% RSD 3.26     
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Accuracy study for analytical method validation of ticlopidine hydrochloride tablets 
 
Recovery 
Level 
Set 
No. 
Mean 
area 
Wight 
(mg) 
Volume 
(ml) 
Amount added Amount found % 
Recovery 
Mean % 
Recovery 
Std 
Dev 
% RSD 
concentration(mg/ml) concentration(mg/ml) 
50% 
Set 1 472072 125.1 100 1.25100 1.23386 98.63 
99.33 1.10 0.38 Set 2 473032 125.2 100 1.25200 1.23637 98.75 
Set 3 481107 125.0 100 1.25000 1.25748 100.60 
100% 
Set 1 975519 250.3 100 2.50300 2.54974 101.87 
101.37 0.43 0.42 Set 2 968023 250.1 100 2.50100 2.53014 101.17 
Set 3 966868 250.0 100 2.50000 2.52712 101.08 
150% 
Set 1 1445999 375.2 100 3.75200 3.77944 100.73 
101.14 0.38 0.38 Set 2 1453194 375.3 100 3.75300 3.79824 101.21 
Set 3 1456133 375.0 100 3.75000 3.80593 101.49 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
100
25100.1
23386.1
covRe% ery  = 98.63 % 
 
2580.0
956590
472072
)/( mlmgFoundAmount  = 0.12724 mg/ml 
 
100
1.125
)/( mlmgAddedAmount  = 0.125100 mg/ml 
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Solution stability study for analytical method validation of ticlopidine hydrochloride 
tablets 
 
 
System suitability of standard preparation for solution stability 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 970670 971207 991499 1021452 1000365 
2 900258 927194 1019167 1002135 1033650 
3 967800 954020 1028562 1026324 1003682 
4 952441 946631 968264 959965 986321 
5 941978 907410 1073370 1022147 993654 
Mean 946629 941292 1016172 1006405 1003534 
Stdev 28424.73 24658.46 39805.86 27594.82 18103.45 
%RSD 3.00 2.62 3.92 2.74 1.80 
 
 
 
 
Solution stability for standard preparation at 2-8 °C 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 971207 991499 1021452 1000365 
2 927194 1019167 1002135 1033650 
3 954020 1028562 1026324 1003682 
4 946631 968264 959965 986321 
5 907410 1073370 1022147 993654 
1 962454 887022 893621 896243 
2 998334 1005833 1023984 863270 
Mean 952464 996245 992804 968169 
Stdev 29608.66 58231.04 49632.38 62904.22 
%RSD 3.11 5.85 5.00 6.50 
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Solution stability for standard preparation at ambient temperature 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 971207 991499 1021452 1000365 
2 927194 1019167 1002135 1033650 
3 954020 1028562 1026324 1003682 
4 946631 968264 959965 986321 
5 907410 1073370 1022147 993654 
1 945106 915667 923531 885421 
2 918529 1063669 1054186 863242 
Mean 938585 1008600 1001391 966619 
Stdev 22036.24 55217.55 44760.60 65069.95 
%RSD 2.35 5.47 4.47 6.73 
Solution stability for test preparation at 2-8 °C 
 
Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 970670 971207 991499 1021452 1000365 
2 900258 927194 1019167 1002135 1033650 
3 967800 954020 1028562 1026324 1003682 
4 952441 946631 968264 959965 986321 
5 941978 907410 1073370 1022147 993654 
Replicate Test area Test area Test area Test area Test area 
1 944295 947729 992581 984624 956320 
2 920145 903261 1005499 1001935 1005499 
Mean 932220 925495 999040 993280 980910 
% Assay 99.6 99.4 99.3 99.8 98.8 
Standard weight (mg) 250.2 250.1 25.1 25.1 24.6 
Test weight (mg) 1438.5 1438.5 1438.5 1438.5 1438.5 
% Difference compare 
to that of initial 
-- 
0.2 
0.2 -0.2 0.8 
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Solution stability for test preparation at ambient temperature 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 970670 971207 991499 1021452 1000365 
2 900258 927194 1019167 1002135 1033650 
3 967800 954020 1028562 1026324 1003682 
4 952441 946631 968264 959965 986321 
5 941978 907410 1073370 1022147 993654 
Replicate Test area Test area Test area Test area Test area 
1 944295 942907 990965 975468 986965 
2 920145 906186 1003937 963650 963937 
Mean 932220 924547 997451 969559 975451 
% Assay 99.6 99.3 99.2 97.4 98.3 
Standard weight (mg) 250.2 250.1 250 250.2 24.6 
Test weight (mg) 1438.5 1438.5 1438.5 1438.5 1438.5 
% Difference 
compare to that of 
initial 
-- 0.3 0.4 2.2 1.3 
 
 
Calculation: 
 
Prototype calculation for one set: 
5.1438
500
100
2.250
946629
942220
% Assay 100
250
8.288
 
 
        = 99.6 % 
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Robustness study for analytical method validation of ticlopidine hydrochloride tablets 
 
 
Oven temp. 
at 260°C 
Oven temp. 
at 280°C 
Injection 
volume 2.5ul 
Injection 
volume 3.5ul 
Carrier gas 
flow 190kPa 
Carrier gas 
flow 210kPa 
Column 
change 
Replicate Standard area Standard area Standard area Standard area Standard area Standard area Standard area 
1 1024932 958202 650220 1236959 9173081 9060999 7813568 
2 922375 880135 701284 1045785 9019316 9058109 7918043 
3 1124932 934578 684123 984674 9220580 9157099 7932029 
4 898775 951245 694158 994572 8902410 9160787 7984272 
5 992375 901458 701245 945861 8707428 9165395 7963510 
Mean 985777 924861 685381 1042752 9004563 9120478 7922284 
Stdev 82122.24 29839.57 19165.12 102803.41 208568.79 55702.54 66095.04 
% RSD 8.33 3.23 2.80 9.86 2.32 0.61 0.83 
Replicate Test area Test area Test area Test area Test area Test area Test area 
1 1040511 1006366 656580 1108456 9096468 9019541 7767073 
2 945142 850970 684872 985259 9100256 9015954 7787106 
Mean 992827 928668 670726 1046858 9098362 9017748 7777090 
Standard 
weight (mg) 
250 250 250 250 250 250 250 
Test weight 
(mg) 
1444.2 1444.2 1444.2 1444.2 1444.2 1444.2 1444.2 
Label claim 
(mg) 
250 250 250 250 250 250 250 
Mean test 
weight (mg) 
288.8 288.8 288.8 288.8 288.8 288.8 288.8 
% Assay 101.8 101.5 98.9 101.4 102.1 99.9 99.2 
 
Calculation: Prototype calculation for one set: 
2.1444
500
100
250
985777
992827
% Assay 100
250
8.288
 = 101.2 % 
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UV-VISIBLE SPECTROPHOTOMETRIC METHOD DEVELOPMENT AND 
VALIDATION OF SPIRONOLACTONE AND FUROSEMIDE IN COMBINED 
DOSAGE FORM. 
 
1 SPECTROSCOPIC  METHODS [1,2] 
It is the branch of science dealing with the study of interaction between 
electromagnetic radiation and matter. It is a most powerful tool available for the study 
of atomic and molecular structure/s and is used in the analyses of wide range of 
samples. Optical spectroscopy includes the region on electromagnetic spectrum 
between 100 Å and 400 μm. The regions of electromagnetic spectrum are: 
 
Region Wavelength 
Far (or vacuum)ultraviolet 10-200 nm 
Near ultraviolet 200-400 nm 
Visible 400-750 nm 
Near infrared 0.75- 2.2 µm 
Mid infrared 2.5-50 µm 
Far infrared 50-1000 µm 
    
 
Ultraviolet-Visible spectrophotometry [3] 
  UV-Visible spectrophotometry is one of the most frequently employed 
technique       in pharmaceutical analysis. It involves measuring the amount of 
ultraviolet or visible radiation absorbed by a substance in solution. Instrument which 
measure the ratio, or function of ratio, of the intensity of two beams of light in the 
U.V.-Visible region are called ultraviolet-visible spectrophotometers.  
  In qualitative analysis, organic compounds can be identified by use of 
spectrophotometer, if any recorded data is available, and quantitative 
spectrophotometric analysis is used to ascertain the quantity of molecular species 
absorbing the radiation. Spectrophotometric technique is simple, rapid, moderately 
specific and applicable to small quantities of compounds. The fundamental law that 
governs the quantitative spectrophotometric analysis is the Beer -Lambert law. 
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Beer’s law  
 It states that the intensity of a beam of parallel monochromatic radiation decreases 
exponentially with the number of absorbing molecules. In other words, absorbance is 
proportional to the concentration. 
Lambert’s law 
 It states that the intensity of a beam of parallel monochromatic radiation decreases 
exponentially as it passes through a medium of homogeneous thickness. 
A combination of these two laws yields the Beer-Lambert law. 
Beer-Lambert’s law 
 When beam of light is passed through a transparent cell containing a solution 
of an  absorbing substance , reduction of the intensity of light may occur.    
Mathematically, Beer-Lambert law is expressed as 
A = a b c 
                              Where, A = absorbance or optical density  
                                           a = absorptivity or extinction coefficient  
                                           b = path length of radiation through sample (cm) 
                                           c = concentration of solute in solution. 
Both b and   a are constant so a is directly proportional to the concentration c 
When c is in gm/100 ml, then the conctant is called A (1%, 1cm) 
bcAA 1%
1cm
 
 Quantification of medicinal substance using spectrophotometer may   carried 
out by preparing solution in transparent solvent and measuring it’s absorbance at 
suitable wavelength. The wavelength normally selected is wavelength of maximum 
absorption   (λ max), where small error in setting the wavelength scale have little 
effect on measured absorbance. Ideally, concentration should be adjusted to give an 
absorbance of approximately, 0.9, around which the accuracy and precision of the 
measurements are optimal. 
The assay of single component sample, which contains other absorbing 
substances, is then calculated from the measured absorbance by using one of three 
principal procedures. They are, use of standard absorptivity value, calibration graph 
and single or double point standardization. 
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In standard absorptive value method, the use of standard A (1%, 1cm) or E 
values are used in order to determine its absorptivity. It is advantageous in situations 
where it is difficult or expensive to obtain a sample of the reference substance. In 
calibration graph method, the absorbances of a number of standard solutions of the 
reference substance at concentrations encompassing the sample concentrations are 
measured and a calibration graph is constructed. The concentration of the analyte in 
the sample solution is read from the graph as the concentration corresponding to the 
absorbance of the solution. The single point standardization procedure involves the 
measurement of the absorbance of a sample solution and of a standard solution of the 
reference substance. The concentration of the substances in the sample is calculated 
from the proportional relationship that exists between absorbance and concentration. 
std
stdtest
test
A
CA
C  
Where Ctest and Cstd are the concentrations in the sample and standard  
solutions respectively and Atest and Astd are the absorbances of the sample         
and standard solutions respectively. 
For assay of substance/s in multi component samples by spectrophotometer; the 
following methods are being used routinely, which includes[4-5] 
 Simultaneous equation method 
 Derivative spectrophotometric method 
 Absorbance ratio method ( Q-Absorbance method) 
 Difference spectrophotometry 
 Solvent extraction method 
 Multicomponent mode 
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We have utilized “MULTI-COMPONENT MODE” of spectrophotometer for the 
determination of Spironolactone and Furosemide. 
 
“MULTICOMPONENT MODE” FOR THE DETERMINATION OF TWO 
COMPONENT IN THE MIXTURE 
The total absorbance of a solution at a given wavelength is equal to the sum of 
absorbances of the individual components present. This relationship makes possible 
the quantitative determination of the individual constituent of a mixture. 
 
The absorbance of mixture at wavelength X1 and X2 may be expressed as follows, 
A’= E’MBCM + E’NBCN-------------------------------at X1  
 
A’’= E’’MBCM+ E’’NBCN-----------------------------at X2 
 
The two absorptivities (E’M, E’N) at one wavelength and the other two 
absorptivities (E’’M, E’’N) at the other wavelength can be recorded from individual 
standard solution of M and N. The absorbance of the mixture A’ and A’’ are 
experimentally determinable and thus from these two equations the concentration of 
the individual constituents CM and CN can be readily calculated.  
  These relationships are valid if Beer’s law is followed and two components 
behave independently of one another. Choosing wavelengths at which the differences 
in molar absorptivities are large, leads to attain greater accuracy in this kind of 
analysis. 
 Mixture containing more than one absorbing species can be analyzed. The 
uncertainties in the resulting data become greater as the number of measurement 
increases. These uncertainties are reduced by newer and computerized 
spectrophotometer. 
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2. INTRODUCTION OF DRUGS 
2.1 Introduction of furosemide 
Furosemide (INN) or Frusemide (former BAN) is a loop diuretic used in the 
treatment of congestive heart failure and edema. It is most commonly marketed by 
Sanofi-Aventis under the brand name Lasix. It has also been used to prevent 
thoroughbred and standardbred race horses from bleeding through the nose during 
races. 
Along with some other diuretics, furosemide is also included on the World 
Anti-Doping Agency's banned drug list due to its alleged use as a masking agent for 
other drugs. 
2.1.1 Description 
Furosemide is chemically 4-Chloro-2-(furan-2-ylmethylamino)-5-sulfa 
moylbenzoic acid (Figure 1). Its CAS number is 54-31-9. Its molecular formula is 
C12H11ClN2O5S  having molecular weight 330.74gm/mole. Furosemide, an anthranilic 
acid derivative, is a potent diuretic that inhibits the active reabsorption of chloride in 
the diluting segment of the loop of Henle, thus preventing the reabsorption of sodium, 
which passively follows chloride [6]. This loop diuretic is commonly used for the 
treatment of renal diseases, congestive heart failure and hypertension [7]. 
 
Cl
S
O
NH2
O
O OH
NH
O
 
 
Figure: 1     4-Chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid 
 
2.1.2 Mechanism of action 
The name of Lasix is derived from lasts six (hours) -- referring to its duration 
of action. Like other loop diuretics, furosemide acts by inhibiting the Na-K-2Cl 
symporter in the thick ascending limb of the loop of Henle. The action on the distal 
tubules is independent of any inhibitory effect on carbonic anhydrase or aldosterone; 
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it also abolishes the corticomedullary osmotic gradient and blocks negative as well as 
positive free water clearance. 
Due to the large NaCl absorptive capacity of the loop of Henle and the fact 
that diuresis is not limited by development of acidosis, as it is with the carbonic 
anhydrase inhibitors. 
By inhibiting the transporter, the loop diuretics reduce the reabsorption of 
NaCl and also diminish the lumen-positive potential that derives from K+ recycling. 
This electrical potential normally drives divalent cation reabsorbtion in the loop, and 
by reducing this potential loop diuretics cause an increase in Mg
2+
 and Ca
2+
 excretion. 
Prolonged use can cause significant hypomagnesemia in some patients. Since Ca
2+
 is 
actively reabsorbed in the distal convoluted tubule, loop diuretics do not generally 
cause hypocalcemia. 
Additionally, furosemide is a noncompetitive subtype-specific blocker of 
GABA-A receptors [8-10]. Furosemide has been reported to reversibly antagonize 
GABA-evoked currents of α6 β2 γ2 receptors at micromole concentrations, but not 
alpha1 β2 γ2 receptors [8, 10]. During development, the alpha6 beta2 gamma2 
receptor increases in expression in cerebellar granule neurons, corresponding to 
increased sensitivity to furosemide [9]. 
 
2.1.3 Clinical use in humans 
Furosemide, as a loop diuretic, is principally used in the following indications 
(Aventis, 1998): 
 Edema associated with heart failure, hepatic cirrhosis, renal impairment, 
nephrotic syndrome  
 Hypertension  
 Adjunct in cerebral/pulmonary edema where rapid diuresis is required (IV 
injection) 
It is also sometimes used in the management of severe hypercalcemia in 
combination with adequate rehydration [11]. Although disputed, [12] it is considered 
ototoxic: "usually with large parenteral doses and rapid administration and in renal 
impairment"[13]. The tendency, as for all loop diuretics, to cause low potassium 
levels (hypokalaemia) has given rise to combination products, either with potassium 
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itself (e.g. Lasix-K) or with the potassium sparing diuretic of amiloride (Co-
amilofruse). 
 
2.1.4 Precautions, side-effects and administration 
Furosemide is injected either intramuscularly (IM) or intravenously (IV), 
usually 0.5-1.0 mg/kg 2x/day, although less before a horse is raced. As with many 
diuretics, it can cause dehydration and electrolyte imbalance, including loss of 
potassium, calcium, sodium, and magnesium. It is especially important to prevent 
potassium loss. Excessive use of Furosemide will most likely lead to a metabolic 
alkalosis due to hypochloremia and hypokalemia as well as retention of bicarbonate as 
a result of fluid volume loss. The drug should therefore not be used in horses that are 
dehydrated or experiencing kidney failure. It should be used with caution in horses 
with liver problems or electrolyte abnormalities. Overdose may lead to dehydration, 
change in drinking patterns and urination, seizures, GI problems, kidney damage, 
lethargy, collapse, and coma. 
Furosemide should be used with caution when combined with corticosteroids (as this 
increases the risk of electrolyte imbalance), aminoglycoside antibiotics (increases risk 
of kidney or ear damage), and trimethoprim sulfa (causes decreased platelet count). It 
may also cause interactions with anesthesics, so its use should be related to the 
veterinarian if the animal is going into surgery, and it decreases the kidney's ability to 
excrete aspirin, so dosages will need to be adjusted if combined with that drug 
Furosemide may cause digoxin toxicity due to hypokalemia.The drug is best 
not used during pregnancy or in a lactating mare, as it has been shown to be passed 
through the placenta and milk in studies with other species. It should not be used in 
horses with pituitary pars intermedia dysfunction (Cushings).Furosemide is detectible 
in urine 36-72 hours following injection. Its use is prohibited by most equestrian 
organizations. 
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2.1.5 Drug interactions 
Furosemide has potential interactions with the following medications:[14] 
 Aminoglycoside antibiotics such as Gentamicin  
 Aspirin and other salicylates  
 Other diuretics (e.g. ethacrynic acid, hydrochlorothiazide)  
 Indomethacin  
 Lithium  
 Synergistic effects with other antihypertensives (e.g. Doxazosin)  
 
2.2 Introduction of spironolactone 
 
Spironolactone (marketed under the trade names Aldactone, Novo-Spiroton, 
Aldactazide, Spiractin, Spirotone, Verospiron or Berlactone) is a diuretic and is used 
as an antiandrogen. 
It is a synthetic 17-lactone drug that is a renal competitive aldosterone 
antagonist in a class of pharmaceuticals called potassium-sparing diuretics, used 
primarily to treat heart failure, ascites in patients with liver disease, low-renin 
hypertension, hypokalemia and Conn's syndrome. On its own, spironolactone is only a 
weak diuretic, but it can be combined with other diuretics. About one person in one 
hundred with hypertension has elevated levels of aldosterone; in these persons the 
antihypertensive effect of spironolactone may exceed that of complex combined 
regimens of other antihypertensives. Due to its anti-androgen effect, it can also be 
used to treat hirsutism, and it is a common component in hormone therapy for male-
to-female transsexual and transgender people. It is commonly used to treat symptoms 
of Polycystic Ovary Syndrome (PCOS) such as excess facial hair and acne. 
2.2.1 Description 
Spironolactone is chemically 7α-Acetylthio-3-oxo-17α-pregn-4-ene-21,17-
carbolactone (Figure 2). Its molecular formula is C24H32O4S having molecular weight 
416.58 gm/mole. Spironolactone inhibits the effect of aldosterone by competing for 
intracellular aldosterone receptors in the distal tubule cells (it actually works on 
aldosterone receptors in the collecting duct). This increases the excretion of water and 
sodium, while decreasing the excretion of potassium. Spironolactone has a fairly slow 
onset of action, taking several days to develop, and similarly the effect diminishes 
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slowly. Spironolactone has anti-androgen activity by binding to the androgen receptor 
and preventing it from interacting with dihydro testosterone [15]. 
O
O
O
H
H
H
H
S
O CH3
H
 
Figure: 2 7α-Acetylthio-3-oxo-17α-pregn-4-ene-21,17-carbolactone 
2.2.2 Mechanism of action 
Spironolactone inhibits the effect of aldosterone by competing for intracellular 
aldosterone receptors in the distal tubule cells (it actually works on aldosterone 
receptors in the collecting duct). This increases the excretion of water and sodium, 
while decreasing the excretion of potassium. Spironolactone has a fairly slow onset of 
action, taking several days to develop, and similarly the effect diminishes slowly. 
Spironolactone has anti-androgen activity by binding to the androgen receptor and 
preventing it from interacting with dihydrotestosterone [15]. 
2.2.3 Pharmacokinetics 
Spironolactone is a synthetic steroid that acts as a competitive antagonist to 
aldosterone. Its onset and duration of action are determined by the kinetics of the 
aldosterone response in the target tissue. Substantial inactivation of spironolactone 
occurs in the liver. Over all, spironolactone has a rather slow onset of action, 
requiring several days before full therapeutic effect is achieved. 
2.2.4 Mortality and morbidity benefit in severe heart failure 
Spironolactone was shown to have a significant mortality and morbidity 
benefit in the Randomized Aldactone Evaluation Study (RALES), which studied 
people with severe congestive heart failure (New York Heart Association functional 
class III or IV).[16] Patients in the study arm of the trial (those receiving 
spironolactone) had a relative risk of death (when compared to the placebo group) 
equal to 0.70 or a 30% relative risk reduction. Patients in the study arm also had fewer 
symptoms of CHF and were hospitalized less frequently. 
The mechanism of this effect is also mediated by inhibiting aldosterone, which 
in conjunction with heart failure leads to myocardial fibrosis, sodium retention, and 
vascular dysfunction. 
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2.2.5 Adverse effects and interactions  
Spironolactone is associated with an increased risk of bleeding from the 
stomach and duodenum, but a causal relationship between the two has not been 
established.[17] Because it also affects androgen receptors and other steroid receptors, 
it can cause gynecomastia, menstrual irregularities and testicular atrophy. Other side 
effects include ataxia, erectile dysfunction, drowsiness and rashes. A carcinogenic 
effect has been demonstrated in rats. Spironolactone has been shown to be 
immunosuppressive in the treatment of sarcoidosis[18]. 
Spironolactone often increases serum potassium levels and can cause 
hyperkalemia, a potentially serious condition. Therefore, it is recommended that 
people using this drug avoid potassium supplements and salt substitutes containing 
potassium [19]. Doctors usually recommend periodic screening of serum potassium 
levels and some patients may be advised to limit dietary consumption of potassium. 
Research has also shown that spironolactone can interfere with the 
effectiveness of antidepressant treatment. The drug is actually (among its other 
receptor interactions) a mineralocorticoid (MR) antagonist, and has been found to 
reduce the effectiveness of antidepressant drugs in the treatment of major depression, 
presumably by interfering with normalization of the hypothalamic-pituitary-adrenal 
axis in patients receiving antidepressant therapy [20]. 
2.2.6 Carcinogenicity  
Studies of spironolactone and the related compound potassium canrenoate 
(which, like spironolactone, metabolizes to canrenone) in rats for one to two year 
periods show an increase in carcinogenesis in the thyroid gland, testes, liver, breasts, 
and myelocytic leukocytes. Mammalian cells, depending on the presence of metabolic 
activation, show mixed results for mutagenicity in vitro [21]. Doses relative to body 
weight were 10 to 150 mg per kg, which is ten to 500 times higher than normal doses 
for treating humans. In light of this research, Sandoz has recommended that 
unnecessary use of spironolactone be avoided. 
2.2.7 Other potential benefits  
It has been suggested that spironolactone can reduce the risk of Alzheimer's 
disease. In one study [22], researchers observed a reduction in the risk of Alzheimer's 
specifically associated with potassium-sparing diuretics. Unpublished findings from 
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other studies, including the Gothenberg Study have suggested that higher potassium 
levels may be associated with a lower risk of dementia. 
It is widely reported that most American diets contain more sodium than is 
necessary and lack the optimal daily intake of potassium. Therefore, spironolactone 
could theoretically counter the effects of the typical American diet as it tends to 
promote sodium excretion and potassium retention. However, there is no proof that it 
is beneficial for persons whose serum potassium and sodium levels are within the 
normal range. Few if any doctors would recommend using spironolactone in the 
absence of conditions for which it is normally indicated. 
Spironolactone has also been shown to help prevent certain types of acne in 
females when taken in combination with oral contraceptives. 
Spectrophotometric…   Part-D  
 
 
237 
 
3. LITERATURE REVIEW 
3.1. Literature review of furosemide 
The literature reviews regarding furosemide suggest that various analytical 
methods were reported for its determination as drug, in pharmaceutical formulation 
and in various biological fluids. The literature reviews for analysis of furosemide are 
as under:  
3.1.1 Santini, A. O.; Pezza, Helena R.; Sequinel, Rodrigo; Rufino, Jose L.; 
Pezza, Leonardo have studied the use of potentiometric sensor for furosemide 
determination in pharmaceuticals, urine, blood serum and bovine milk. The 
construction, evaluation, and analytical application of a potentiometric sensor, 
namely, Pt|Hg|Hg2(Fur)2|Graphite, where Furosemide 4-chloro-N-furfuryl-5-
sulphamoyl-anthranilate ion, are described.  The electrode shows easy construction, 
low-cost, fast response time (within 10-20 s), and can be used for 6 month without 
significant change in its performance characteristics. [23].   
3.1.2 Dias, Iara Lucia Tescarollo; Martins, Jorge Luiz S.; de Oliveira Neto, 
Graciliano have developed first-derivative spectrophotometric method for 
Furosemide in tablet and liquid pharmaceutical preparations entirely and after 
photolytic degradation, by direct UV 1st derivative spectrophotometry 1D at 262 nm.  
At this wavelength, it was possible to eliminate the decomposition product 
interference.  A linear response range between 1.0 and 10.0 µg mL
-1
 was obtained in 
optimized conditions.  The estimation of relative standard deviation was within the 
range 0.37-2.4% (n = 10) [24]. 
3.1.3 Salim, Edward F.; Haussler, A.; Vaughan, J. B.  have studied  qualitative 
and quantiative tests for furosemide. Physical properties, identity tests, purity tests, 
and assay procedure are described for furosemide [25]. 
3.1.4 Xie, Juan; Yang, Fang; Zhai, Yu; Yao, Jie; Zhang, Weiqun   have 
developed determination of the related substances in furosemide for injection by 
HPLC. The samples were separated on Hypersil ODS column.  The mobile phase was 
water-tetrahydrofuran-acetic acid (70:30:1) at a flow rate of 1.0 mL/min
-1
 at the 
wavelength of 254 nm and the injection volume was 20 µL.  [26]. 
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3.1.5 Wesley-Hadzija, B.; Mattocks, A. M. have developed TLC method for 
determination of furosemide and 4-chloro-5-sulfamoylanthranilic acid in plasma and 
urine. As little as 10 ng can be accurately measured and fluorescence is linear up to 
160 ng.  The metabolite or decomposed product 4-chloro-5-sulfamoylanthranilic acid  
[3086-91-7] is well separated and measured quantity in the procedure. [27] 
3.1.6 He, Shu-hua; Li, Chao-yin have developed flow injection 
chemiluminescence’s method for the determination of furosemide based on KMnO4-
Na2S2O4 reaction.  A novel flow injection chemiluminescence (FI-CL) system for 
determination of furosemide was presented.  It was based on the chemiluminescence 
reaction of sodium hydrosulfite with potassium permanganate in the vitriol acid 
solution. The emission intensity can be enhanced greatly by furosemide.  The 
chemiluminescence intensity was proportional to furosemide concentration over the 
range 0.01-5.0 mg/L.  The detection limit is 5.7μg/L and the relative standard 
deviation is 3.7% for the furosemide concentration 0.5 mg/L (times measuring n = 
11). [28] 
3.1.7 Semaan, Felipe Silva; Cavalheiro, Eder Tadeu Gomes have developed 
spectrophotometric determination of furosemide based on its complexation with Fe 
(III) in ethanolic medium using a flow injection procedure. The proposed method was 
applied to tablets and ampoules and urine sample spiked with the analyte without an 
effect from the other substances present in the formulation [29]. 
3.1.8 Mishra, Pradeep; Katrolia, D.; Agrawal, R. K. have developed  
colorimetric estimation of furosemide in dosage forms, tablets and injections by 
treatment with Cu(OAc)2 and measurement of the Cu complex obtained at 742 and 
730 nm in MeOH and Ethyl acetate respectively. The metal to ligand ratio in the 
complex was 1:2 and the structure was proposed.  The recovery was 98-100% and the 
sensitivity was 1-5 mg/mL [30]. 
3.1.9 Dreux, C.; Halter, D.    Serv. Biochim., Hop. St.-Louis, Paris, Fr.,  have 
developed spectrofluorimetric determination of furosemide in biological fluids and 
application to pharmaco- and biokinetic studies. The method is described for the 
determination of furosemide [54-31-9] in blood serum and urine. The sensitivity of 
this method is 0.02 and 0.5 μg/ml for serum and urine, respectively [31].   
3.1.10 Guerello, Lilo O.; Dobrecky, Jose have developed spectrophotometric 
determination of triamterene and furosemide in pharmaceutical mixtures. Triamterene 
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and furosemide in tablets are determined by spectrophotometry at 275 and 370 nm., 
using 50% EtOH as a solvent [32]. 
3.1.11 Goelcue, A.  has developed spectrophotometric method was developed for the 
assay of furosemide (FUR), which is based on the complexation of the drug with 
copper(II) at pH 3.2 using Mclivaine buffer solution to produce a green adduct.  The 
latter has maximum absorbance at 790 nm and obeys Beer's law within the 
concentration range 5-30 μg/mL.  Regression analysis of the calibration data showed a 
good correlation coeff. (r = 0.9997) with min. detection limit of 0.23 μg/mL.  The 
proposed procedure was successfully applied to the determination of this drug in 
tablets [33]. 
3.1.12 Hanna, George M.; Lau-Cam, Cesar A.  have developed stability-indicating 
proton nuclear magnetic resonance spectroscopic assay method for furosemide in 
tablets and injections. This method was developed for the identification and assay for 
furosemide and its degradation product, 4-chloro-5-sulfamoylanthranilic acid (CSA), 
in tablets and injections. Dissolution of the sample in D2O-NaOD resulted in a 
solution yielding the required separation among the resonance signals of furosemide, 
CSA, and tert-BuOH, the internal standard.  The mean standard deviation recovery 
values of furosemide and CSA from 10 synthetic formulations were 99.6 and 98.9%, 
respectively [34]. 
 
3.2. LITERATURE REVIEW OF SPIRONOLACTONE 
The literature reviews regarding spironolactone suggest that various analytical 
methods were reported for its determination as drug, in pharmaceutical formulation 
and in various biological fluids. The literature reviews for analysis of spironolactone 
are as under  
3.2.1 Tang, Zhen; Liu, Fuqiang; Go, Yuhui; Guo, Ye; Ren, Yulin have reported 
nondestructive quantitative analysis method of spironolactone pharmaceutical powder 
by artificial neural network and near- infrared spectrometry. An artificial neural 
network model to predict unknown samples was based on the data from near-IR 
diffuse reflectance spectra of spironolactone pharmaceutical powders [35]. 
3.2.2 Mahrous, Mohamed S.; Issa, Ahmed S.; Soliman, Nabil S. have developed 
colorimetric methods for the determination of spironolactone in tablets. Three 
different methods were developed for the colorimetric determination of 
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spironolactone, either in its pure form or in tablets.  The methods utilize either the 
alkaline picrate reagent, isonicotinic acid hydrazide solution or hydroxamic acid 
formation for the evaluation of spironolactone.  The sensitivity of the proposed 
procedures was discussed and the results obtained were compared with the 
pharmacopeial methods [36]. 
3.2.3 Moussa, Bahia A.; El Kousy, Naglaa M., have developed colorimetric 
analysis method of some diuretic drugs: hydrochlorothiazide and spironolactone.  
Hydrochlorothiazide [58-93-5] and spironolactone [52-01-7] were determined inbulk 
and tablets by colorimetry.  Hydrochlorothiazide reacted with BuNH2 [109-73-9] and 
CoCl2 in anhydride medium, giving a blue-violet color. The absorbance at 570 nm of 
0.2-1.12 mg/mL hydrochlorothiazide obeyed Beer's law. Spironolactone 
determination was dependent on the reaction with isoniazid [54-85-3].  The 
absorbance was measured at 450 nm.  Beer's law was obeyed over the concentration 
range 4-20 µg/mL [37]. 
3.2.4 Shingbal, D. M.; Rao, V. Ramakrishna have developed colorimetric 
analysis method for spironolactone and its dosage forms. Spironolactone [52-01-7] 
was determined in tablets by a colorimetric method based on spironolactone 
dissolution in EtOH and mixing of an aliquot of this solution with p-dinitrobenzene 
[100-25-4] and NaOH solution and measurement of the absorbance of the yellow 
solution at 400 nm.  The color was stable for 6 hour at room temperature. Common 
tablet excipients did not interfere in the determination. The recovery was 98.8-99.76% 
[38]. 
3.2.5 Nevrekar, Vinay have developed spectrophotometric estimation of 
spironolactone. Spironolactone [52-01-7] was determined in tablets by dissolving in 
EtOH, diluted with MeOH, mixing with 2,3,5-triphenyltetrazolium chloride [298-96-
4] and Me4NOH in MeOH, heating the solution at 45°C for 55 min, and measuring 
the absorbance at 480 nm.  Beer's law held for 10-70 µg/mL, and recoveries were 
99.9-100.1% [39].  
3.2.6 Shingbal, D. M.; Prabhudesai, J. S.  have developed a spectrophotometric 
estimation method for spironolactone in pharmaceutical dosage form, based on 
reaction with isoniazid  [54-85-3] in CHCl3 and MeOH in acid medium and 
measuring the absorbance of the resulting yellow solution at 375 nm.  Beer's law was 
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obeyed in the concentration range 5-40 µg/mL. The standard deviation was 0.613-
0.652 and the recovery 99% [40].   
3.2.7 Chamberlain, Joseph has developed, a gas chromatographic determination 
method for levels of aldadiene in human plasma and urine following therapeutic doses 
of spironolactone. Aldadiene was extracted from the samples into dichloroethane and 
dissolved in EtOH for electron-capture gas chromatography on a 2% OV
-1
/CQ 
column at 250°with N carrier gas and with androst-4-ene-3, 6, 17-trione as the 
internal standard.  The mean recovery was 96% with < 4% standard deviations, and 
the detector response (relative peak height) was linear for 15 mg aldadiene/1 ml urine 
and 150 μg aldadiene/100 ml. plasma. Aldadiene levels in plasma reached a 
maximum of 10-15 g/100 ml. approximately 3 hour after administration of 100-mg 
spironolactone, and approximately 4 mg aldadiene was excreted 24-hr following the 
spironolactone dose [41]. 
3.2.8 Belal, Fathalla has studied polarographic behavior and determination of 
spironolactone. The polarogaphic behavior of spironolactone in Britton-Robinson 
buffers content 40% MeOH as a solubilizer was studied. Over the pH range 3-12 a 
cathodic wave was produced. The wave was characterized as irreversible, diffusion-
controlled and partially affected by adsorption phenomena. The number of electrons 
involved in the reduction was found by coulometric measurements at a controlled 
potential [42].   
3.2.9 Dyade, G. K.; Sharma, A. K. have developed two methods for simultaneous 
spectrophotometric determination of spironolactone and hydroflumethiazide in tablet 
formulations. The methods were multi-wavelength spectroscopy and the isoabsorptive 
point method.  Spironolactone and hydroflumethiazide had absorption maxima at 
238.0 and 273.0 nm, respectively in MeOH. Both the drugs obeyed Beer's law in the 
concentration ranges employed for these methods [43].  
3.2.10 Ma, Hong-Yan; Qi, Guang-Cai. have developed method for determination of 
spironolactone by micellar enhanced spectrofluorimetry. In the presence of sodium 
dodecyl sulfate (SDS), This method was successfully applied to the determination of 
spironolactone in tablets with satisfactory results [44].  
3.2.11 Parimoo, P.; Bharathi, A.; Padma, K. have developed Fluorimetric 
determination of spironolactone in the presence of frusemide and hydroflumethiazide 
in drug formulations. Spironolactone was determined in pharmaceuticals from its 
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strong fluorescence in 62% H2SO4 and ethanol (excitation 324 nm, emission 530 nm).  
The presence of HFT did not affect the fluorescence of SPN, however FRU caused a 
slight decrease in fluorescence intensity.  The limit of detection for SPN was 8.3 
µg/mL [45]. 
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4. AIM OF PRESENT WORK 
In recent time, there is increased tendency towards the development of 
stability-indicating assays [46-48], using the approach of stress testing as enshrined in 
the International Conference on Harmonization (ICH) guideline Q1A (R2) [49]. Even 
this approach is being extended to drug combinations [50, 51] to allow accurate and 
precise quantitation of multiple drugs in presence of their degradation products and 
interaction product if any. 
Various publications are available regarding determination method of 
Spironolactone and Furosemide but most of the methods are applicable to alone 
Spironolactone or Furosemide in pharmaceutical dosage form or in biological fluids. 
Potentiometric, colorimetric estimation, thin-layer chromatography, fluorometrically, 
complexation, flow injection chemiluminescence method, proton nuclear magnetic 
resonance spectroscopic and HPLC methods are reported. Only four methods are 
reported for the simultaneous determination of spironolactone and furosemide. As far 
as our knowledge is concern, no method for the determination of spironolactone and 
furosemide in combine dosage forms has been published. The previous published 
methods are not directly applicable for this issue and need more investigation for 
method development and validation.  
The aim and scope of the proposed work are as under: 
 To developed suitable UV spectrophotometric method for simultaneous 
determination spironolactone and furosemide in tablet formulation. 
 Perform the validation for the developed method. 
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5. EXPERIMENTAL 
5.1. Materials 
Spironolactone and Furosemide standard was provided by Aarti Drugs Ltd., 
Boisar (India). Spironolactone and Furosemide tablets containing 50mg 
Spironolactone and 20mg Furosemide and the inactive ingredient used in drug matrix 
were obtained from market. HPLC grade methanol and water were obtained from 
Spectrochem Pvt. Ltd., Mumbai (India). 
 
5.2. Instrumentation 
The UV-Visible double beam spectrophotometer with matched quartz cells (1cm) 
 Model: PharmaSpec1700 
 Make: Shimadzu Corporation, Kyoto, Japan. 
 
5.3. Solvent used 
A mixture of Methanol : Water (50:50, v/v) (HPLC grade) is used as the 
diluent. 
 
5.4. Preparation of standard stock solution 
25 mg each of Spironolactone and 10mg of furosemide were weighed 
separately and transferred in two different 50 ml volumetric flasks. Both the drugs 
were dissolved in 25 ml of methanol by vigorous shaking and diluted to then volume 
was made upto the mark with diluent to obtain 500 and 200 µg/ml concentration of 
Spironolactone and furosemide respectively.  
 
5.5. Preparation of individual and mixed standard solution 
To prepare individual standard solution 2ml of each standard stock solution 
was taken into different 50 ml volumetric flask and diluted upto the mark with diluent 
to obtain 20 and 8 µg/ml concentration of spironolactone and furosemide respectively.  
For the preparation of mixed standard solution, 2 ml of each standard stock 
solution is taken into single 50 ml volumetric flask and diluted upto the mark with 
diluent. The final concentration of each drug comes out to be 20 and 8 µg/ml in the 
mixed standard. 
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6. RESULTS AND DISCUSSION 
 
6.1. Development and optimization of the spectrophotometric method 
Proper wavelength selection of the methods depends upon the nature of the 
sample and its solubility. To develop a rugged and suitable spectrophotometric 
method for the quantitative determination of spironolactone and furosemide, the 
analytical condition were selected after testing the different parameters such as 
diluent, wavelength selection, water and organic solvent ratio.  
Our preliminary trials using different composition of diluents consisting of 
water and methanol or acetonitrile. By using diluent consist of methanol – water (50: 
50, v/v) best result was obtained. 
Selection of sampling wavelength for analysis  
By appropriate dilutions of the standard drug solution with diluent, two 
solutions containing 20 µg/ml of spironolactone and 8 µg/ml of furosemide were 
prepared separately each solution was scanned between 300 nm to 200 nm in 
“Multicomponent mode” and the overlain spectra of both the drugs was recorded. The 
wavelengths, which could be utilized for simultaneous analysis of the two drugs using 
the “Multicomponent mode”, were observed to be 241 nm (high absorbance peak for 
spironolactone) and 276 nm (high absorbance peak for furosemide) as shown in 
[Figure 1-5]. 
 
Figure 1: Spectrum scan of blank preparation 
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Figure 2: Spectrum scan of spironolactone standard 
 
Figure 3: Spectrum scan of Furosemide standard 
 
Figure 4: spectra of mixed standards 
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Figure 5: Overlay spectra of spironolactone and furosemide in “Multicomponent Mode” 
 
Standardization of the method by analysis of the powder mixture of known 
composition: 
Two wavelengths 241 nm and 276 nm were fed in the memory of the 
instrument in “Multicomponent mode”. Pure standards of spironolactone and 
furosemide the mixed standard of spironolactone and furosemide, which prepared 
earlier, were scanned in the “Multicomponent mode” of the instrument (300 nm to 
200 nm). The spectrums of these samples were fed in the memory of the instrument. 
The analyte solutions of the mixture were analyzed and the results were displayed on 
the screen when the analyte solutions were kept in the sample holder. 
 
Procedure for analysis of tablet formulation: 
Twenty tablets of spironolactone and Furosemide in combination were 
weighed and their average weight was determined and the tablets were crushed to 
powder sample. From the triturate, tablet powder equivalent to 50 mg of 
spironolactone and 20 mg of Furosemide was weighed and transferred to 100 ml 
volumetric flask and dissolved in 50 ml diluent and the content was kept in 
ultrasonicator for 20 min. Finally the volume was made upto the mark with diluent. 
The solution was filtered through a 0.41 µm syringe filer. 
Further 20 ml of this tablet solution was diluted to 50 ml with diluent to obtain 
20 µg/ml for and 8 µg/ml concentration of spironolactone and furosemide. This 
solution was subjected to analysis in the “Multicomponent mode” of instrument. This 
analysis procedure was repeated five times. 
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The results of the analysis of tablet formulation are reported in Table 1, 2 and 
data for statistical validation are given in Table 3. 
7. Method validation   
7.1 Selection of analytical concentration range: 
For each drug appropriate aliquots were pipetted out from the standard stock 
solution into series of 10 ml volumetric flask. The volume was made upto the mark 
with methanol to get a set of solutions having the concentration 8-32 µg/ml for 
spironolactone and 3.2-12.8µg/ml for furosemide. The absorbance of each of these 
solutions were measured at the selected wavelengths (i.e., 241 and 276 nm) and 
plotted against concentration. The concentration range over which the drugs obeyed 
Beer’s law was chosen. [Table 4] 
Linearity of Spironolactone
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Figure 9: Calibration curve for spironolactone 
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Figure 9: Calibration curve for Furosemide 
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7.2 Procedure for recovery studies: 
Recovery studies were carried out by applying the method to drug sample 
present in tablet dosage form to which known amount of spironolactone and 
furosemide corresponding to 50, 100, 150% of label claim was added (standard 
addition method). In 50% recovery study amount of standard added is 25 mg of 
spironolactone and 10 mg of furosemide (i.e., 50% addition). In 100% recovery study 
the amount of standard added is 50 mg of spironolactone and 20 mg of furosemide 
(i.e., 100% addition). In 150% recovery study the amount of standard added is 75 mg 
of  and 30 mg of furosemide (i.e., 150% addition). After the addition of standard 
drugs at different levels, the contents were transferred to 100 ml volumetric flask and 
dissolved in 50 ml methanol and were kept for ultrasonification for 20 min. Finally 
the volume was made upto the mark with methanol. The solution was filtered through 
0.45µ nylon filter. 
This solution was subjected to analysis in the “Multicomponent mode” of 
instrument. The analysis was performed by using previously optimized pure standard. 
At each level three determinations were performed and results obtained. The results 
for recovery studies and statistical evaluation are shown in Table No. 5 and 6 
respectively. 
 
7.3 Procedure for precision 
Precision of the method was determined with the tablet sample. Twenty tablets 
of spironolactone and furosemide in combination were weighed and their average 
weight was determined and the tablets were crushed to fine powder. The tablet 
powder equivalent to 50 mg of spironolactone and 20 mg of furosemide B was 
weighed and transferred to 100 ml volumetric flask and dissolved in 50 ml diluent and 
the content was kept in ultrasonicator for 20 min. Finally the volume was made upto 
the mark with diluent. The solution was filtered through 0.45µ syringe filter.  
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This tablet solution was further diluted with diluent to obtain mixed sample 
solutions containing 20 μg/ml of spironolactone and 8 μg/ml of furosemide 
respectively. This solution was subjected to analysis in the “Multicomponent mode” 
of the instrument. In intraday precision sample was scanned six times at different time 
interval in the same day. Interday precision was obtained by the assay of six sample 
sets on different days. The results are shown in Table No. 7, 8 and 9. 
 
Table 1: Data for powder mixture analysis 
Sr. 
No. 
Amount present in 
µg/ml 
Amount found in 
µg/ml 
 
Amount found in % 
Spiro Furo Spiro Furo Spiro Furo 
1. 20 8 20.24 8.01 101.20 100.13 
2. 20 8 20.13 8.04 100.65 100.50 
3. 20 8 19.94 7.98 99.70 99.75 
4. 20 8 20.09 8.02 100.45 100.25 
5. 20 8 19.82 7.97 99.10 99.63 
6. 20 8 19.74 7.99 99.88 99.88 
 
Table 2: Analysis of tablet formulation 
Sr. 
No. 
Label Claim (mg/tab) Amount Found (mg/tab) % of Label claim 
Spiro Furo Spiro Furo Spiro Furo 
1. 50 20 49.89 20.02 99.78 100.10 
2. 50 20 50.03 19.95 100.06 99.75 
3. 50 20 50.05 19.97 100.10 99.85 
4. 50 20 49.98 20.04 99.96 100.20 
5. 50 20 49.98 19.98 99.96 99.90 
6. 50 20 49.94 19.99 99.95 99.95 
 
 
Table 3: Statistical validation for the tablet formulation 
Component Mean* 
Standard 
deviation* 
Co-efficient of 
variation* 
Standard 
error* 
spironolactone 99.96 0.1111 0.1111 0.04534 
Furosemide 99.95 0.1655 0.1656 0.06760 
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Table 4: Calibration Table for pironolactone and furosemide 
Sr. 
No. 
Spironolactone Furosemide 
Concentration 
(µg/ml) 
Absorbance 
at 276 nm. 
Concentration 
(µg/ml) 
Absorbance 
at 241 nm. 
1 8 0.5415 3.2 0.2335 
2 12 0.8165 4.8 0.348 
3 16 1.0805 6.4 0.456 
4 20 1.39 8.0 0.581 
5 24 1.6405 9.6 0.683 
6 28 1.922 11.2 0.796 
7 32 2.2095 12.8 0.9115 
 
Table 5: Recovery studies 
Level of 
% 
Recovery 
Amount 
present 
(mg/tab) 
Amount of 
standard added 
(mg) 
Total amount 
recovered 
(mg) 
% Recovery 
Spiro Furo Spiro Furo Spiro Furo Spiro Furo 
50 50 20 25 10 24.95 10.01 99.80 100.10 
50 50 20 25 10 24.97 10.02 99.88 100.20 
50 50 20 25 10 25.04 9.97 100.16 99.70 
100 50 20 50 20 50.02 20.04 100.04 100.20 
100 50 20 50 20 50.07 19.96 100.14 99.80 
100 50 20 50 20 49.99 20.01 99.98 100.05 
150 50 20 75 30 74.96 30.02 99.95 100.07 
150 50 20 75 30 74.88 30.03 99.84 100.10 
150 50 20 75 30 75.03 29.99 100.04 99.97 
 
Table 6: Statistical validation for recovery studies 
 
Level of 
% 
Recovery 
% Mean 
recovery* 
Standard 
deviation* 
Co-efficient of 
variation* 
Standard error* 
Spiro Furo Spiro Furo Spiro Furo Spiro Furo 
50 99.94 100.0 0.1890 0.2645 0.1891 0.2645 0.1091 0.1527 
100 100.05 100.01 0.0807 0.2020 0.0807 0.2020 0.0461 0.1166 
150 99.94 100.04 0.1001 0.068 0.1002 0.0680 0.0578 0.0393 
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Precision study: 
Table 7: Results of precision study 
 Set 
Spironolactone (%Assay) Furosemide (%Assay) 
Intraday 
(n = 6) 
Interday 
(n = 6) 
Intraday 
(n = 6) 
Intraday 
(n = 6) 
1 100.7 100.7 100.4 98.9 
2 101.1 100.9 100.5 98.9 
3 99.0 100.3 98.4 98.7 
4 100.7 99.7 98.0 98.5 
5 100.2 100.8 99.3 98.5 
6 101.6 100.3 100.9 98.4 
Mean 100.5 100.4 99.6 98.6 
Standard deviation 0.87 0.46 1.18 0.20 
% RSD 0.87 0.46 1.19 0.20 
 
Table 8: Intra – day precision 
Drug % Mean* S.D* % R.S.D.* S.E.* 
Spironolactone 100.55 0.8910 0.8910 0.364 
Furosemide 99.58 1.202 1.201 0.1821 
* n=6 
 
Table 9: Inter – day precision 
Drug % Mean* S.D.* % R.S.D.* S.E.* 
Spironolactone 100.45 0.4461 0.4460 0.1821 
Furosemide 98.65 0.2168 0.2167 0.0885 
* n=6 
 
The % mean, standard deviation (S.D.), relative standard deviation (%R.S.D.) and 
standard error (S.E.) calculated are low, indicating high degree of precision of the 
method. The %R.S.D. is also less than 2% as required by USP and ICH guidelines. 
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